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Abbreviations 
Abbreviation  Explanation 
AHL N-acyl homoserine lactone 
ADP Adenosine-5’-diphosphate 
AMP Adenosine-5’-monophosphate 
APCI Atmospheric pressure chemical ionization 
ATP Adenosine-5’-triphosphate 
BLAST Basic local alignment search tool 
CDW Cell dry weight 
CDWmax Maximal cell dry weight 
CoA Coenzyme A 
DMSP Dimethylsulfoniopropionate 
DNA Deoxyribonucleic acid 
DO Dissolved oxygen 
DSMZ 
German Collection for Microorganisms and Cell Cultures 
(Braunschweig, Germany) 
EC Enzyme commission number 
EDTA Ethylenediaminetetraacetic acid 
EI Electron ionization 
ESI Electrospray ionization 
et al. Latin: et alii, and others 
FAD Flavine adenine dinucleotide 
FBA Flux balance analysis 
FLD Fluorescence detector 
FMOC fluorenylmethylchloroformate 
GAM Growth-associated maintenance energy 
GC Gas chromatography 
HPLC High performance liquid chromatography 
ICBM 
Institute for Chemistry and Biology of the Marine 
Environment (Carl von Ossietzky University Oldenburg) 
kb kilobase 
LC Liquid chromatography 
LTA Lipoteichoic acid 
m/z Mass to charge ration 
MB medium Marine bouillon medium 
MS Mass spectrometry 
MSTFA N-methyl-N-(trimethylsilyl)-trifluoro-acetamide 
MTBE Methyl-tert-butylether 
NAD+/NADH Nicotinamide adenine dinucleotide (oxidized/reduced) 
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Abbreviation  Explanation 
NADP+/NADPH 
Nicotinamide adenine dinucleotide phosphate 
(oxidized/reduced) 
NGAM Non-growth-associated maintenance energy 
OD600 Optical density, measured at 600 nm 
ODmax Maximal optical density, measured at 600 nm 
OPA O-phthalaldehyde 
OTR Oxygen transfer rate 
OUR Oxygen uptake rate 
PHB Poly-(R)-3-hydroxybutanoate 
qO2 Specific oxygen uptake rate 
qS Specific substrate uptake rate 
RI Retention index 
RNA Ribonucleic acid 
rpm Rotations per minute 
RPKM Reads per kilobase of gene per million reads 
SDS Sodium dodecyl sulphate 
SPE Solid phase extraction 
TDA Tropodithietic acid 
TMS Trimethylsilyl 
TOF Time of flight 
x g x-fold acceleration 
µ Specific growth rate 
µlin Linear growth rate 
Units were abbreviated according to the international unit system (SI, Systéme 
international d’unités), except for molar concentrations (mol L-1), which were 
abbreviated with the capital letter M. Furthermore, chemical elements were 
abbreviated by their symbols of the periodic table of elements.  
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Summary 
Extrachromosomal elements play a crucial role in adaptation and survival of many 
marine bacteria in their natural habitat providing essential features and facilitating 
lateral gene transfer. Phaeobacter inhibens DSM 17395 carries three plasmids with 
advantageous functions: 65-kb (biofilm, motility), 78-kb (siderophores) and 262-kb 
(tropodithietic acid). 
The metabolic role of the 262-kb plasmid of P. inhibens DSM 17395 with a focus on 
biosynthesis of TDA were studied as part of this thesis applying both, non-targeted 
GC- and LC-MS based analyses. Experimental data were complemented by in silico 
analyses with the reconstructed metabolic model iPin571. 
Deletion of the 262-kb plasmid improved growth efficiency with only minor changes 
on metabolic level which can be attributed to the pipecolate oxidase-dependent lysine 
catabolism encoded by the plasmid.   
Combined metabolomics and transcriptomics showed that the wild-type strain 
entered stationary growth phase due to the inhibitory effect by its own produced TDA. 
Sufficient carbon provided by amino acids were still available in the medium. 
Contrary to that, the Δ262-kb plasmid-cured mutant strain was carbon-limited. 
Detailed analyses indicated the degradation of the storage compound 
polyhydroxybutanoate to produce a proposed lipoteichoic acid as a response to a 
starvation triggered phage.  
A new biosynthetic pathway for TDA was proposed based on metabolome and 
transcriptome data revealing an unexpected strategy for sulfur incorporation via an 
episulfide. Furthermore, a methylated (“pre”-) TDA was observed with a proposed 
associated methyltransferase, encoded on the chromosome, for conversion into TDA.   
Metabolic model-based analyses showed that growth efficiency for TDA-free 
cultivations were optimal while TDA biosynthesis decreased biomass yield and 
increased oxygen consumption. The major drawback is based on the inhibitory effect 
by the disruption of the proton gradient.  
Taken together, this study clearly shows that TDA production by P. inhibens DSM 
17395 and some closely related strains is an advantage in its natural habitat despite 
the consequences for its own energy metabolism.
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Zusammenfassung 
Extrachromosomale Elemente spielen eine essentielle Rolle in der Adaptation und 
den Überlebensstrategien mariner Bakterien in ihrem natürlichen Habitat und 
können sich über lateralen Gentransfer zwischen Stämmen verbreiten. Phaeobacter 
inhibens DSM 17395 besitzt drei Plasmide unterschiedlicher Größe mit relevanten 
Funktionen: 65-kb (Biofilm, Motilität), 78-kb (Siderophore) und 262-kb 
(Tropodithietsäure). 
Die metabolische Funktion des 262-kb Plasmids von P. inhibens DSM 17395 wurde in 
Bezug auf die Biosynthese von TDA im Rahmen dieser Arbeit untersucht, indem 
ungezielte GC- und LC-MS basierte Analysen angewendet wurden. Zudem wurde das 
metabolische Modell iPin571 erstellt und für in silico Analysen genutzt. 
Die Deletion des 262-kb Plasmids verbesserte die Wachstumseffizienz während nur 
geringfügige Unterschiede auf Metabolomebene sichtbar waren. Diese Änderungen 
können im Wesentlichen auf den Plasmid-codierten und Pipecolatoxidase-
abhängigen Lysinabbau zurückgeführt werden.  
Die Kombination von Metabolomics und Transcriptomics zeigte, dass der Wildtyp auf 
Grund des inhibitorischen Effekts des vom Organismus selbst produzierten TDAs in 
die stationäre Wachstumsphase übergeht. Im Gegensatz dazu war die Δ262-kb 
Plasmidmutante am Ende der Kultivierung kohlenstofflimitiert. Detaillierte Analysen 
deuten darauf hin, dass der Speicherstoff Polyhydroxybutanoat abgebaut wurde, um 
eine Verbindung ähnlich zu Lipoteichonsäuren als Antwort auf einen Phagen zu 
produzieren, der durch den Nährstoffmangel induziert wurde.  
Basierend auf Metabolom- und Transkriptomdaten wurde ein neuer Stoffwechselweg 
für die TDA-Biosynthese mit einem Schwefeleinbau über ein Episulfid postuliert. 
Außerdem konnte ein methyliertes („Pre“-) TDA beobachtet werden, welches durch 
eine putative Methyltransferase, die auf dem Chromosom codiert ist, in TDA 
umgewandelt werden kann. 
Metabolische, modellbasierte Analysen zeigten, dass die Wachstumseffizienz für 
TDA-freie Kultivierungen optimal war, während die TDA-Biosynthese die 
Biomasseausbeute verringerte und den Sauerstoffverbrauch erhöhte. Der größte 
Effekt basiert dabei auf dem inhibitorischen Effekt durch die Zerstörung des 
Protonengradienten. 
ZUSAMMENFASSUNG  IX 
 
Zusammengefasst zeigt dies, dass die Produktion von TDA durch P. inhibens DSM 
17395 und einiger nah verwandter Stämme, unabhängig von den Auswirkungen auf 
den eigenen Energiemetabolismus, einen Vorteil im natürlichen Habitat bietet. 
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1 Introduction 
1.1 The marine environment as habitat for Rhodobacteraceae 
The most important ecosystem on the earth - the ocean with a volume of 1.3 x 109 km3 
(Charette and Smith 2010) - covers about 70% of the earth’s surface and provides 
habitats for over 240000 different species with over 2000 species classified as 
bacteria (WoRMS, 11/2017). However, the absolute number for bacteria species is 
underestimated (Appeltans et al. 2012) and even more species are expected. 
Alphaproteobacteria (37%), Gammaproteobacteria (14%) and Bacteroidetes (12%) 
form the majority of the marine bacterioplankton with the SAR11 clade as the most 
abundant marine group of the Alphaproteobacteria (Wietz et al. 2010). Marine 
Rhodobacteraceae, designated as Roseobacter group (Simon et al. 2017) and 
belonging to the Alphaproteobacteria, is another major marine group and represents 
up to 20% of coastal and 15% of mixed-layer ocean bacterioplankton communities 
(Buchan et al. 2005). In contrast to the SAR11 clade, many members of the 
Roseobacter group are cultivable. Furthermore, they are ecological all-rounder 
(Newton et al. 2010) and one of the most abundant and most active bacterial clade 
upon seasonal collapse of algae blooms (Alonso-Sáez et al. 2007; Alonso-Sáez, Gasol 
2007). 
Ecological niches in the marine habitat are diverse due to differences in temperature, 
pressure, pH, salinity, light, dissolved gases and nutrient supply dependent on the 
distance to coastal regions, the sea layer and the latitude (Fuhrman et al. 2008). Thus, 
bacteria developed different strategies for successful survival in the various marine 
environment. For Alphaproteobacteria, a variety of features to adapt to different 
niches are found on extrachromosomal elements, especially within the 
Rhodobacteraceae (Pradella et al. 2010; Petersen et al. 2011; Petersen et al. 2013; 
Trautwein et al. 2016; Kleist et al. 2016; Wagner-Döbler et al. 2010; Thole et al. 2012; 
Frank et al. 2014; Michael et al. 2016). 
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1.2 Extrachromosomal elements of the Rhodobacteraceae 
Microbial evolution is dominated by horizontal gene transfer including plasmid 
transfer by conjugation, transformation by direct DNA uptake and transduction by 
phages or gene transfer agents (Koonin 2016). Extrachromosomal elements are 
widely spread within the Rhodobacteraceae with species carrying up to 12 plasmids 
per cell (Pradella et al. 2010). They provide the possibility for rapid adaptation to 
ecological niches by genetic flexibility and horizontal exchange (Petersen et al. 2013). 
1.2.1 Classification of extrachromosomal elements  
Extrachromosomal elements can be classified according to their replication modules 
RepABC, RepA, RepB and DNA-like (Petersen et al. 2011; Petersen et al. 2013). 
Plasmids with a RepABC module are only found in Alphaproteobacteria (Pinto et al. 
2012), DNA-like replicons are restricted to Rhodobacterales and RepA- and RepB-type 
plasmids are further observable in Beta- and Gammaproteobacteria (Petersen et al. 
2013). Chromids, extrachromosomal elements with genetic footprint similar to those 
of the chromosome (Harrison et al. 2010), were identified in Rhodobacterales species 
additionally to the chromosome and plasmids. While plasmids often contain the 
RepABC-type replication system, chromids are mainly replicated by RepA, RepB and 
DNA-like modules (Petersen et al. 2013). For example, the three extrachromosomal 
elements of the model organism Phaeobacter inhibens DSM 17395 containing RepA-I 
(65-kb), RepB-I (78-kb) and DNA-like I (262-kb) replication types and were all 
classified as chromids by Petersen et al. (2013). The model organism Dinoroseobacter 
shibae DFL12T carries five extrachromosomal elements, two of them are chromids 
(153-kb and 72-kb) and three are plasmids (86-kb, 191-kb, 126-kb). Harrison et al. 
(2010) assumes that chromids are essential for the bacterial host. However, all three 
chromids of P. inhibens DSM 17395 were curable (Petersen et al. 2013; Trautwein et 
al. 2016). Thus, chromids that a curable have to be considered as essential in their 
natural habitat but not as essential per se. For reasons of simplicity, “chromids” will 
be further on designated as “plasmids”.  
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1.2.2 Functional role of extrachromosomal elements  
A variety of functions of the extrachromosomal elements were observed within the 
Rhodobacteraceae. Most of these functions are associated with the habitat and 
provide benefits for the successful survival in the marine habitat. The 153-kb plasmid 
of D. shibae DFL12T was shown to be essential for dealing with high salinity (Kleist et 
al. 2016) and encodes a gene cluster for degradation of aromatic compounds. 
Furthermore, its 86-kb plasmid harbors genes for sugar metabolism and the 72-kb 
plasmid carries cox operons contributed to energy production (Wagner-Döbler et al. 
2010). Wagner-Döbler et al. (2010) identified three copies of thiC, essential for 
thiamine (vitamin B1) biosynthesis, on three plasmids (191-kb, 153-kb and 86-kb) 
while all other genes of this pathway are localized on the chromosome. Furthermore, 
heavy metal resistance genes were found on plasmids of D. shibae DFL12T and other 
Rhodobacteracea, e.g. Roseobacter litoralis OCh149 or Rosevarius nubinhibens ISM 
(Kalhoefer et al. 2011). Kalkhoefer et al. (2011) identified the photosynthesis gene 
cluster (PGC) encoded on the 94-kb plasmid of R. litoralis which was found on the 
chromosome of Roseobacter denitrificans OCh114 indicating a translocation of these 
genes in R. litoralis from the chromosome to the plasmid. This translocation of the PGC 
could explain the dispersed presence of the aerobic anoxygenic photosynthesis 
amongst the Rhodobacteraceae (Petersen et al. 2013). The 65-kb plasmid of 
P. inhibens DSM 17395 is crucial for motility and colonization of marine algae 
associated with a functional biofilm formation (Frank et al. 2014). These RepA-I-type 
biofilm plasmids are widely distributed amongst Rhodobacteraceae (Michael et al. 
2016). P. inhibens DSM 17395 and the closely related P. inhibens 2.10 produce 
siderophores under iron-limiting conditions. The gene clusters for biosynthesis and 
transport of these iron-chelating siderophores are located on the 78-kb or 95-kb 
plasmid, respectively (Thole et al. 2012). P. inhibens DSM 17395 and some closely 
related Rhodobacteracea produces the antibacterial compound tropodithietic acid 
(TDA). The biosynthetic gene cluster is encoded on the 262-kb plasmid of P. inhibens 
DSM 17395 (Thole et al. 2012) . 
Overall, some features are widespread amongst the Rhodobacteraceae but others are 
specific for only a few species. Thus, every species within the Roseobacter group 
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developed its own successful survival strategy and obtained some of these functions 
by horizontal gene transfer. 
1.3 The model organism Phaeobacter inhibens DSM 17395 
Phaeobacter species are strictly aerobe, motile, brown-pigmented, Gram-negative 
ovoid rods with chemoheterotrophic metabolism. The optimal salinity ranges from 
0.51 to 0.68 M, the optimum pH is 7.5 and the optimal temperature is 27-29 °C 
(Martens 2006). 
P. inhibens DSM 17395 was originally reclassified from Roseobacter gallaeciensis 
(Ruiz-Ponte et al. 1998) to P. gallaeciensis DSM 17395 (Martens 2006). However, the 
alleged type strains P. gallaeciensis CIP 105210 and P. gallaeciensis DSM 17395 are 
not identical. The strain CIP 105210 most likely corresponds to the original 
P. gallaeciencsis type strain BS107T while strain DSM 17395 shows a closer relation 
to P. inhibens DSM 16374T (T5T) resulting in reclassification to P. inhibens DSM 17395 
(Buddruhs et al. 2013).  
The genome of P. inhibens DSM 17395 comprises a 3.8 million basepairs (bp) long 
chromosome and three plasmids of 65-kb, 78-kb and 262-kb described in chapter 1.2. 
P. inhibens DSM 17395 is a nutritionally versatile organism with a broad substrate 
range including amino acids, carbohydrates and further different short-chain 
carboxylic acids (Zech et al. 2009; Zech et al. 2013a; Zech et al. 2013b; Drüppel et al. 
2014; Wiegmann et al. 2014). P. inhibens DSM 17395 catabolizes glucose via the 
Entner-Douderoff pathway. The 6-phosphofructokinase is missing in the genome of 
P. inhibens DSM 17395, but all necessary genes for gluconeogenesis are annotated  
(Zech et al. 2009). Furthermore, Zech et al. (2009) identified the enzymes to produce 
the storage compound polyhydroxybutanoate (PHB). 
P. inhibens DSM 17395 shows different morphotypes depending on the substrate 
(Drüppel et al. 2014). Furthermore, the typical rosette formation is correlated with 
the ability of surface attachment (Frank et al. 2014).  
The organism is able to synthesize different secondary metabolites like quorum 
sensing molecules (acyl homoserine lactones), roseobacticides or the antibaterial 
compound TDA (Berger et al. 2011; Thole et al. 2012). 
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1.4 The antibacterial compound tropodithietic acid 
Tropodithietic acid was firstly described as its isomer thiotropocin which was 
isolated from Pseudomonas sp. CB-104 (Kintaka et al. 1984). A thicarbonyl-enol 
tautomerism between both structures is assumed based on computational studies 
(Greer et al. 2008) (figure 1.1). Greer et al. (2008) suggest a barrierless process in the 
gas phase. In aqueous solution a stabilization relative to a transition state is 
anticipated to produce a small barrier for tautomerization of thiotropocin to the more 
stable TDA (figure 1.1).   
 
Figure 1.1 Suggested tautomerization of thiotropocin to tropodithietic acid via 
a transition state by Greer et al. 2008. 
In the presence of Fe3+, TDA forms a [FeIII(TDA)2]x complex which shows a 
characteristic brown color and could be precipitated by acidification (D'Alvise et al. 
2015) explaining the co-occurrence of the yellow-brown pigment and TDA (Brinkhoff 
et al. 2004; Bruhn et al. 2007; Bruhn et al. 2005; Geng and Belas 2010, 2011; Geng et 
al. 2008; Berger et al. 2011). 
TDA shows antibacterial activity against a broad range of Gram-negative and Gram-
positive bacteria including human-pathogenic bacteria, e.g. Staphylococcus aureus 
NCTC 12493 (Porsby et al. 2011). TDA is proposed to disrupt the proton gradient by 
a proton antiport mechanism, in which extracellular protons are exchanged for 
cytoplasmic cations (Wilson et al. 2016). Furthermore, Wilson et al. (2016) suggests 
a self-resistance mechanism of P. inhibens DSM 17395 by uptake of glutamate and 
export of γ-aminobutyric acid for proton export catalyzed by enzymes encoded on the 
262-kb plasmid neighboring the TDA biosynthetic gene cluster (figure 1.2). Attempts 
by Porsby et al. (2011) to isolate stable TDA resistant or tolerant strains were not 
successful. Even more, the TDA-producing Phaeoabacter strain 27-4 itself was also 
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inhibited by TDA. In studies by Harrington et al. (2014) observed tolerances were not 
associated with native TDA production. 
 
Figure 1.2 TDA biosynthetic gene cluster. Resistance genes proposed by Wilson et 
al. (2016) are shown in blue. 
TDA was recently described as signaling molecule in global gene regulation of 
P. inhibens DSM 17395 and causes a regulatory effect similar to the effect of the 
quorum sensing molecule AHL (Beyersmann et al. 2017). Both, TDA and AHL, were 
proposed to positively regulate TDA and AHL biosynthesis and negatively regulate 
motility and biofilm associated genes. In Pseudovibrio neither autoinduction nor AHL 
mediated induction of TDA production was observed (Harrington et al. 2014). 
Furthermore, TDA shows a cytotoxic effect on mammalian cells of the nervous system 
resulting in oxidative stress and cell death (Wichmann et al. 2015). DMSP was shown 
to be protective against TDA induced cytotoxicity (Wichmann et al. 2016). Thus, 
DMSP provided by the algal host might be essential for resistance of TDA producing 
marine bacterial strains.  
Phenylacetyl-CoA was shown to be the precursor for TDA biosynthesis and is mainly 
produced by degradation of phenylalanine (Berger et al. 2012; Thole et al. 2012). 
Brock et al. (2014) proposed a biosynthetic pathway starting with phenylacetyl-CoA 
resulting in a tropone ring (figure 1.3) followed by dehydrogenation and water 
elimination.  
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Figure 1.3 Proposed TDA biosynthetic pathway. The proposed biosynthetic steps 
by Brock et al. (2014) starting from phenylacetyl-CoA is shown with associated 
involved enzymes.  
Recently, the L-cystine β-Lyase PatB from P. inhibens DSM 17395 was characterized 
and shown to be active with L-cystine resulting in the unstable compound S-thio-L-
cysteine (Dickschat et al. 2017). Sulfur incorporation was proposed by transfer of 
sulfur from S-thio-L-cysteine to the TDA precursor (Brock et al. 2014). 
1.5 Metabolome analyses 
1.5.1 Metabolomics 
The metabolome is the set of metabolites produced by a biological system as a result 
of its metabolism (Fiehn 2002; Villas-Bôas et al. 2005). The analysis of the 
metabolome is an essential step on functional genomics because the metabolome is 
the most predictive of a phenotype (Dettmer et al. 2007). Genetic or environmental 
changes lead to different metabolite levels which can be regarded as the ultimate 
response of a biological system (Fiehn 2002). The metabolic fingerprinting is used to 
compare patterns of metabolites without identifying each metabolite in a response to 
a treatment. Furthermore, the metabolic profiling could be used if only a small 
number of metabolites are identified and quantified based on e.g. same biochemical 
pathway or compound class (Fiehn 2002; Dettmer et al. 2007). 
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A metabolome analysis should be fast, reliable, sensitive, amenable for automation 
and it should cover a significant number of metabolites (Strelkov et al. 2004; Fiehn 
2002). Currently, there is no single or combined analytical method to cover the whole 
metabolome (Allwood, Goodacre 2010). Thus, the choice of the right analytical 
method depends on the aim of the analysis.   
1.5.2 Sample preparation 
Sample preparation is the most challenging step in metabolomics.  Remaining enzyme 
activity could lead to metabolic changes as stress response while sampling. Thus, 
metabolism has to be stopped immediately. Plant tissues can be easily frozen in liquid 
nitrogen (Fiehn 2002), but this technique is not transferrable to aqueous cell 
suspensions. There are mainly two possible methods to stop the metabolome of 
bacterial cell cultures: i) separation and ii) quenching. The separation can be 
conducted by filtration (Bolten et al. 2007) or centrifugation (Spura et al. 2009) 
followed by washing of the cells with an appropriate solution. A faster method is 
quenching with cold-buffered organic solutes, e.g. methanol, leading to protein 
degradation. However, this method has to be adapted to the respective organism. 
Quenching can lead to cell leakage resulting in loss of metabolites (Bolten et al. 2007; 
Spura et al. 2009) . 
Usually, a liquid-liquid or solid phase extraction is performed after metabolism is 
stopped depending on the targeted metabolite class. The analytes are concentrated to 
facilitate the detection of low abundant metabolites (Dettmer et al. 2007). 
1.5.3 Gas chromatography – mass spectrometry 
Gas chromatography (GC) coupled to mass spectrometry (MS) is one of the most used 
techniques for high-throughput metabolomics (Dettmer et al. 2007). Volatile 
compounds can be directly analyzed by the headspace technique. However, many 
metabolites are not volatile and need a derivatization procedure prior to 
vaporization. In this study a two-step derivatization procedure is performed using 
methoxyamine-hydrochloride for stabilization of the open-chain structure of sugars 
and MSTFA for silylation of functional chemical groups resulting in volatile 
compounds (figure 1.4). Silylation is sensitive to moisture. Thus, samples and agents 
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have to be completely dry to prevent degradation or less effective derivatization 
(Dettmer et al. 2007). Derivatization often results in several derivatives of one analyte 
containing different amounts of silyl-groups. These derivatives have to be combined 
because distribution pattern can differ (Kanani and Klapa 2007). 
 
Figure 1.4 Derivatization reaction for GC-MS analysis. Shown is the two-step 
derivatization reaction with (A) methoxymation of carbonyl-groups and (B) silylation 
of exchangeable protons from glycine (example). MSTFA: N-Methyl-N-
(trimethylsilyl)-trifluoro-acetamide, TMS: trimethylsilyl 
Vaporization of the derivatized metabolites is conducted by a programmed 
temperature vaporizing (PTV) injector. The vaporized compounds are transported by 
the mobile phase (an inert gas, e.g. helium) over a coated separation column. The 
compounds interact with the column material (e.g. silicon) depending on their 
structure and functional groups. Thus, the analytes have different retention times 
according to their interaction with the column, their mass and steric configuration. 
Usually, a temperature gradient is applied for elution of the compounds from the 
column. 
The analytes have to be ionized prior to the MS detection. This is usually conducted 
by the standardized and reproducible electron ionization (EI) with an electron energy 
of 70 eV. This hard ionization techniques results in fragmentation reactions 
characteristic for each analyte. Identification of the compounds is possible by 
comparison with several open and commercial MS libraries (Dettmer et al. 2007). 
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1.5.4 Liquid chromatography - mass spectrometry 
The major advantage of liquid chromatography coupled to mass spectrometry (LC-
MS) compared to GC-MS is the possibility to analyze larger molecules. In the field of 
metabolomics, it is suitable for the analysis of for example coenzyme A intermediates. 
Furthermore, with different columns and mobile phases a broad range of substance 
classes can be analyzed. Usually, a soft ionization method as electrospray ionization 
(ESI) is used for ionization of the analytes. These are vaporized into fine aerosol and 
molecular ions with either a positive [M+H]+ or negative [M+H]- charge could be 
detected. Thus, with the information of the accurate mass and isotopic pattern it is 
possible to predict molecule formula. This information can help at structure 
elucidation of so far unidentified compounds. The major drawback of the method is 
the lack of standardization and libraries. Due to a higher instrument-dependent 
variability, the comparison of ionization, spectra and retention times is difficult 
(Dettmer et al. 2007). 
1.6 Metabolic model-based analyses 
Metabolic models can be used for applications like metabolic engineering, 
identification of metabolic capabilities or analysis of the growth efficiency of bacteria   
(Becker et al. 2011; Imam et al. 2011; Lee et al. 2014; Orth et al. 2011; Puchałka et al. 
2008; Hintermayer and Weuster-Botz 2017). Combining experimental and 
theoretical data can help to understand the complex adaptation strategies of bacteria 
to their natural habitat with respect to utilization of carbon sources and maintenance 
energy requirements. 
1.6.1 Metabolic model reconstruction 
The most common approach is the constraint-based reconstruction and analysis 
(COBRA) (Price et al. 2003). These models, created in a bottom-up manner, can be 
used for a variety of predictions such as simulating the growth of a cell for a given 
condition (Thiele, Palsson 2010; Varma, Palsson 1994a; Schilling et al. 2000).  
Stoichiometric models can be used to describe a metabolic network as a numerical 
matrix of the stoichiometric coefficients of each reaction (Orth et al. 2010). A steady 
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state is assumed for constraint-based models to reduce the set of differential 
equations (Schilling et al. 2000). 
1.6.2 Flux-balance and flux-variability analyses 
Flux-balance analysis (FBA) calculates the flow of metabolites through a metabolic 
network with linear optimization to a defined biological objective. For prediction of 
growth the objective function is the biomass production represented by a biomass 
reaction including precursor metabolites. Usually, this reaction is scaled and equal to 
the growth rate µ (Orth et al. 2010). 
The flux-variability analysis (FVA) is used for prediction of maximum and minimum 
of a flux to analyze the solution space. Thus, it is possible to identify variable fluxes 
with still the optimal solution or a solution near the optimum (e.g. 95%) (Mahadevan, 
Schilling 2003). 
1.6.3 Growth efficiency and maintenance energy 
The basic concept to quantitively describe bacterial growth was given by Monod 
(1949). He introduced the growth rate as a constant for the exponential growth phase. 
This growth phase is a steady state where all metabolites and all enzymes are constant 
(Monod 1949). Energy requirements for maintenance were neglected by this classical 
approach and the concept of energy maintenance was introduced by Pirt (1965). Pirt 
(1982) proposed a model which accounts for the energy requirement for growth 
including a constant maintenance energy term independent of the specific growth 
rate and a term which decreases linearly with increase in specific growth rates. Based 
on these concepts, energy requirements are considered as growth- and non-growth-
associated maintenance energy (GAM and NGAM) in metabolic models. NGAM is 
defined as mmolATP gCDW -1 h-1 and GAM is defined as additional mmolATP required per 
unit of biomass produced (Varma et al. 1993). The experimental determination of 
both parameters is generally performed using continuous cultivation based on the 
relationship between substrate concentration and growth rate (Schulze, Lipe 1964; 
Varma et al. 1993; Varma, Palsson 1994b). FBAs usually predict the maximal possible 
growth rate dependent on an experimentally determined substrate uptake rate (Orth 
et al. 2010).  Based on these data it is possible to calculate the optimal biomass yield 
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(Y). However, predicted biomass yield obtained by FBA could be unrealistic high, but 
is well suited for organisms which show no overflow metabolism (Adadi et al. 2012; 
Hintermayer, Weuster-Botz 2017). This begs the question of which expression is 
describing growth efficiency more accurate. Many review articles discuss the complex 
relationship between growth rate and growth yield (Lipson 2015). The biomass yield 
is the simplest term to express growth yield (Lele and Gwatve 2014). A positive 
relationship between bacterial growth rate and bacterial growth efficiency (BGE) was 
described for natural planktonic bacteria (del Giorgio, Cole 1998). BGE was defined 
as bacterial production divided by the sum of production and respiration. Lipson 
(2015) proposed a relationship between growth rate and yield across a broad range 
of environmental conditions and ecological strategies. He described a positive 
relationship from a stress tolerance strategy (low biomass yield, slow growth rate) to 
a high efficiency strategy (high biomass, average growth rate) followed by a negative 
relationship after Beardmore et al. (2011) to the rapid growth strategy (low biomass 
yield, high growth rate). Thus, for marine bacteria like the Rhodobacteracea, biomass 
yields should be compared to analyze the growth efficiency dependent on nutrient 
supply. 
1.7 Objectives 
The alphaproteobacterial Roseobacter group (marine Rhodobacteraceae) is one of the 
most abundant lineages of the oceans and members of the group carry a variety of 
extrachromosomal elements. The nutritionally versatile model organism Phaeobacter 
inhibens DSM 17395 harbors three extrachromosomal elements (262-kb, 78-kb and 
65-kb plasmid) and has been widely analyzed regarding to metabolic abilities.  
This study focuses on the metabolic role of the 262-kb plasmid in the context of the 
endogenously produced antibiotic TDA. 
Initially, all three plasmids should be characterized with respect to their influence on 
the growth efficiency of P. inhibens DSM 17395 to analyze a possible energetic burden 
by carrying these plasmids.  
One main part is the detailed characterization of the largest plasmid (262-kb) on 
metabolomic and transcriptomic level to study the features with respect to successful 
survival in the natural habitat. These studies include the analysis of the biosynthetic 
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pathway of TDA which is not yet fully described with experimental evidence. 
Furthermore, structures for so far unknown metabolites should be proposed based 
on mass spectra data.   
The second study should investigate the theoretical and actual growth efficiency of 
P. inhibens DSM 17395 with different amino acids regarding maintenance energy 
requirements. This study includes analysis of possible decreasing biomass yields due 
to costs for the biosynthesis of TDA. 
Overall, these studies should provide new insights into the function of the 262-kb 
plasmid of P. inhibens DSM 17395 and should clarify the benefit of carrying this 
plasmid in the natural habitat. 
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2 Material and methods 
Experiments including cultivation in process-controlled bioreactors were conducted 
in cooperation with the research group of Prof. Ralf Rabus (ICBM, Carl von Ossietzky 
University Oldenburg) whose co-workers performed cultivation and sampling. 
Associated transcriptomic analyses (RNA-seq) were conducted by the group of Robert 
Geffers (Helmholtz centre for infection research, Braunschweig). All experiments 
conducted in Erlenmeyer flasks were independently realized as part of this work. 
2.1 Chemicals 
Chemicals and reagents with highest quality (“purest” or “for analytical purpose”) 
purchased from the manufacturers Carl Roth (Karlsruhe, Germany), Sigma-Aldrich 
(Steinheim, Germany), Fisher Scientific (Schwerte, Germany) and CS GmbH 
(Langerwehe, Germany) were used.  
2.2 Bacterial strains 
All strains of Phaeobacter inhibens DSM 17395 used in this study are listed in table 2.1 
and 2.2. For long-time storage marine bouillon medium (chapter 2.3.1) was 
inoculated with colonies from the agar plates.  800 µL of growing cells were mixed 
with 200 µL 100% glycerol, incubated for 20 minutes on ice and stored at -80 °C. 
Table 2.1 Wild-type and plasmid-cured mutant strains of P. inhibens DSM 17395 
used in this work. All strains were provided by the (DMSZ) German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany.  
Strain Genetic modification Reference 
DSM 17395 Wild-type strain DSMZ 
Δ262-kb Curation of the 262-kb plasmid  Trautwein et al. 2016 
Δ78-kb Curation of the 78-kb plasmid Trautwein et al. 2016 
Δ65-kb Curation of the 65-kb plasmid Trautwein et al. 2016 
Δ78Δ65-kb Curation of the 78- and 65-kb plasmid Trautwein et al. 2016 
Δ262Δ78-kb Curation of the 262- and 78-kb plasmid Trautwein et al. 2016 
Δ262Δ65-kb Curation of the 262- and 65-kb plasmid Trautwein et al. 2016 
Δ262Δ78Δ65-kb Curation of all three plasmids Trautwein et al. 2016 
Transposon mutants were transferred twice to fresh marine bouillon agar plates 
containing 120 μg mL-1 kanamycin and incubated for 2-3 days to exclude 
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contaminations with wild-type cells attached to the antibiotic resistant transposon 
mutant strains. Then marine bouillon containing 120 μg mL-1 kanamycin was 
inoculated with colonies from the agar plates and glycerol stocks were prepared as 
previously described.  
Table 2.2 Transposon mutant strains of P. inhibens DSM 17395 used in this 
work. Transposon mutants were taken from a transposon library of P. inhibens DSM 
17395 provided by Pascal Bartling (working group of Jörn Petersen, DSMZ). 
Strain Insertion site Insertion locus Reference 
Tm1693 107502+ PGA1_262p00980 Will et al. 2017 
Tm2750 106916- PGA1_262p00970 Will et al. 2017 
Tm3519 105936+ PGA1_262p00960 Will et al. 2017 
Tm2690 104157- PGA1_262p00940 Will et al. 2017 
Tm2361 389043+ PGA1_c04030 this work 
Tm510 390721- PGA1_c04040 this work 
Tm4090 390914- PGA1_c04050 this work 
Tm970 393104- PGA1_c04080 this work 
Tm2428 394153+ PGA1_c04090 this work 
Tm3938 1205517+ PGA1_c11650 this work 
Tm2456 1700287+ PGA1_c16390 this work 
Tm774 2353034+ PGA1_c22710 this work 
Tm225  2799630+ PGA1_c26830 this work 
Tm3860 3305902+ PGA1_c31650 this work 
Tm3922 3413439- PGA1_c32550 this work 
Tm757 3412773- PGA1_c32550 this work 
Tm1215 3462719- PGA1_c33040 this work 
Tm2415 90491- PGA1_262p00800 this work 
Tm2567 238764- PGA1_262p02210 this work 
Tm299 256398- PGA1_262p02330 this work 
 
2.3 Media and solutions 
Salt-free, particle filtered water (ddH2O) from ultra pure water systems (Arium, 
Sartorius) was used for all media and solutions. Autoclaving of media was conducted 
for 20 min at 121 °C and 1 bar overpressure.  
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2.3.1 Marine Bouillon 
For complex medium 40.1 g L-1 Marine-Bouillon (Carl Roth, Karlsruhe, Germany) was 
prepared and autoclaved. 15 g L-1 agar was added prior to autoclaving if solid medium 
was used. 
2.3.2 Defined salt water medium 
The defined salt water medium was prepared immediately before inoculation with 
the respective carbon source. The medium always consisted of Basic A, Basic B, trace 
elements, a carbon source and was filled up with ddH2O. For transposon mutant 
strains kanamycin was added in the precultures.  
Basic A 
Basic A was prepared as 5x stock solution with ddH2O. The Stock solution was 
autoclaved for sterilization. Final concentration in the medium: 
NaCl    20.0 g L-1 
Na2SO4   4.0 g L-1 
MgCl2 x 6 H2O   3.0 g L-1 
KCl    0.5 g L-1 
NH4Cl    0.25 g L-1 
KH2PO4   0.2 g L-1 
CaCl2 x 2 H2O   0.15 g L-1 
Basic B 
Basic B was prepared as 10x stock solution with ddH2O. The stock solution was sterile 
filtrated. Final concentration in the medium: 
NaHCO3   0.19 g L-1 
Trace element stock solution  
Trace elements were prepared as 1000x stock solution as follows:  
 H2O     25 mL 
 Fe(II)SO4 x 7 H2O  1.05 g 
 HCl, 25% (w/v)  6.5 mL 
 Tritiplex III (Na2EDTA) 2.6 g 
Dissolved and pH adjusted to 6.0-6.5 before adding next components. 
 H3BO3    15 mg 
 MnCl2 x 4 H2O  50 mg 
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 CoCl2 x 6 H2O   95 mg 
 NiCl2 x 6 H2O   12 mg 
 CuCl2 x 2 H2O   1 mg 
 ZnSO4 x 7 H2O  72 mg 
 Na2MoO4 x 2 H2O  18 mg 
The stock solution was filled up to 500 mL with ddH2O and sterile filtrated. 
Carbon sources 
Carbon sources were prepared as 5x stock solutions with ddH2O. pH was adjusted to 
6.5 and stock solutions were sterile filtrated. Final concentrations in the medium: 
Casamino acids  10 g L-1 
L-alanine   30 mM     
L-phenylalanine  10 mM 
L-leucine   15 mM 
L-lysine   15 mM 
L-threonine   22.5 mM 
Kanamycin stock solution 
Kanamycin was prepared as 1000x stock solution (120 mg mL-1), sterile filtered, 
aliquoted and stored at -20 °C. 
2.3.3 Solutions for HPLC analysis 
Sodium tetraphenylborate 
0.25 M sodium tetraphenylborate was prepared prior to usage for precipitation of 
ammonium. 
Eluent A (sodium acetate)  
10 mM, 25 mM or 100 mM sodium acetate was prepared prior to usage, pH was 
adjusted to 6.5 and the solution was filtered.  
Derivatization reagents 
OPA reagent (10 mg mL-1  each of O-phthalaldehyde and 3-mercaptopropoinic acid in 
0.4 M borate buffer) and FMOC reagent (2.5 mg mL-1 of 9-
fluorenylmethylchloroformate in acetonitrile) were purchased from Agilent 
Technologies (Waldbronn, Germany). One vial was opened and aliquoted prior to 
usage. Aliquots were stored at 4 °C and used for maximal 7-10 days.  Furthermore, 
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borate buffer (0.4 N, pH 10.2) was purchased from Agilent Technologies (Waldbronn, 
Germany) and stored at 4 °C. 
Injection diluent 
100 mL solution containing Na2HPO4 and Na2B4O7 (10 mM each) was prepared and 
0.4 mL concentrated H3PO4 was added. The solution was stored at 4 °C.  
Amino acid standard mix 
The purchased 1 mM amino acid standard mix (Agilent Technologies, Waldbronn, 
Germany) was diluted to obtain calibration curves in the range of 5-500 µM. The 
diluted amino acid standard was stored at -20 °C. 
Internal standard mix 
A stock solution with 1 mM norvaline and 1 mM sarcosine was prepared, aliquoted 
and stored at -20 °C. 
2.3.4 Solutions for GC-MS analysis 
Ribitol stock solution 
0.2 g L-1 ribitol stock solution was prepared, sterile filtered, aliquoted and stored at     
-20 °C.  
Methoxyamine/pyridine solution 
20 mg mL-1 methoxyamine hydrochloride (dissolved in pyridine) was prepared prior 
to use. 
Alkan time standard (retention index calibration mix) 
Decane, C10H22  12.5 mg (17.1 µL) 
Dodecane, C12H26  12.5 mg (16.7 µL)      
Pentadecane, C15H32  12.5 mg (16.2 µL) 
Nonadecane, C19H40  12.5 mg 
Docosane, C22H46  12.5 mg 
Octacosane, C28H58  12.5 mg 
Dotriacontane, C32H66 12.5 mg 
Hexatriacontane, C36H74 12.5 mg 
The alkanes were dissolved in 25 mL cyclohexane (0.5 g L-1 for each alkane). For GC-
MS measurement 6 µL of this stock solution were added to 48 µL cyclohexane. 
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2.3.5 Solutions for LC-MS analysis 
Eluent A (50 mM ammoniumformiate, pH 8.1) 
450 mL ddH2O was mixed with 943 µL formic acid. Subsequently, the pH was adjusted 
to 8.1 with 1:2 diluted ammonium hydroxide solution and filled up to 500 mL with 
ddH2O. The eluent was freshly prepared prior to use and degassed for 30 min in an 
ultrasonic bath. 
Eluent B (methanol), Eluent C (ddH2O), Eluent D (acetonitrile) 
Eluents were freshly filled up and degassed for 30 min in an ultrasonic bath prior to 
usage. 
Calibrationmix (Na-formiate cluster) 
 ddH2O    4.95 mL 
 Isopropyl alcohol  4.95 mL 
 Formic acid    10 µL 
 1 M NaOH   100 µL 
Components were mixed and stored at 4 °C. 
Sample buffer (25 mM ammoniumformiate, pH 3.5, 2% methanol) 
40 mL ddH2O were mixed with 47.2 µL formic acid. Subsequently, pH was adjusted to 
3.5 with 1:2 diluted ammonium hydroxide solution. 1 mL methanol were added and 
the solution was filled up to 50 mL with ddH2O. The buffer was stored at 4°C. 
2.4 Microbial techniques 
2.4.1 Measurement of cell density and cell dry weight 
The cell density was determined photometrically at a wavelength of 600 nm (OD600). 
Samples were diluted in Basic A if OD600 values were above 0.5. To transfer OD600 
values into cell dry weight (CDW) correlations between both values were determined. 
Cells were grown according to 2.4.2 in Erlenmeyer flasks with at least 4 biological 
replicates. Each biological replicate was harvested at a different time point to get OD-
CDW correlations over the complete growth curves. From each biological replicate 2 x 
40 mL culture volume was harvested by centrifugation (12000 x g, 5 min, 4 °C). Cells 
were resuspended in 1 mL 3.7% sodium chloride and transferred into dry, weighted 
2 mL reaction tubes. Sodium chloride was discarded after centrifugation (12000 x g, 
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5 min, 20 °C) and the cell pellets were dried to constant weight (80 °C, 72 h). 
Determined OD-CDW correlations for the different carbon sources and strains are 
listed in table 2.3. 
Table 2.3 Determined OD-CDW correlations for casamino acids and single 
amino acids. 
Carbon source Strain OD-CDW correlation 
Casamino acids 
WT OD = 2.43 * CDW – 0.23 
Δ262-kb OD = 1.70 * CDW 
tdaE (Tm2690) OD = 2.00 * CDW 
L-phenylalanine 
WT OD = 2.30 * CDW 
Δ262-kb OD = 2.07 * CDW 
tdaE (Tm2690) OD = 1.92 * CDW 
L-alanine 
WT OD = 1.87 * CDW 
Δ262-kb OD = 1.73 * CDW 
tdaE (Tm2690) not determined 
L-leucine 
WT OD = 2.61 * CDW 
Δ262-kb OD = 2.03 * CDW 
tdaE (Tm2690) OD = 2.14 * CDW 
 
2.4.2 Cultivation procedure 
Cultivations were performed in Erlenmeyer flasks with three baffles filled to 1/5 of 
their maximum volume with medium. Cultures were incubated at 28 °C and 150 rpm 
(Certomat BS-1, orbit 50 mm, Sartorius).  
For every cultivation precultures with casamino acids containing defined salt water 
medium were inoculated with colonies from MB agar plates. Second precultures 
containing defined salt water medium with the respective carbon source were 
inoculated with the casamino acids preculture to an OD600 of 0.01. Then, main cultures 
(100 mL medium in 500 mL Erlenmeyer flasks) were inoculated with the second 
preculture to an OD600 of 0.01.  
Adaptation to single amino acids 
For adaptation to single amino acids, two consecutive transfers into cultures 
containing the respective amino acids were performed starting with a casamino acids 
preculture. Glycerol stocks according to chapter 2.2 were generated from growing 
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cells of the second culture with the single amino acids. One glycerol stock was used 
for inoculation of a preculture with defined salt water medium containing the 
respective single amino acid. Then, main cultures were inoculated with growing cells 
from the preculture.  
Cultivation of transposon mutant strains 
For cultivation of transposon mutant strains 120 μg mL-1 kanamycin was added to the 
medium in the precultures. Main cultures were then realized without addition of 
antibiotics. 
Medium exchange  
For the medium exchange experiment (chapter 3.2.2), cultivations were performed in 
250 mL Erlenmeyer flasks containing 50 mL defined salt water medium with 
casamino acids as carbon source. At about ½ ODmax, cultures were transferred into 
50 mL reaction tubes and harvested by centrifugation. Culture supernatants were 
sterile filtered and cells were resuspended in either their own (references) or the 
culture supernatant of another strain. Subsequently, cultivation was continued and 
growth was determined by OD measurement for calculation of linear growth rates 
(figure 2.1). 
 
Figure 2.1 Medium exchange experiment. Shown is the scheme for the exchange of 
culture supernatant between the wild-type and TDA-free mutant strains. Arrows 
indicate the medium (red: with TDA, grey: without TDA).  
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2.4.3 Determination of growth parameters 
Specific growth rate µ 
The specific growth rate µ is the increase of biomass over time: 
μ =  ∙ 1                                                           (1) 
Integration yields: 
μ = () − () −                                                    (2) 
Thus, the specific growth rate µ is constant over the exponential growth phase and µ 
was determined by a linear fit of the logarithmized CDW value over time. For cultures 
growing not exponentially, µ was determined by fitting the logarithmized growth 
curve followed by differentiation of the fit using OriginPro 2016G yielding specific 
growth rates µ (h-1) at each specific time point.  
Linear growth rate µlin 
Additionally, the linear growth rate µlin (g L-1 h-1) was determined for cultures 
showing a section with linear growth achieved by linear fits of the CDW values over 
time. 
Specific substrate uptake rate qS 
The specific substrate uptake rate is described by formula 3. 
!" = [$] ∙ 1                                                       (3) 
Due to the changing specific growth rate of cultures growing not exponentially, the 
specific substrate uptake rates were also not necessarily constant. Thus, the substrate 
uptake rate was determined by differentiation of the fitted substrate concentrations. 
Afterwards, the determined substrate uptake rates (mmolS L-1 h-1)  were related to 
the CDW at the specific time point yielding the specific substrate uptake rate qS 
(mmolS gCDW-1  h-1). 
Biomass yield YX/C 
The biomass yield YX/C is defined as produced CDW per mol carbon. Therefore, the 
consumed carbon was determined by measurement of the substrate and transfer of 
molsubstrate into molcarbon.  
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2.4.4 Online measurement of dissolved oxygen 
Erlenmeyer flasks with attached optical oxygen sensor spots (SP-PSt3-YAU-D7-YOP; 
PreSens, Regensburg, Germany) were used for determination of the oxygen 
consumption. The incubator was equipped with an online oxygen monitoring device 
(Shake Flask Reader; PreSens, Regenburg, Germany) and dissolved oxygen (DO) was 
measured based on fluorescing quenching (Schneider et al. 2010). Data acquisition 
was carried out with the Shake Flask Reader Software v2.0.0 (PreSens, Regenburg, 
Germany). Measured DO as % air saturation was transferred into absolute 
concentrations with an estimation of the oxygen solubility in the used salt water 
medium to 6.8 mg L-1 based on values for different temperatures and salt 
concentrations (PreSens, Regensburg, Germany). Oxygen transfer rates (OTR) were 
determined for each data point according to formula 4. Oxygen uptake rates (OUR) 
were then calculated with formula 5 and a kLa value of 132 h-1 which was estimated 
with the Presens kLa Calculator (PreSens, Regensburg, Germany). 
'() = ['*]                                                               (4) 
',) = -./ ∙ (['*∗] − ['*]) − '()                                            (5) 
For selected data points calculated OUR in mmolO2  L-1 h-1 were referred to the 
associated CDW to obtain the respective specific oxygen uptake rate qO2 in 
mmolO2  gCDW-1  h-1. Absolute oxygen consumption (mmolO2  gCDW-1 ) at the specific time 
point was calculated with the respective growth rate (h-1). 
2.4.5 Determination of biomass composition 
For determination of the biomass composition cells of 6 biological replicates were 
harvested and centrifuged at 4 °C and 10000 x g for 5 min. Supernatant was discarded 
and cells were resuspended in 3.7% sodium chloride. Suspended cells were split to 
get 1-3 mg CDW for DNA, RNA, protein content, protein composition and PHB each, 
10-30 mg for lipid and 10-30 mg for determination of CDW, followed by 
centrifugation. Supernatant was discarded and cell pellets were frozen in liquid 
nitrogen. Cell pellets for determination of lipids were resuspended in 1.5 mL 
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methanol prior to freezing. Cell pellets for determination of CDW were resuspended 
in 1 mL 3.7% sodium chloride and transferred into dried weighted 2 mL reaction 
tubes and were dried for 72 h at 80°C.    
Protein content 
Cells were resuspended in protein lysis buffer (0.5 M NaOH, 2% SDS). Volume of lysis 
buffer was adjusted to harvested CDW to obtain a final concentration of 1 gCDW L-1. 
Resuspended cells were incubated at 80 °C for 30 min in an ultrasonic bath followed 
by centrifugation (12000 x g, 5 min, 20 °C). Cell lysate was diluted 1:5 with ddH2O. 
Protein concentration in the cell lysate was determined using the Bicinchoninic acid 
Protein Assay Kit (Sigma-Aldrich, Germany). A calibration curve with bovine serum 
albumin was prepared for each measurement in 96-well plates using the Tecan 
infinite Reader (Tecan GmbH, Germany). 
DNA 
Isolation of DNA was performed using the Genomic DNA from tissue Kit 
(Macherey&Nagel, Düren, Germany) according to the protocol of the manufacturer. 
The isolated DNA was quantified by measuring the absorbance at 260 using Tecan 
NanoQuant Plate (Tecan GmbH, Germany). 
RNA 
Isolation of RNA was performed using the RNA Isolation Kit (Macherey&Nagel, Düren, 
Germany) according to the protocol of the manufacturer with minor modification. 
Homogenization was performed for 10 min at room temperature to minimize 
degradation of RNA. The isolated RNA was quantified by measuring the absorbance 
at 260 using Tecan NanoQuant Plate (Tecan GmbH, Germany). 
Lipids 
The lipid content was determined by extraction with methyl-tert-butyl ether (MTBE) 
adapted from Matyash et al. (2008). Cell lysis was performed at 70 °C for 15 min in an 
ultrasonic bath. 5 mL MTBE was added and incubated for 1 h at room temperature 
under shaking. Then, 1.25 mL ddH2O was added followed by incubation for another 
10 min at room temperature and shaking. Phase separation was conducted by 
centrifugation (10 000 x g, 10 min, 20 °C). The upper organic phase was transferred 
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step by step into dried, weighted glas vials and dried under vacuum and with rotation. 
A mix of 1.29 mL MTBE and 0.387 mL methanol was added to the bottom phase and 
was incubated for 1 h at room temperature under shaking. Subsequently, 0.323 mL 
ddH2O was added, incubated for another 10 min (room temperature, shaking), 
centrifuged (10 000 x g, 10 min, 20 °C) and the upper organic phase was added to the 
prior dried organic phase. Lipids were quantified by determination of difference in 
weight of the dried vials with and without lipids. 
Polyhydroxybutanoate (PHB) 
For hydrolyzation of polyhydroxybutanoate (PHB) cell pellets were resuspended in 
1 mL 2 M NaOH and incubated at 95 °C and 350 rpm for 60 min. The suspension was 
neutralized with 1 mL 2 M HCl and centrifuged for 5 min and 12 000 x g. The content 
of 3-hydroxybutanoate in the lysate was then quantified with the D-3-Hydroxybutyric 
acid enzymatic assay (r-biopharm, Darmstadt, Germany). 
Protein composition and peptidoglycan 
For determination of protein composition and estimation of peptidoglycan content, 
cells were hydrolyzed with 200 µL 6 M HCl for 24 h at 95 °C followed by neutralization. 
Amino acids of the proteins and total diaminopimelate were quantified by HPLC-FLD 
(chapter 2.5).  
2.4.6 Cell harvesting for metabolome analysis 
Harvesting for cultivations in processed-controlled bioreactors (chapter 3.1.1-3.1.3) 
were performed as previously described (Zech et al. 2013a) by the working group of 
Prof. Ralf Rabus (ICBM). 
For analyses in Erlenmeyer flasks, cultures were grown according to chapter 2.4.2 
with the strains and carbon source of interest. Cells were harvested in 50 mL reaction 
tubes by centrifugation (12 000 x g, 3 min, 4 °C). For cells growing on L-lysine as sole 
carbon source the first centrifugation step was performed in 250 mL bottles with 
30 000 x g for 10 min at 4 °C (Beckmann Coulter, Krefeld, Germany) followed by 
transfer of the cells into 50 mL reaction tubes. 1 mL of the supernatant was 
transferred into 2 mL reaction tubes and stored at -20 °C. The remaining supernatant 
was discarded. Cell pellets for LC-MS analyses were resuspended in 1 mL methanol, 
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frozen in liquid nitrogen and stored at -80 °C. Cells for GC-MS analysis were washed 
twice with 20 mL ice cold 3.7% NaCl with centrifugation steps of 3 min at 4 °C and 
12 000 x g.  Afterwards cell pellets were frozen in liquid nitrogen and stored at -80 °C. 
At least 20 mg CDW for GC-MS and 10 mg CDW for LC-MS analyses were harvested. 
Higher amounts were harvested as backup if sufficient amount of biomass was 
available. Harvesting volume was calculated by OD-CDW correlations (table 2.3). 
2.5 Amino acid analysis by HPLC-FLD 
2.5.1 Sample preparation 
To precipitate ammonia in the samples, 100 µL 0.25 M sodium tetraphenylborate 
were added to 100 µL of the sample, mixed vigorously for 5 min and centrifuged 
(10 min, 12 000 x g, 20 °C). When necessary, the clear supernatant was diluted in 
ddH2O prior to analysis.  
Cell hydrolysates were filtered to remove residual cell fragments. 
2.5.2 HPLC-FLD analysis 
Amino acids were quantified with a 1260 Infinity HPLC system equipped with a 
fluorescence detector (Agilent Technologies, Waldbronn, Germany). Separation was 
conducted with a Poroshell HPH-C18 separation column (4.6 x 100 mm, particle size 
2.7 mm; Agilent Technologies, Germany). Derivatization of the amino acids were 
performed online in the sample loop with OPA and FMOC as derivatization reagents 
prior to injection as follows: 2.5 µL borate buffer was mixed with 1 µL sample and 
0.1 µL internal standard followed by incubation with 0.5 µL OPA reagent and 
afterwards with 0.4 µL FMOC reagent. To stop derivatization 32 µL injection diluent 
was drawn, mixed and then 20 µL were injected. Separation was performed at 25 °C 
with a flow rate of 1.5 mL min-1. Gradients were adjusted depending on the used 
concentration of sodium acetate (table 2.4). Fluorescence of OPA derivatives were 
measured with an excitation wavelength of 340 nm and an emission wavelength of 
450 nm. After elution of lysine, wavelengths were switched to detect FMOC 
derivatives (excitation 266 nm, emission 305 nm).   
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Table 2.4 Gradients for amino acid analysis for different used sodium acetate 
concentrations (100 mM, 25 mM, 10 mM). Listed are the runtime with 
corresponding % of mobile phase A (sodium acetate) and B (acetonitrile). 
100 mM  25 mM  10 mM 
min % A % B  min % A % B  min % A % B 
0.00 97 3  0.00 97 3  0.00 97 3 
5.30 97 3  5.30 97 3  5.30 97 3 
5.35 94 6  5.35 96 4  5.35 94 6 
10.00 90 10  10.00 93 7  10.00 93 7 
11.00 90 10  12.00 85 15  11.00 93 7 
12.00 85 15  22.00 85 15  12.00 85 15 
25.00 85 15  22.50 75 25  22.00 85 15 
35.00 65 35  24.50 75 25  22.50 75 25 
35.10 0 100  27.00 70 30  24.50 75 25 
38.00 0 100  27.10 0 100  27.00 70 30 
    30.00 0 100  27.10 0 100 
        30.00 0 100 
For analyses of single amino acids, the method was shortened to 20 min with a 
gradient as follows: 15 min from 3% B to 30% B followed by 2 min increasing B to 
100% and 3 min isocratic at 100% B. Furthermore, derivatization procedure was 
conducted without FMOC reagent because only OPA derivatives were analyzed.   
2.6 Analysis of polar metabolites by GC-EI-MS 
2.6.1 Sample preparation 
Extraction of intracellular metabolites 
Cell pellets were resuspended in methanol containing 4% ribitol stock solution. 
1.5 mL of the methanol/ribitol solution was used per 20 mgCDW. Cell lysis was 
performed in an ultrasonic bath for 15 min at 70 °C followed by cooling on ice. 1.5 mL 
ddH2O per 20 mgCDW was added and mixed vigorously for 1 min. Then, 1 mL 
chloroform was added followed by another 1 min of mixing for extraction of non-polar 
compounds. Phase separation was conducted by centrifugation (12 000 x g, 5 min, 
4 °C). 500 µL of the polar phase was transferred into glass vials, dried in a vacuum 
concentrator with rotation at 4°C, capped and stored at -20 °C until GC-MS analysis. 
The residual polar phase was transferred into 2 mL reaction tubes and stored at -80 °C 
as backup samples.  
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Preparation of culture supernatants 
10 µL of the culture supernatants were transferred into glas vials and spiked with 
200 µL of ethanol containing 3.5% ribitol stock solution (193 µL ethanol + 7 µL 
ribitol). The samples were dried in a vacuum concentrator with rotation at 4°C, 
capped and stored at -20 °C until GC-MS analysis. 
Derivatization procedure 
The two-step automated derivatization was performed prior to injection with the MPS 
2 XL autosampler equipped with a mVorx unit (Gerstel, Mülheim a.d. Ruhr, Germany) 
coupled to the Leco Pegasus 4D GC x GC TOF MS (Leco Instruments, 
Mönchengladbach, Germany). 40 µL methoxyamine/pyridine solution were added to 
the dried samples, mixed at 1300 rpm for 1 min with the mVorx unit and incubated 
for 90 min at 30 °C with constant agitation. In this step carbonyl groups are 
substituted with a methoxyl group. Then, silylation of amino- and hydroxyl groups 
was achieved by adding 60 µL MSTFA and incubation for 30 min at 37 °C under 
constant shaking followed by 1 h incubation at 18 °C without shaking. 
2.6.2 GC-EI-MS analysis 
Samples were analyzed using a Leco Pegasus 4D GC x GC TOF MS (Leco Instruments, 
Mönchengladbach, Germany) equipped with a MPS 2 XL autosampler (Gerstel, 
Mülheim a.d. Ruhr, Germany) and operated in GC-TOF mode. 1 µL of the sample was 
injected into a programmed temperature vaporizing (PTV) injector (Gerstel, Mülheim 
a.d. Ruhr, Germany) equipped with a 71 x 1 mm CIS 4 glass liner filled with silanized 
glass wool. Injection was performed in splitless mode. Vaporizing was conducted with 
initial 70 °C for 0.02 min and stepwise increase with 12 K s-1 up to 330 °C followed by 
5 min at a constant temperature of 330 °C. Separation was conducted with a 7890 
Agilent GC equipped with a ZB-5MS column (Phenomenex, Aschaffenburg, Germany) 
or a DB5MS (Agilent Technologies, Waldbronn, Germany) and a constant helium flow 
of 1.2 or 1.8 mL min-1. The temperature of the transfer line was set to 275 °C. 
Inoization was performed with an electron impact mode at 70 eV and an ion source 
temperature of 250 °C. The detector voltage was adjusted to the daily performance of 
the instrument (about 200 V higher than the output of automatic tuning). Solvent 
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delay was adjusted according to the deterioration of the column. Full mass spectra 
were collected from 45 to 600 m/z with 8 scans/s. 
2.6.3 GC-EI-MS data processing and analysis 
Raw data was exported using the ChromaTOF software as NetCDF (network common 
data format) files. Data were further processed with the software MetaboliteDetector 
(Hiller et al. 2009). The by Christian Nieke (TU Braunschweig) further developed 
version 2.2N-2013-01-15 was used for all analyses. The software automatically 
deconvolutes all mass spectra from the imported chromatograms and calculates the 
retention indices (RI) based on formula (6) using the measured alkane mix as RI 
marker. 
)5(6) = 100 ∙ 8(9 − :) ∙ ; <=(>) − <=(?)<=@AB − <=(?)C + :E                           (6) 
   with RI(T) = retention index in a temperature gradient, 
  x = number of carbon atoms of the alkane eluting before the analyte, 
  y = number of carbon atoms of the alkane eluting after the analyte, 
  ti = retention time of the analyte, 
  tx = retention time of the alkane eluting before the analyte, 
  ty = retention time of the alkane eluting after the analyte. 
Additionally, the calculated RIs of the analytes were corrected by alignment to the 
internal standard ribitol. Automatic identification of compounds was achieved by 
comparison of mass spectra and RI with a defined library and a cut-off score for 
similarity of 70%. Quantification was performed with an appropriate, specific 
fragment ion for the respective compound. The library also includes unidentified 
compounds which were reproducibly detected in different strains analyzed at the 
institute labeled with the prefix “Unknown”. Unidentified compounds originated from 
the Golm Metabolome Database are labeled with the prefix “NA” or “D”. 
Data were checked and if necessary peak areas were added manually. The data were 
normalized to the peak area of the internal standard ribitol. The different derivatives 
of one compound were summed using the institute intern script itool. 
2.6.4 Statistical data analysis 
Significance test was conducted with OriginPro 2016G using the implemented non-
parametric Wilcoxon-Mann-Whitney test (Mann, Whitney 1947). Differences 
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between two conditions were regarded as significant for p-values < 0.001. 
Furthermore, fold changes (quotient of the mean values “test state” and “reference 
state”) were calculated and values ≥ 2 or ≤ 0.5 were considered when the Wilcoxon-
Mann-Whitney test was significant. Errors of fold changes (fc) were determined using 
propagation of uncertainty (formula 7). 
GH(IJ) = KL; GH()MN/()C
* + ; GH(O)MN/(O)C
*P ∙ ;MN/()MN/(O)C                       (7) 
  with t = test state, 
  r = reference state, 
  se = standard error 
2.7 Analysis of CoA derivatives by LC-ESI-MS 
2.7.1 Extraction of CoA-esters 
10 mg CDW were harvested and resuspended in 1 mL methanol. The suspension was 
transferred into 2 mL reaction tubes containing 0.6 g glass beads (70 - 110 µM 
diameter). Cell lysis was realized with the oscillating mill MM400 (Retsch GmbH, 
Haan, Germany) using -80 °C cold milling cups for 2 mL reaction tubes. Three cycles 
of 1 min and 30 Hz were carried out for homogenization. The lysate was transferred 
into 15 mL reaction tubes containing 10 mL ice cold ammonium acetate (25 mM, 
pH 6), centrifuged for 5 min at 10 000 x g and 4 °C and stored on ice until solid phase 
extraction. 
The solid phase extraction columns Strata XL-AW (Phenomenex, Aschaffenburg, 
Germany) were conditioned by sequential application of 1 mL methanol, 1 mL 
methanol/water/formic aicd (50:45:5) and 1 mL water. The supernatants of the cell 
lysates were loaded onto the conditioned columns with 800 – 900 mbar vacuum. 
Afterwards, the columns were washed with 1 mL ammonium acetate (25 mM) and 
1 mL methanol and dried at 700 mbar for 5 min. Elution was performed using 1 mL 
methanol containing 0.5 % ammonia. Subsequently, the samples were dried in a 
vacuum concentrator with rotation at 4 °C and stored at -80 °C until measurement.  
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2.7.2 LC-ESI-MS analysis 
For measurement, the samples were dissolved in 200 µL sample buffer and 
transferred into vials for HPLC. Analysis was performed on a Dionex ultimate 3000 
system (Thermo Scientific Inc., Schwerte, Germany) coupled to a Bruker MicroTOF 
QII mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany) equipped with an 
electrospray ionization interface. 50 µL of the sample were injected and separated 
based on the protocol described by Peyraud et al. (2009) with a C18 analytical column 
(Gemini 150 x 2.0 mm, particle size 3 µm; Phenomenex, Aschaffenburg, Germany) at 
35 °C and a flow rate of 220 μL min-1. Following stepwise gradient was applied: 0-1 
min 5% B, 1-19 min increase to 30% B, 19-26 min increase to 95%B, 26-30 min 95%B 
followed by reequilibration of the column. MS analysis was performed in ESI+ mode 
with a rate of 3 Hz for data acquisition and automated MS/MS acquisition. Mass range 
was set to m/z 90-1178 with an end plate offset of -500 V and capillary voltage of 
4500 V. Nebulizer pressure of 1.2 bar, dry gas flow rate of 8 L min-1 and dry 
temperature at 200 °C were used.  
2.7.3 LC-ESI-MS data processing and analysis 
The raw data was recalibrated to the sodium formate cluster and data was exported 
as MZXML files using DataAnalysis automation scripting (Bruker Daltonic, Bremen, 
Deutschland). Peak detection and alignment was conducted with the R package XCMS.  
Identification of CoA derivatives was conducted by comparison of the accurate masses 
and retention times with commercial available coenzyme A standards. Furthermore, 
sum formula predictions were performed for unidentified compounds using 
SmartFormula implemented in the DataAnalysis software.  
2.8 Transcriptomic analysis 
Transcriptomic analyses were conducted by the group of Robert Geffers (Helmholtz 
centre for infection research, Braunschweig) using RNA-seq technology. The quality 
and integrity of total RNA was controlled on Agilent Technologies 2100 Bioanalyzer 
(Agilent Technologies, Waldbronn, Germany). The RNA sequencing library was 
generated from 100 ng total RNA using TruSeq RNA Sample Prep Kits v2 (Illumina) for 
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mRNA purification followed by ScriptSeq v2 RNA-Seq Library Preparation Kit 
(Epicentre) according to manufacturer’s protocols. The libraries were sequenced on 
Illumina HiSeq2500 using TruSeq SBS Kit v3-HS (50 cycles, single ended run) with an 
average of 3 x 107 reads per RNA sample. The data was provided as Rockhopper output 
(expression levels). 
2.9 Metabolic model reconstruction 
2.9.1 Metabolic Pathways 
The metabolic model iPin571 was reconstructed based on genome and experimental 
data (Thole et al. 2012; Berger et al. 2012; Berger et al. 2011; Brock et al. 2014; 
Drüppel et al. 2014; Wiegmann et al. 2014; Zech et al. 2013a; Zech et al. 2013b; Zech 
et al. 2009). The web service EnzymeDetector was used for prediction of enzyme 
functions for implemented reactions (Quester and Schomburg 2011). The bottom-up 
approach was used to reconstruct the model step-by-step from central carbon 
metabolism up to all necessary biosynthetic pathways and known degradation 
pathways for 32 different substrates including 20 amino acids, some carbohydrates 
and further carboxylic acids. TDA biosynthesis was included as overall reaction based 
on the published proposed biosynthesis pathway by Brock et al. (2014). Non-
sequenced based reactions were added to fill necessary gaps in the model. The model 
was checked for internal cycles and reversibility was changed if necessary.  
The inhouse program simia (Rex 2013), further developed by Helge Stark, was used 
to export reactions based on EC numbers from the database BKM-react (Lang et al. 
2011) and transfer them into the metano format (Riemer 2013). Reactions which 
were not included in one of the databases were manually added to the model.  
2.9.2 Biomass composition 
The biomass reaction includes experimental, literature and genome data. The content 
of DNA, RNA, protein, PHB and lipids were experimentally determined as described 
in chapter 2.4.5. Total concentrations of amino acids and diaminopimelate (free and 
bonded) in cell hydrolysates were determined by HPLC-FLD measurement (chapter 
2.5).  
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The content of peptidoglycan was estimated with the assumption that total 
diaminopimelate is bonded in the peptidoglycan. For the protein composition 
determined glutamate and alanine were corrected for the content in peptidoglycan 
based on diaminopimelate. Furthermore, glutamate was corrected for intracellular 
levels based on quantification for D. shibae by Kleist et al. (2016). Estimation of 
asparagine, glutamine, tryptophan and cysteine was based on ratio assumptions in 
the protein sequence.  
The shares of nucleotides in DNA and RNA were estimated based on GC-content. 
Further biomass components were estimated based on literature data (table S15). 
2.9.3 Determination of GAM and NGAM 
Growth rates µ and specific substrate uptake rates qS were determined as described 
in chapter 2.4.3. The qS were referred to 1 mol carbon. Thus, an amino acid 
overarching determination of GAM and NGAM with TDA-free cultivations was 
possible (see chapter 3.3.5).  
NGAM is included as separate ATP hydrolyzation reaction. GAM is included as ATP 
hydrolyzation in the biomass reaction. 
2.10 In silico analyses 
FBAs were performed with the metano software (Riemer 2013) to calculate optimal 
biomass production with experimentally determined substrate uptake rates qS. 
Maximal possible ATP yields were determined by optimizing NGAM reaction instead 
of the biomass reaction. The upper bound of the biomass reaction was set to the 
experimentally determined growth rate for calculations of TDA dependent carbon 
flux.  
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3 Results and discussion 
3.1 Metabolic role of the 262-kb plasmid 
The 262-kb plasmid encodes several genes with a variety of functions including 
transporter for substrates and dipeptides as well as biosynthesis genes for an 
exopolysaccharide and the antibiotic TDA. First studies with plasmid-cured mutant 
strains and casamino acids as substrate showed that the deletion of the 262-kb 
plasmid led to a higher growth efficiency associated with higher amino acid 
consumption compared to the wild-type strain (Hensler 2014). All possible mutant 
strains missing one (Δ262-kb, Δ78-kb, Δ65-kb), two (Δ262Δ78-kb, Δ262Δ65-kb, 
Δ78Δ65-kb) or all three (Δ262Δ78Δ65-kb) plasmids were cultivated in process-
controlled bioreactors in collaboration with the working group of Prof. Dr. Ralf Rabus 
(ICBM, Oldenburg) for physiological analyses. Furthermore, a systems biology 
approach of the Δ262-kb mutant strain was performed in process-controlled 
bioreactors to get a deeper understanding of the function of the 262-kb plasmid. 
Cultivation in process-controlled bioreactors and sampling were performed by the 
working group of Prof. Dr. Ralf Rabus (ICBM, Oldenburg). Here, the results on 
metabolic level will be discussed and compared with changes on transcriptomic level.  
Data for analysis of growth physiology of plasmid-cured mutant strains were 
published in Trautwein et al. (2016). The observation of L-pipecolate as L-lysine 
degradation intermediate was published in Will et al. (2017) and Reimer et al. (2017). 
3.1.1 Growth physiology of plasmid-cured mutant strains 
Growth characteristics at ODmax were compared for all plasmid-cured mutant strains 
and the wild-type strain to analyze the effect on the growth behavior of lacking single, 
double or all three plasmids. Maximally reached optical densities (OD) and cell dry 
weights (CDW) were dependent on the available plasmids (figure 3.1). Deletion of the 
262-kb plasmid led to more than 2-fold higher CDWs. Maximal OD values were not 
correlating with maximal CDW values which might be due to disturbance of OD 
measurement by nonviable cells and the production of an exopolysaccharide. Thus, 
only trends are identifiable but not exact differences as determination of living cells 
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would be necessary. It is noticeable that the deletion of the 65-kb or the 78-kb plasmid 
only, did not influence the maximally reached CDW compared to the wild-type strain. 
The 65-kb plasmid is known as the “biofilm plasmid” as it is required for biofilm 
formation, motility and the colonization of marine algae (Frank et al. 2014). In 
process-controlled bioreactors, P. inhibens DSM 17395 does not grow in biofilms. 
Consequently, the smallest plasmid is not crucial which is represented by the similar 
CDW values. However, the Δ65-kb mutant strain depleted less available carbon 
compared to the wild-type strain. Thus, the lack of the biofilm-related polysaccharide 
production increased the biomass yield but not the maximally reached CDW. This 
effect is only slightly observable between the Δ262-kb and the Δ262Δ65-kb mutant 
strains. In previous studies with Erlenmeyer flask cultivations the difference between 
both strains was more pronounced (Hensler 2014).  
 
Figure 3.1 Growth characteristics at ODmax of the wild-type and plasmid-cured 
mutant strains for cultivation in process-controlled bioreactors with casamino 
acids as carbon source. Shown are maximal OD (red) and CDW (grey) values with 
corresponding mmolC L-1 (provided by amino acids) left in the medium (blue). 
Cultivation, sampling and measuring of OD and CDW were performed by the working 
group of Ralf Rabus (ICBM) (Trautwein et al. 2016). 
For the Δ78-kb mutant strain similar amounts of carbon were detected in the 
supernatant compared to the Δ65-kb mutant strain. However, lacking the 78-kb 
plasmid led to secretion of glycine due to the missing glycine cleavage system (Zech 
et al. 2013b). Threonine, which is degraded via glycine (Drüppel et al. 2014), is 
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exported as glycine leading to higher glycine levels at ODmax compared to the initial 
medium. Besides the necessity for glycine catabolism the 78-kb plasmid encodes the 
only known copy for the catalase (PGA1_78p00050). Thus, this plasmid might be 
important for detoxification of reactive oxygen species. Comparison of mutant strains 
lacking the 78-kb plasmid with the other strains is difficult due to the secreted glycine 
and different ratios between ODmax and CDWmax values. As mentioned above, 
determination of living cells would be necessary because the missing detoxification 
by the catalase might increase the number of nonviable cells.  
Analysis of the plasmid-cured mutant strains revealed one important information: the 
262-kb plasmid shows a growth restriction effect leading to stop of growth even 
though there are still amino acids left in the medium. Thus, the 262-kb plasmid plays 
the key role in growth differences with casamino acids as carbon source and will be 
analyzed in the following.  
3.1.2 Metabolome analysis of the Δ262-kb plasmid-cured mutant strain 
compared to the wild-type strain 
Metabolome analysis was performed for cells harvested at ½ ODmax and ODmax of the 
wild-type strain and the Δ262-kb plasmid-cured mutant strain, respectively. Different 
unidentified compounds were only detectable in the Δ262-kb mutant strain (figure 
3.2 A and C) and will be discussed in chapter 3.1.3. Besides these unidentifed 
compounds there are only a few noticeable differences in the metabolome at ½ ODmax. 
Higher amounts of pipecolate and cadaverine but smaller amounts of 2-aminoadipate 
were detected when the 262-kb plasmid was missing (figure 3.2 A). Furthermore, 5-
aminopentanoate was lower in the Δ262-kb mutant strain at ODmax (figure 3.2 C). 
Cadaverine, 5-aminopentanoate and 2-aminoadipate are intermediates of L-lysine 
catabolism of P. inhibens DSM 17395 (Drüppel et al. 2014). Pipecolate was 
accumulating over time in the Δ262-kb mutant strain until ODmax (figure 3.2 A and C). 
It was about 3.5-fold higher in the Δ262-kb mutant strain at ½ ODmax (table 3.1) and 
about 5-fold higher at ODmax (table 3.2) compared to the wild-type strain. 
Furthermore, pipecolate was already secreted at ½ ODmax by the Δ262-kb mutant 
strain while it was only detected in smaller amounts in the wild-type strain 
supernatant at ODmax (figure 3.2 B and D). A degradation pathway of L-lysine via 
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pipecolate was found to be active in Pseudomonas putida KT2440 (Revelles et al. 
2005) but is not yet described for P. inhibens DSM 17395 and will be discussed in 
chapter 3.1.4.   
 
Figure 3.2 Comparison of intracellularly and extracellularly detected 
metabolites by GC-MS analysis in the wild-type and Δ262-kb plasmid-cured 
mutant strains at ½ ODmax and ODmax with casamino acids as carbon source 
(process-controlled bioreactors). Shown are logarithmized, normalized peak areas 
of intracellularly (A and C) and extracellularly (B and D) detected metabolites for cells 
harvested at ½ ODmax (A and B) and ODmax (C and D). Values of the Δ262-kb mutant 
strain are plotted over the wild-type strain. Shown are mean values of four biological 
replicates with standard errors. Metabolites detected only in one strain are labeled in 
blue. Furthermore, metabolites with significantly higher (green) and significantly 
lower (red) abundance in the Δ262-kb mutant strain are highlighted. All detected 
metabolites are listed in table S1 (intracellular) and S2 (extracellular). Cultivation and 
sampling were performed by the working group of Ralf Rabus (ICBM). PEP: 
phosphoenolpyruvate. 
Higher amounts of dipeptides, e.g. glycylproline and glycylglycine, in the Δ262-kb 
mutant strain could be related to missing genes coding for dipeptide transport 
relating proteins (table S4). Serine, as the precursor for cysteine biosynthesis, was 
about 2.7-fold higher in the Δ262-kb the mutant strain at ½ ODmax (figure 3.2 A, table 
3.1). At ODmax serine was lower, but cysteine was about 17-fold higher in the Δ262-kb 
mutant strain because it was only detectable in one of the wild-type replicates (figure 
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3.2 C, table 3.2). Cysteine is discussed as one possible source for the incorporation of 
sulfur in TDA catalyzed by enzymes encoded on the 262-kb plasmid (Brock et al. 
2014). Thus, cysteine is maybe produced in higher amounts than necessary in the 
Δ262-kb mutant strain which led to accumulation at ODmax. 
Table 3.1 Fold changes of selected intracellularly detected metabolites at ½ 
ODmax with casamino acids as carbon source (process-controlled bioreactors). 
Shown are metabolites with fold changes ≥2.0 or ≤0.5 compared to the wild-type 
strain and p-values < 0.001 (Wilcoxon-Mann-Whitney test). Metabolites only detected 
in the Δ262-kb mutant strain are listed with “+”. Fold changes with corresponding p-
values for all metabolites are listed in table S3. Cultivation and sampling were 
performed by the working group of Ralf Rabus (ICBM). 
Higher abundance in  
Δ262-kb mutant strain 
Lower abundance in  
Δ262-kb mutant strain 
Metabolite Fold change Metabolite Fold change 
D200302_2009.31 + 2-aminoadipate 0.12 ± 0.02 
NA714 + Uric acid 0.45 ± 0.03 
Unknown#2442.5-pin-
mhe_059 
+ Tyrosine 0.46 ± 0.03 
Cadaverine 7 ± 2 Putrescine 0.46 ± 0.06 
Glycylproline 5 ± 1 2-isopropylmalate 0.50 ± 0.04 
Phosphoenolpyruvate 4.6 ± 0.7   
Pipecolate 3.5 ± 0.1   
Serine 2.7 ± 0.1   
NA_1703.1 2.2 ± 0.2   
Phosphoenolpyruvate was about 4.6-fold more abundant in the Δ262-kb mutant 
strain compared to the wild-type strain at ½ ODmax (figure 3.2 A, table 3.1). The Δ262-
kb mutant strain already depleted the complete available aspartate (figure 3.3) which 
can be easily degraded via oxaloacetate to phosphoenolpyruvate to feed 
gluconeogenesis. Thus, a higher phosphoenolpyruvate level is explainable by the 
higher aspartate consumption.  
Previous studies showed a time-resolved utilization of the available amino acids by 
P. inhibens DSM 17395 (Zech et al. 2013b).  Zech et al. (2013b) divided the amino acids 
in four groups according to their depletion rate. Thus, different amino acids 
availability could have an influence on the metabolome at ½ ODmax and ODmax. Besides 
aspartate, also glycine is almost completely consumed at ½ ODmax by the Δ262-kb 
mutant strain (figure 3.2 B, figure 3.3). These two amino acids are also preferred by 
the wild-type strain while all other amino acids were not completely depleted. 
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Especially glutamate and alanine as easy accessible amino acids were not completely 
consumed by the wild-type strain, which indicates a massive growth restriction by 
the 262-kb plasmid as previously mentioned (chapter 3.1.1). 
Table 3.2 Fold changes of selected intracellularly detected metabolites at ODmax 
with casamino acids as carbon source (process-controlled bioreactors). Shown 
are metabolites with fold changes ≥2.0 or ≤0.5 compared to the wild-type strain and 
p-values < 0.001 (Wilcoxon-Mann-Whitney test). Metabolites only detected in the 
Δ262-kb mutant strain are listed with “+” and metabolites only detected in the wild-
type strain with n.d. (not detected). Fold changes with corresponding p-values for all 
metabolites are listed in table S3. Cultivation and sampling were performed by the 
working group of Ralf Rabus (ICBM). 
Higher abundance in  
Δ262-kb mutant 
Lower abundance in  
Δ262-kb mutant 
Metabolite Fold change  Metabolite Fold change 
NA714 + Homoserine n.d. 
D200302_2009.31 + 
Unknown#2260-cgl-
sst_001 
n.d. 
Glycylproline + Isoleucine 0.15 ± 0.03 
Cysteine 17 ± 17 2-isopropylmalate 0.15 ± 0.02 
Unknown#2557.6-
pin-mhe_067 
7 ± 1 Leucine 0.17 ± 0.03 
Glycylglycine 5 ± 1 2,6-diaminopimelate 0.21 ± 0.04 
Pipecolate 4.9 ± 0.4 Tyrosine 0.25 ± 0.03 
Lysine 2.4 ± 0.3 2-Aminoadipate 0.27 ± 0.02 
3-Hydroxybutanoate 2.3 ± 0.4 5-Aminopentanoate 0.28 ± 0.06 
Ethanolamine 2.2 ± 0.3 Phenylalanine 0.28 ± 0.04 
  NA199017_1996.71 0.29 ± 0.05 
  Glutarate 0.30 ± 0.03 
  2,4-diaminobutanoate 0.30 ± 0.08 
  Serine 0.35 ± 0.04 
  Alanine 0.38 ± 0.06 
  Alanyl-alanine 0.41 ± 0.03 
  Putrescine 0.41 ± 0.06 
  Malate 0.42 ± 0.05 
Interestingly, the classification groups of Zech et al (2013b) are not entirely reflecting 
the observed depletion order. Here, only 50% of arginine and lysine were used by the 
Δ262-kb mutant strain and even less by the wild-type strain. This could indicate a 
problem with excess nitrogen since both amino acids provide more nitrogen 
compared to the other available amino acids. Furthermore, arginine and lysine are 
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alkaline amino acids. Glutamate and aspartate as acidic amino acids were completely 
depleted by the Δ262-kb mutant. Thus, uptake of alkaline substrates might be limited 
due to intracellular pH.  
 
Figure 3.3 Amino acid depletion profiles at ½ ODmax and ODmax for cultivations 
in process-controlled bioreactors with casamino acids as carbon source. Shown 
are the available amino acids in the medium at ½ ODmax and ODmax for the wild-type 
(red bars) and the Δ262-kb mutant (grey bars) strains determined by HPLC as 
percentage of the initial concentration. Absolute concentrations are listed in table S5. 
Cultivation and sampling were performed by the working group of Ralf Rabus (ICBM). 
Classification groups I to IV were abstracted by Zech et al. (2013b). 
Overall, the wild-type strain has only consumed about 10% of the available carbon at 
½ ODmax while the Δ262-kb mutant strain already depleted 40% of the available 
carbon (table 3.3). This difference is connected to the stage of growth which means 
½ ODmax for the wild-type strain is lower than for the Δ262-kb mutant strain. At ODmax 
the Δ262-kb mutant strain had only 16% of the carbon left while the wild-type strain 
entered stationary growth phase with still 72% carbon available in the medium.  
The Δ262-kb mutant strain and the wild-type strain had more amino acids left 
compared to the previous study (chapter 3.1.1). Here, the medium contains about 280 
mmolC L-1 which is about 55 mmolC L-1 more than in the previous study and could be 
attributed to a different casamino acid batch used in this study. However, in both 
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studies deletion of the 262-kb plasmid led to higher growth efficiency compared to 
the wild-type strain.  
Table 3.3 Available carbon at ½ ODmax and ODmax for cultivations in process-
controlled bioreactors with casamino acids as carbon source. Listed are the mmolC L-1 in the medium at ½ ODmax and ODmax for the Δ262-kb mutant strain and the 
wild-type strain based on quantification of all amino acids in the supernatant with 
HPLC. Cultivation and sampling were performed by the working group of Ralf Rabus 
(ICBM). 
Strain 
0.5 ODmax ODmax 
mmolC L-1 % of initial concentration mmolC L-1 % of initial concentration 
Wild-type 248 ± 4  89 ± 1 200 ± 14 72 ± 5 
Δ262-kb 172 ± 13  61 ± 5 45 ± 8 16 ± 3 
The minor differences observed at ½ ODmax could also be confirmed by analysis of 
certain nucleotides and cofactors which revealed no differences at ½ ODmax between 
the wild-type and the Δ262-kb mutant strain (figure 3.4). Higher levels of NAD+ and 
lower levels of NADP+ at ODmax in the Δ262-kb mutant strain are in accordance with 
the growth state indicating a lack of energy.  
 
Figure 3.4 Intracellularly detected nucleotides and cofactors at ½ ODmax and 
ODmax for the wild-type and Δ262-kb mutant strains for cultivations in process-
controlled bioreactors with casamino acids as carbon source. Shown are peak 
areas of intracellular nucleotides and cofactors of the wild type (red bars) and the 
Δ262-kb mutant (grey bars) of four biological replicates with standard errors at ½ 
ODmax and ODmax. Cultivation and sampling were performed by the working group of 
Ralf Rabus (ICBM). 
Thus, differences on the metabolic level due to different growth states associated with 
different amino acid availability should be considered. Many amino acids are 
degraded via CoA intermediates (Drüppel et al. 2014) which are analyzed in the 
following.  
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Intermediates of the branched chain amino acid (valine, leucine, isoleucine) 
degradation pathways (2-oxoisovalerate, 2-oxoisocaproate, and 3-methyl-2-
oxopentanoate) are secreted by the wild-type strain at ODmax (figure 3.2 D). 
Corresponding CoA intermediates of the further degradation (isobutanoyl-CoA, 
isovaleryl-CoA, 2-methylbutanoyl-CoA, 3-hydroxy-2-methylbutanoyl-CoA) were 
accumulating in the wild-type strain at ½ ODmax (figure 3.5, figure 3.6). On 
transcriptomic level genes coding for enzymes involved in the degradation of the CoA 
intermediates (isovaleryl-CoA dehydrogenase, methylcrotonyl-CoA carboxylase, 3-
hydroxyacyl-CoA dehydrogenase, acyl-CoA dehydrogenase, 3-hydroxyisobutyryl-CoA 
hydrolase, 3-hydroxyisobutyrate dehydrogenase) were down-regulated in the wild-
type strain at ODmax (table S6, figure 3.6) which is in accordance with the observations 
on metabolic level. 2-isopropylmalate is a sideproduct of 2-oxoisovalerate (valine 
degradation) which led to higher intracellular levels at ODmax in the wild-type strain 
compared to the Δ262-kb mutant strain (figure 3.2 C, table 3.2, figure 3.6). Propanoyl-
CoA as degradation intermediate of different amino acids is also accumulating at 
½ ODmax. Furthermore, the affected lysine degradation pathways due to the missing 
262-kb plasmid is also reflected by higher levels of glutaryl-CoA in the wild-type 
strain at both harvesting points (figure 3.5).  
 
Figure 3.5 Identified CoA intermediates at ½ ODmax and ODmax for the wild-type 
and Δ262-kb mutant strains for cultivations in process-controlled bioreactors 
with casamino acids as carbon source. Shown are peak areas of intracellularly 
detected CoA intermediates of the wild-type (red bars) and the Δ262-kb mutant (grey 
bars) of four biological replicates with standard errors at ½ ODmax and ODmax. 
Cultivation and sampling were performed by the working group of Ralf Rabus (ICBM). 
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Figure 3.6 Overview of the degradation pathways of all amino acids present in 
casamino acids and differences on metabolic and transcriptomic level between 
the Δ262-kb mutant strain and the wild-type strain. Intracellular metabolites 
significantly higher (green squares) and lower (red squares) in the Δ262-kb mutant 
strain compared to the wild-type strain are labeled for ½ ODmax (filled) and ODmax 
(striped). Transcriptomic data is analogously represented by circles. Extracellularly 
detected intermediates are labeled with blue triangles for the wild-type and blue 
reversed triangles for the Δ262-kb mutant strain. PEP: phosphoenolpyruvate. The 
overview of the pathways was reconstructed based on published data (Zech et al. 
2009; Drüppel et al. 2014). Dashed lines represent more than one reaction. 
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A lower level of 3-hydroxybutanoyl-CoA and a higher level of 3-hydroxybutanoate 
could be observed in the Δ262-kb mutant strain at ODmax indicating a possible PHB 
degradation due to starvation (table 3.2, figure 3.5, figure 3.6). 
Phenylacetyl-CoA, an intermediate of the phenylalanine degradation and precursor of 
TDA biosynthesis (Berger et al. 2012), is more abundant in the wild-type strain 
compared to the Δ262-kb mutant strain (figure 3.5). Intracellular levels of 
phenylacetyl-CoA and TDA (figure 3.7) were similar in the wild-type strain at ½ ODmax 
and ODmax indicating similar TDA production per gCDW independent of the growth 
phase. The Δ262-kb mutant strain is not able to produce any TDA due to the missing 
TDA biosynthesis gene cluster tdaABCDE coding on the 262-kb plasmid (Geng et al. 
2008; Brock et al. 2014; Thole et al. 2012). 
 
Figure 3.7 Intracellularly detected TDA and unidentified sulfur-containing 
compounds at ½ ODmax and ODmax for the wild-type and Δ262-kb mutant strains 
for cultivations in process-controlled bioreactors with casamino acids as 
carbon source. Shown are peak areas of intracellular TDA, one compound similar to 
TDA with additional methyl-moiety and four unidentified CoA intermediates of the 
wild type strain (red bars) and the Δ262-kb mutant strain (grey bars) of four 
biological replicates with standard errors at ½ ODmax and ODmax. Cultivation and 
sampling were performed by the working group of Ralf Rabus (ICBM). 
A similar compound to TDA was detectable at ODmax in the wild-type strain with an 
additional CH3-moiety ([M]226.0_RT1451) and might be the “pre-TDA” observed by 
D’Alvise et al. (2015). Furthermore, four unidentified CoA derivatives could be 
detected (figure 3.7). Sum formula predictions revealed sulfur containing moieties 
bound to the CoA indicating a relation to TDA biosynthesis (table 3.4). The CoA-
bonded structure of [M]993.1_RT888 is similar to TDA (C8H4O3S2) but includes one 
more carbon and an additional oxygen. The lower retention time (RT) might indicate 
an open structure, because a higher RT compared to the other compounds would be 
expected due to additional moieties. The predicted sum formula is contrary to the 
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proposed biosynthesis pathway of TDA by Brock et al. (2014) where water 
elimination and cyclization were proposed to be prior to sulfur incorporation.  
Table 3.4 Postulated sum formula for TDA-related unidentified compounds 
detected in the wild-type and Δ262-kb mutant strains with casamino acids as 
carbon source. Predictions were performed with SmartFormula, implemented in 
DataAnalysis 4.0. Cultivation and sampling were performed by the working group of 
Ralf Rabus (ICBM). 
Compound 
m/z 
measured 
mSigma m/z Sum Formula 
[M]226.0_RT1451 226.9836 14.3 226.9831 C9H6O3S2 
[M]903.1_RT1276 452.5608 12.7 425.564 C28H40N7O17P3S2 
[M]917.1_RT1337 459.5717 16.1 459.5718 C29H42N7O17P3S2 
[M]993.1_RT888 497.5493 8.2 497.5528 C30H42N7O19P3S3 
[M]883.2_RT1404 442.5821 12.6 442.5797 C26H44N7O17P3S2 
Furthermore, S-thio-L-cysteine was used as sulfur donor in their hypothesis. 
However, no compound with the m/z of a TDA precursor with a bounded S-thio-L-
cysteine could be detected. Furthermore, no differences between the wild-type and 
the Δ262-kb mutant strain could be observed for patB (PGA1_c00860) on 
transcriptomic level (figure 3.8, table S7). PatB was recently characterized as L-
cystine β-lyase catalyzing the reaction of cystine to L-thio-L-cysteine but might also 
act on L-methionine resulting in methanethiol (Dickschat et al. 2017). Methionine is a 
component of casamino acids which was used in the systems biology approach. 
Interestingly, [M]883.2_RT1404 was only detectable in the Δ262-kb mutant strain 
and the predicted sum formula would fit to 4-methylthiobutanoyl-CoA indicating a 
possible relation to the degradation of a methionine-related sulfur donor. S-thio-L-
cysteine is not stable (Dickschat et al. 2017) and  thus, methanethiol might be a more 
effective sulfur donor in the described set-up. Two neighboring genes to patB showed 
different expression levels. PGA1_c00840 (glutathione transferase-like protein) was 
higher expressed in the wild-type strain at ODmax and PGA1_00850 (hypothetical 
protein) was higher expressed in the Δ262-kb mutant strain at ODmax (figure 3.8, table 
S7) indicating a possible role in the degradation or biosynthesis of the respective 
sulfur donor compound.  
[M]903.1_RT1276 and [M]917.1_RT1337 include only one sulfur atom and might be 
intermediates of the first sulfur incorporation step.  
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Figure 3.8 Heat map of expression levels of putative TDA biosynthesis related 
genes. Data was plotted using MultiExperiment Viewer. Expression levels for putative 
TDA biosynthesis related genes of the wild-type (WT) and the Δ262-kb mutant strain 
(D262) at ½ ODmax (0.5) and ODmax (max) are shown. Expression levels are indicated 
by a two-color scale: Blue to black (0-1000) and black to yellow (1000-20000). For 
detailed values see table S7. Cultivation and sampling were performed by the working 
group of Ralf Rabus (ICBM). 
 
The transcriptome data showed very high expression levels (over 10000) for the TDA 
biosynthetic gene cluster tdaABCDE (figure 3.8). Genes coding for the phenylacetic 
acid degradation proteins had significantly lower expression levels (about 100-300) 
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except for paaA with expression levels of 600-700 at ODmax. Genes coding for enzymes 
necessary for L-phenylalanine degradation (paaI, paaG, paaZ) showed no significant 
expression levels (about 20) indicating that L-phenylalanine is not catabolized for 
energy but only used as precursor for TDA production. Analyses of cultures spiked 
with 13C9-15N-labeled L-phenylalanine proved that L-phenylalanine degradation is not 
active in the wild type strain because acetyl-CoA and succinyl-CoA were unlabeled 
(figure 3.9). In contrast, the transposon mutant affecting the TDA biosynthetic gene 
tdaE showed an active L-phenylalanine degradation (labeled acetyl-CoA and succinyl-
CoA). Furthermore, TDA and two unidentified compounds ([M]993.1_RT867 and 
[M]899.2_RT982) could be detected and were labeled. [M]993.1_RT867 is the 
previously described sulfur-containing TDA precursor ([M]993.1_RT888) with a 
retention time shift. [M]899.2_RT982 was matched with phenylglyoxylyl-CoA but 
could also be another isomeric structure.     
The annotated 4-hydroxyphenylpyruvate dioxygenase hpd (PGA1_c07610) showed 
unexpected high expression levels for the wild-type strain (about 4000-7000) and the 
Δ262-kb mutant strain (about 800-1100) indicating a major role in TDA biosynthesis 
and early L-phenylalanine degradation. Overall, hpd is one of the highest expressed 
chromosome genes in the wild-type strain. This enzyme is involved in the degradation 
of tyrosine and additionally it is proposed to catalyze the reaction of phenylpyruvate 
to 2-hydroxyphenylacetate in P. inhibens DSM 17395 (Drüppel et al. 2014). In the 
study by Drüppel et al. (2014) 2-hydroxyphenylacetate was described as dead-end 
product because there is no known L-phenylalanine degradation pathway via 2-
hydroxyphenylacetate and the compound was detected extracellularly. However, in 
the described study P. inhibens DSM 17395 was adapted to L-phenylalanine as sole 
carbon source and on proteomic level the 4-hydroxyphenylpyruvate dioxygenase 
showed the highest fold change of all L-phenylalanine related proteins (Drüppel et al. 
2014). Thus, expression of hpd is independent of available tyrosine and the high 
expression levels observed with casamino acids as carbon source might be connected 
to an active TDA biosynthesis.  
Furthermore, the uroporphyrinogen-III-C-methyltransferase CobA (PGA1_c20740) is 
noticeable because the gene was up-regulated in the wild-type strain compared to the 
Δ262-kb mutant strain (figure 3.8, table S7). Thole et al. (2012) observed an 
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interruption of the TDA biosynthesis for a transposon mutant strain affecting this 
methyl transferase. 
 
Figure 3.9 Isotope labeling patterns of L-phenylalanine degradation and 
proposed TDA biosynthesis intermediates. The wild-type, the paaA and tdaE 
transposon mutant strains were cultivated with casamino acids supplemented with 
13C915N-L-phenylalanine. n.d: not detected 
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These results clarify the necessity of further experiments to understand the 
uncommon biosynthesis pathway for TDA. Thus, LC-MS-analysis was performed with 
transposon mutant strains of the tdaABCDE gene cluster and of the phenylacetic acid 
degradation pathway (table 3.5).  
Table 3.5 Analyzed transposon mutant strains with corresponding locus tag and 
proposed enzyme function. Enzyme functions were proposed based on literature, 
SwissProt and InterPro hits. 
Gene Locus tag Enzyme function or domains  
paaZ_c PGA1_c26830 Bifunctional protein PaaZ 
paaZ_p PGA1_262p00800 Aldehyde dehydrogenase, Hot-Dog superfamily 
paaJ PGA1_c04090 beta-ketoadipyl-CoA thiolase PaaJ 
paaA PGA1_c04080 1,2-phenylacetyl-CoA epoxidase subunit PaaA 
paaD PGA1_c04050 1,2-phenylacetyl-CoA epoxidase subunit PaaD 
paaE PGA1_c04040 1,2-phenylacetyl-CoA epoxidase subunit PaaE 
tdaA PGA1_262p00980 Transcriptional regulator, LysR family  
tdaB PGA1_262p00970 
Thioredoxin-like superfamily, glutathionine S-
transferase 
tdaC PGA1_262p00960 no hit 
tdaE PGA1_262p00940 acyl-CoA dehydrogenase/oxidase  
Based on the previously predicted sum formula, the expression levels and the 
associated observed differences for the transposon mutant strains a new TDA 
biosynthesis pathway was suggested (figure 3.10). Similar amounts of TDA were 
produced in the wild-type and paaZ_c transposon mutant strains. TDA production was 
reduced in the paaZ_p and paaJ transposon mutant strains showing that both are 
involved in the TDA biosynthesis. The observation of paaJ as involved gene is contrary 
to the TDA biosynthesis pathway proposed by Brock et al. (2012). The 13C-labeled 
data and the expression levels already showed that phenylalanine degradation via the 
pathway by Teufel et al. (2010) is inactive in the wild-type strain. Three isomeric 
structures with a molecular mass of 902.1 Da were detected at a retention time of 
1338, 1423 and 1563 s. Probably, two of them are oxepin-CoA ([M]901.2_RT1423) 
and 1,2-epoxyphenylacetyl-CoA ([M]901.2_RT1338). The third one 
([M]901.2_RT1563) might be 2-hydroxyphenylacetyl-CoA which would fit to the 
observed high expression level of hpd.  
 
50  3 RESULTS AND DISCUSSION 
 
 
Figure 3.10 Proposed TDA biosynthesis pathway. Shown are the degradation steps 
of phenylacetyl-CoA by Teufel et al. (2010) which were proposed to provide the 
precursor for TDA biosynthesis by Brock et al. (2014). The new proposed 
biosynthesis pathway is shown with newly detected so far unidentified sulfur-
containing compounds with proposed structures based on sum formula predictions. 
Furthermore, peak areas for different transposon mutant strains are shown for the 
detectable compounds compared to the wild-type strain. Expression levels at ODmax 
in the wild-type strain are labeled with colored circles. For detailed expression levels 
see figure 3.8 and table S7.  
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PaaA, paaD and paaE were necessary to produce TDA. Thus, 1,2-epoxyphenylacetyl-
CoA could be a possible precursor for the first sulfur incorporation step to 
[M]917.1_RT1329 which might be catalyzed by enzymes of the tdaABCDE gene 
cluster. There is no reliable annotation for these genes and bioinformatic analyses 
only revealed some domain structures (table 3.5). TdaB might catalyze the transfer of 
sulfur from a sulfur donor compound to 1,2-epoxyphenylacetyl-CoA. The further 
steps might be catalyzed by TdaF, PaaZ_p and enzymes coded on two neighbouring 
genes (PGA1_262p00780 and PGA1_262p00840). [M]917.1_RT1329 was higher 
abundant in the paaZ_p and paaJ transposon mutant strains. [M]903.1_RT1276 was 
less abundant in both strains compared to the other TDA-producing strains. This 
effect was stronger in the paaJ transposon mutant strain and the decreased TDA 
production seems to be connected to the decreased production of [M]903.1_RT1276 
indicating an important role of this observed “degradation” compound. A 
demethylation step is necessary to obtain TDA and [M]903.1_RT1276 might act as 
methyl-acceptor.  
Overall, the presented data revealed new insights into the TDA biosynthesis pathway 
of P. inhibens DSM 17395 and is the first experimental evidence of sulfur-containing 
TDA precursors. Contrary to previous proposed TDA biosynthesis pathways the 
actual data suggest sulfur incorporation prior to cyclization and water elimination. 
However, further experiments will be necessary to prove the proposed pathway. 
3.1.3 Identification of unidentified compounds 
One major difference between the wild-type and the Δ262-kb mutant strain was the 
detection of so far unidentified compounds by GC-EI-MS analysis (figure 3.2 A and C). 
Three of them (NA714, D200302_2009.31, Unknown#2442.5-pin-mhe_059) were 
only detectable in the Δ262-kb mutant strain and showed similar EI fragmentation 
pattern (figure 3.11). EI fragmentation pattern of compound 3 is also found in 
compound 2 and 1. Furthermore, all ions of compound 2 were found in compound 1. 
The basic fragmentation pattern involved typical ions for a pyranose (Simoneit et al. 
2004; Kleist et al. 2016), glycerate and 3-hydroxybutanoate, the degradation product 
of the storage compound PHB (table 3.6). Glycerate could be detected at ODmax and 
was 1.6-fold higher abundant (p-value < 0.005) in the Δ262-kb mutant strain 
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compared to the wild-type strain (table S1) and 3-hydroxybutanoate was 2.3-fold 
higher (table 3.2). 
 
Figure 3.11 EI spectra of unidentified compounds detected in the Δ262-kb 
mutant strain by GC-MS analysis. Numbers in blue were used in the text for better 
traceability. 
Additionally, in compound 1 and 2 the ions at m/z 169 and 375 were characteristic. 
Fragments at m/z 169 and 361 are typically found in compounds with glycosidic 
bonds as disaccharides (Simoneit et al. 2004) or also pyranoses bond to glycerate like 
2-O-(α-D-glucopyranosyl)-glycerate, an osmoprotectant found in D. shibae DFL12 
(Kleist et al. 2016). Thus, the detected ions at m/z 169 and 375 could indicate a 
glycosidic bond with a structure containing one nitrogen atom which would explain 
the shift from m/z 361 to 375 (table 3.6). 
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Table 3.6 Observed fragmentation patterns with corresponding structure 
properties.  1: NA417, 2: Unknown#2442.5-pin-mhe_059, 3: D200302_2009.31, 4: 
Unknown#2557.6-pin-mhe_067, 5: NA1703.1, 6: Unknown#2260-cgl-sst_001. Italic: 
only some ions were found in the respective compound. Bold: characteristic ions 
found in compound 1. 
Fragmentation pattern (m/z) Found in Possible structure properties 
147, 191, 204, 217 1 ,2, 3 Pyranose 
117, 133, 147, 189, 217, 292 1, 2, 3 Glyceric acid 3TMS 
169 1, 2, 4 Sugar with glycosidic bond 
375 1, 2 Glycosidic bond (361) + nitrogen 
117, 147, 191, 233 1, 2, 3 3-hydroxybutanoate 2TMS 
147, 211, 227, 243, 285, 299, 315 1, 5 Glycerol-2-phosphate 4TMS 
147, 241, 257, 299, 329, 357, 387 1, 2, 4  Glycerol-3-phosphate 4TMS 
128, 147, 156, 174, 200, 317 6 Lysine 4TMS 
Three other so far unidentified compounds were detected in both strains (figure 
3.12). Compound 4 and 6 were more abundant in the Δ262-kb mutant strain and 
compound 5 was only detectable in the wild-type strain at ODmax (table 3.1 and 3.2). 
Compound 6 is a lysine containing compound (table 3.6) which is in accordance with 
higher levels of lysine in the Δ262-kb mutant strain (table 3.2). Furthermore, 2,6-
diaminopimelate was lower which could imply a role of compound 6 in the 
peptidoglycan structure. However, this compound is independent from the other 5 
compounds because the typical ions at m/z 156 and 174 were not found in any other 
compound. Compounds 4 and 5 are of peculiar interest because the EI spectra 
includes parts of the typical fragmentation pattern for glycerol-2-phosphate and 
glycerol-3-phosphate (table 3.6). Furthermore, the specific ion at m/z 257 is found in 
compound 1 and 2 as well as ion at m/z 285 is also present in compound 1. This led 
to the assumption that addition of compound 4 to compound 3 results in compound 
2. Further addition of compound 5 would then end in compound 1, the most abundant 
so far unidentified metabolite with the highest RI.  
Overall, NA714 is supposed to be a nitrogen containing, glycosidic-bonded pyranose-
glycerate structure with glycerol and 3-hydroxybutanoate residues.  
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Figure 3.12 EI spectra of unidentified compounds detected in the wild-type and 
Δ262-kb mutant strain by GC-MS analysis. Numbers in blue were used in the text 
for better traceability. 
The high molecular weight and the low abundance of this compound impeded a 
successful analysis with GC-APCI-MS. Thus, it was not possible to identify a molecule 
ion for this compound. However, besides CoA thioesters it is also possible to detect 
other acidic compounds by the previously used LC-ESI-MS analytics. With this method 
compounds without a bonded CoA were detected which were accumulating in the 
Δ262-kb mutant strain at ODmax (figure 3.13) indicating a relation to the unidentified 
compounds detected by GC-EI-MS. ESI is a soft ionization technique generating mass 
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spectra with a detectable molecule ion which could be used for sum formula 
predictions due to the high resolution of the qTOF detector.   
 
Figure 3.13 Intracellularly detected unidentified compounds at ½ ODmax and 
ODmax for the wild-type and Δ262-kb mutant strains by LC-MS-analysis. Shown 
are peak areas of unidentified polymeric compounds of the wild type (red bars) and 
the Δ262-kb mutant (grey bars) of four biological replicates with standard errors at 
½ ODmax and ODmax and associated predicted sum formula (table S8). Cultivation and 
sampling were performed by the working group of Ralf Rabus (ICBM). 
Sum formula predictions revealed similar structures for all compounds with iterating 
units and include a single nitrogen atom (table S8). Detected components could be 
divided in two groups which differ by one carbonyl group (figure 3.13 and figure 
3.14). Furthermore, within a group the residue bound to 3-hydroxybutanoate as 
iterating units differ by one acetyl residue. Proposed structures for the detected 
compounds are glucosamine-PHB, N-acetylglucosamine-PHB, glucosaminate-PHB 
and N-acetylglucosaminate-PHB (figure 3.14). Retention times (RT) were higher for 
compounds of group 1 when components of the same length are compared indicating 
that glucosamine and N-acetylglucosamine were present in cyclic form but the ring 
opened while ionization. 3-hydroxybutanoate as iterating unit is in accordance with 
the observed higher abundance in the Δ262-kb mutant strain at ODmax (table 3.2) and 
the observed fragmentation patterns in unidentified compounds detected by GC-MS 
(table 3.6).  
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Figure 3.14 Proposed structures for the detected unidentified compounds by 
LC-MS analysis.  
However, the GC-MS analysis revealed also fragmentation patterns indicating 
glycerate and glycerol involved in the polymeric structures. On transcriptomic level a 
gene cluster (PGA1_c13580 to PGA1_c13830) which was highly up-regulated in the 
Δ262-kb mutant strain at ODmax could be related to the detected compounds. This 
cluster is coding for proteins like D-alanine-poly(phosphoribitol) ligase, long-chain-
fatty-acid-CoA ligase, long-chain specific acyl-CoA dehydrogenase, 
phosphopantetheine binding protein, 4'-phosphopantetheinyl transferase-like 
protein and a monooxygenase. Furthermore, this cluster includes a secretion protein 
and an ABC transporter ATP-binding protein. Thole et al. (2012) already described 
this gene cluster and assumed an uncommon cell envelope composition as D-alanine-
poly(phosphoribitol) ligase is an enzyme known to be involved in the biosynthesis of 
D-alanyl-lipoteichoic acid, a compound in the cell wall of Gram-positive bacteria 
(Neuhaus and Baddiley 2003). Sulfitobacter brevis KMM 6006, a marine Gram-
negative bacterium, produces a teichoic acid containing 
poly(glycosylribitophosphate) and poly(glycerophosphate) (Gorshkova et al. 2007). 
For the linkage of each unit phosphate is required. Genes coding for phosphate 
transport proteins (PGA1_c15730 to PGA1_c15800) were up-regulated at ODmax in the 
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Δ262-kb mutant strain. The units forming the basis of the teichoic acid could be 
similar to the teichoic aicd found in S. brevis KMM 6006 with glycerate instead of 
ribitol. This teichoic acid could be then bound via phosphate to the four detected PHB-
bounded amino sugars/sugar acids (figure 3.14), resulting in a lipoteichoic acid 
(LTA). The PHB residues indicating that the possible LTA is probably not anchored in 
the membrane as the chain is too polar with the hydroxy groups. Thus, this polymeric 
structure could have another function than a usual membrane compound. The LTA of 
Lactococcus lactis subsp. cremoris SK110 and SK112 consist of glycerol, glucose, 
rhamnose, alanine, fatty acids and protein (Sijtsma et al. 1990). Sijtsma et al. (1990) 
showed that the LTA of the phage-resistant strain SK110 additionally includes 
galactose which was not detected in the phage-sensitive strain SK112. Furthermore, 
inactivation of phages by LTAs is dependent on the substitution (Räisänen et al. 2007). 
This is interesting because a gene cluster containing a phage (PGA1_c18210 to 
PGA1_c18560) is up-regulated in the Δ262-kb mutant strain at ODmax. Thus, 
production of LTA could be a reaction to a starvation triggered phage. The expression 
of the phage would also explain the rapid die off at ODmax observed for the Δ262-kb 
mutant strain (Trautwein et al. 2016). 
3.1.4 Refinement of L-lysine catabolism 
The metabolome analysis revealed differences in intermediates of lysine catabolism. 
While the L-lysine degradation via cadaverine was well described by Drüppel et al. 
(2014) nothing is known for a degradation via L-pipecolate in P. inhibens DSM 17395 
ecxept for the observation of an accumulation of L-pipecolate in the Δ262-kb mutant 
strain (Reimer et al. 2017, Will et al. 2017). Thus, further studies were performed with 
help of bioinformatic approaches and transposon mutant strains to propose a 
degradation pathway via L-pipecolate. Furthermore, enzymes necessary for growth 
on L-lysine as sole carbon source were identified.  
Degradation via L-pipecolate 
The degradation of L-lysine via L-pipecolate is not well-known for bacteria. In 
Streptomyces hygroscopicus the direct conversion of L-lysine to L-pipecolate by a 
lysine cyclodeaminase (EC 4.3.1.28) is part of the rapamycin gene cluster (Gatto et al. 
2006). BLASTp analysis revealed PGA1_c16390 as possible gene locus coded for an 
58  3 RESULTS AND DISCUSSION 
 
enzyme in P. inhibens DSM 17395 analogous to S. hygroscopicus (table S9, figure 3.15). 
This gene is annotated as ornithine cyclodeaminase (EC 4.3.1.12). Gatto et al. (2006) 
observed a cyclization of ornithine by the lysine cyclodeaminase of S. hygroscopicus 
but with a reduced rate compared to lysine. Thus, besides ornithine also L-lysine 
could be a possible substrate of the ornithine cyclodeaminase of P. inhibens DSM 
17395.  
 
Figure 3.15 Postulated degradation pathways via L-pipecolate to 2-
aminoadipate. Possible enzymes involved in the degradation of L-lysine via L-
pipecolate were predicted based on bioinformatic analyses (table S9). 
The BLASTp analysis provided also a putative Δ1-piperideine-2-carboxylate 
reductase (1.5.1.21) (Paracoccus denitrificans PD1222) as predicted protein function 
for PGA1_c31650. This enzyme catalyzes the conversion of Δ1-piperideine-2-
carboxylate to L-pipecolate and is well described for Pseudomonas putida ATCC 12633 
and Pseudomonas syringae pv. tomato DSM 50315 (Muramatsu et al. 2005; Goto et al. 
2005). Furthermore, the BLASTp analyses revealed PGA1_262p01410 as possible Δ1-
piperideine-2-carboxylate reductase. Δ1-piperideine-2-carboxylate is formed by 
spontaneously cyclization of 6-amino-2-oxohexanoate (Revelles et al. 2007). A 
transamination reaction is necessary to obtain 6-amino-2-oxohexanoate. One 
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possible enzyme for this reaction is the annotated arginine-pyruvate transaminase 
(PGA1_262p02330). For Pseudomonas aeruginosa PAO1 this enzyme is well 
characterized, and L-lysine is an alternative substrate to L-arginine resulting in Δ1-
piperideine-2-carboxylate as product (Yang and Lu 2007). Thus, besides the direct 
conversion of L-lysine to L-pipecolate another pathway via Δ1-piperideine-2-
carboxylate could be possible (figure 3.15).  
For Pseudomonas putida KT2440, two enzymes necessary for L-pipecolate 
degradation were identified (L-pipecolate oxidase AmaA and Δ1-piperideine-6-
carboxylate dehydrogenase AmaB). In mutant strains lacking these enzymes L-
pipecolate was accumulating (Revelles et al. 2005). An accumulation of L-pipecolate 
was observed for the Δ262-kb mutant strain of P. inhibens DSM 17395 (table 3.1 and 
3.2) indicating a gene locus on this plasmid coding for an oxidoreductase for the 
conversion of L-pipecolate to Δ1-piperideine-6-carboxylate. BLASTp analyses 
revealed PGA1_262p02210 as possible gene locus coding for an oxidoreductase 
similar to AmaA in P. putida (table S9). The pipecolate oxidase (EC 1.5.3.7) is well 
known for eukaryotic organisms. However, the occurrence of this enzyme in 
prokaryotic organisms is still new. A genome-wide analysis of lysine catabolism in 
bacteria revealed genes similar to amaA gene in 61 organisms. These organisms 
belong all to the phylum proteobacteria (Neshich et al. 2013). Thus, the transposon 
mutant Tm2567 of P. inhibens DSM 17395 without a functional predicted pipecolate 
oxidase (PGA1_262p02210) was cultivated on casamino acids and additionally with 
L-lysine as sole carbon source compared to the Δ262-kb mutant strain and the wild-
type strain. An accumulation of L-pipecolate could be observed in the transposon 
mutant strain for both carbon sources (figure 3.16). The effect is higher if more L-
lysine is available (2.1 mM in casamino acids and 15 mM if L-lysine is used as sole 
carbon source) underlying the assumption that L-pipecolate is a degradation product 
of L-lysine and that PGA1_262p02210 is coding for an enzyme with pipecolate oxidase 
function.  
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Figure 3.16 Accumulation of L-pipecolate in the Δ262-kb mutant strain and 
transposon mutant strain Tm2567 (PGA1_262p02210). Shown are normalized 
peak areas of intracellularly detected L-pipecolate for cultures with casamino acids 
(grey) and 15 mM L-Lysine as carbon source (red). Cultures with casamino acids were 
harvested at approximately half-maximal OD and with L-Lysine at maximal OD.   
The conversion of Δ1-piperideine-6-carboxylate to 2-amino-6-oxohexanoate is 
spontaneous followed by a dehydrogenation to 2-aminoadipate (figure 3.15). In 
P. putida this step is catalyzed by the Δ1-piperideine-6-carboxylate dehydrogenase 
AmaB (Revelles et al. 2005). Neshich et al. (2013) could identify 177 proteobacteria 
having a gene coding for a similar enzyme described as α-aminoadipic semialdehyde 
dehydrogenase (EC 1.2.1.31). No distinct aldehyde dehydrogenase could be identified 
in P. inhibens DSM 17395 for this reaction step. In previous studies of the degradation 
pathways of amino acids in P. inhibens DSM17395 an aldehyde dehydrogenase 
(PGA1_c33040) was identified in the proteome which was slightly up regulated with 
L-lysine as carbon source compared to other amino acids (Drüppel et al. 2014). 
However, this aldehyde dehydrogenase could also be only active in the degradation 
pathway via cadaverine.  
Degradation via cadaverine  
To analyze whether the degradation pathway via L-pipecolate is a possible alternative 
pathway, transposon mutant strain of the cadaverine pathway were analyzed. In 
previous studies by Drüppel et al. (2014) the lysine/ornithine decarboxylase 
(PGA1_c11650) was identified on proteomic level for the first degradation step. 
Furthermore, PGA1_c33040 was identified as an important aldehyde dehydrogenase 
involved in L-lysine catabolism. Transposon mutant strains affected those two genes 
could not be adapted to L-lysine as sole carbon source (figure 3.17 A).   
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Figure 3.17 Adaptation of the wild-type strain and the transposon mutant 
strains affecting PGA1_c33040 (aldehyde dehydrogenase) and PGA1_c11650 
(lysine/ornithine decarboxylase) to L-lysine as sole carbon source and L-lysine 
uptake by those strains with casamino acids as carbon source.  Shown are OD600 
values of cultures with 15 mM L-Lysine which were inoculated with growing cells of 
casamino acids cultures (A) and uptake of L-lysine for cultures growing on casamino 
acids (B) for the wild-type (grey), the transposon mutant strain Tm1215 
(PGA1_c33040, red) and the transposon mutant strain Tm3938 (PGA1_c11650, blue). 
Adaptation of transposon mutant strains was attempted twice. All cultures already 
reached ODmax at 34 h. 
Both mutant strains grew on casamino acids and showed a decreased lysine uptake 
compared to the wild-type strain (figure 3.17 B). This effect is higher for the 
transposon mutant strain Tm3938 lacking the lysine/ornithine decarboxylase 
(PGA1_c11650) which is necessary for the first L-lysine degradation step to 
cadaverine (Drüppel et al. 2014). Metabolome analysis of Tm1215 (PGA1_c33040) 
revealed a bottleneck in the conversion of cadaverine to 5-aminopentanoate (figure 
3.18) which is in accordance with the proposed function of this aldehyde 
dehydrogenase by Drüppel et al. (2014). The detected 5-aminopentanoate and 
glutarate could be explained by another, less specific aldehyde dehydrogenase. 
However, this activity is not sufficient for a growth with L-lysine as sole carbon 
source. Thus, growth with L-lysine is only possible via the cadaverine pathway and 
both analyzed genes (PGA1_c11650 and PGA1_33040) are essential for this 
degradation pathway.  
Overall, L-pipecolate is not a possible alternative to obtain biomass and L-pipecolate 
might have another function and it should be more regarded as a biosynthesis of L-
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pipecolate. Neshich et al. (2013) observed an accumulation of L-pipecolate under high 
salt concentrations. L-pipecolate as osmoprotectant was already described in 1992 
and 1994 (Gouesbet et al. 1992; Gouesbet et al. 1994). Therefore, the biosynthesis of 
L-pipecolate by marine bacteria could be an advantage in their natural habitat. 
 
Figure 3.18 Intracellularly detected lysine degradation metabolites for the 
wild-type and the transposon mutant Tm1215 (PGA1_c33040). Shown are 
normalized peak areas for the wild-type strain (grey) and the transposon mutant 
strain Tm1215 (PGA1_c33040, red). 
Overall, the main metabolome is similar for the wild-type and the Δ262-kb mutant 
strain. Different levels of amino acids and corresponding degradation intermediates 
are mainly attributed to different growth states which are caused by the growth 
restriction. Small differences in lysine catabolism could be observed which have only 
minor influence on the growth behavior. Accumulation of sugar-containing 
compounds in the Δ262-kb mutant strain at ODmax could be connected to a possible 
lipoteichoic acid production which might be a response to a starvation triggered 
phage. However, these observations could not explain the growth inhibition of the 
wild-type strain by the 262-kb plasmid. On the contrary, main differences in the 
metabolome at ODmax could be connected to highly different amino acid depletion 
profiles which are caused by the growth inhibition of the wild-type strain. Thus, the 
missing TDA production in the Δ262-kb mutant strain has to be considered and will 
be discussed in the next chapter. 
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3.2 Growth inhibition by TDA 
The antibacterial compound TDA acts by disruption of the proton motive force 
(Wilson et al. 2016). Efforts by Porsby et al. (2011) to generate TDA resistant strains 
were not successful and in their study the TDA-producing P. inhibens strain 24-7 was 
inhibited by TDA. Thus, the influence of the endogenously produced TDA on the 
growth behavior was analyzed aided by transposon mutant strains missing enzymes 
of the TDA biosynthesis (TDA-free strains). 
Data presented here were published in Will et al. (2017). 
3.2.1 Growth physiology and metabolome of TDA-free mutant strains 
Four transposon mutant strains (tdaA, tdaB, tdaC and tdaE) were cultivated in 
addition to the wild-type and the Δ262-kb mutant strains with casamino acids as 
carbon source to analyze if the observed growth inhibition by the 262-kb plasmid is 
connected to the TDA production. A similar growth behavior could be observed for 
the transposon mutant strains and the Δ262-kb mutant strain (figure 3.19). In 
absence of a functional TDA biosynthesis, maximal biomass was reached after 15-20 h 
while the wild-type strain entered the stationary growth phase after 30 h. Besides a 
2 h longer lag phase the transposon mutant strains reached 10% lower CDWmax and 
YX/C compared to the Δ262-kb mutant strain (figure 3.19). These minor differences 
might be attributed to the necessary replication of the plasmid and production of an 
exopolysaccharide with encoding genes on the 262-kb plasmid and sequence 
similarities to the succinoglycan biosynthesis of Rhizobium meliloti 1021 (Reuber, 
Walker 1993) (table S10). Furthermore, the TDA-free mutant strains showed the 
same amino acid depletion as the Δ262-kb mutant strain (table S12). The wild-type 
strain reached only 50% of the CDWmax and 60% of the biomass yield YX/C compared 
to the Δ262-kb mutant strain. Thus, only minor effects can be attributed to plasmid 
carriage and exopolysaccharide production and the major growth restriction effect 
described in chapter 3.1.1 and 3.1.2 is connected to the TDA biosynthesis. 
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Figure 3.19 Growth characteristic of the wild-type strain, Δ262-kb mutant 
strain and transposon mutant strains (tdaA, tdaB, tdaC and tdaE) on casamino 
acids. Shown are cell dry weights (CDW) over time for the wild-type strain (black 
squares), Δ262-kb mutant strain (grey circles), tdaA (orange triangles), tdaB (red 
triangles), tdaC (green triangles) and tdaE (blue triangles) transposon mutant strain 
with corresponding CDWmax and YX/C. Lag phases were corrected. Data were published 
in Will et al. (2017). 
No conspicuous metabolites, which would explain the growth restriction, could be 
identified by metabolome analysis of the tdaE transposon mutant strain in addition 
to the Δ262-kb mutant and wild-type strains (which were already analyzed in chapter 
3.1). As previously discussed, the wild-type strain shows higher levels of amino acids 
and their degradation intermediates (valine, tyrosine, isoleucine, leucine, 2-
isopropylmalate), especially from the branched chain amino acids (figure 3.20 A). 
These differences are mainly attributed to the different amino acid availability (table 
S13). This effect is also observed with higher amounts of valine, isoleucine and 3-
aminoisobutanoate (side product of valine degradation) in the Δ262-kb mutant strain. 
The differences in lysine degradation (discussed in chapter 3.1.2 and 3.1.4) were only 
observed when the complete 262-kb plasmid was missing (figure 3.20 B) reinforcing 
the assumption that the changes in lysine degradation are not responsible for the 
growth restriction. The unidentified compound D2003002 described in chapter 3.1.3 
was only detectable in the Δ262-kb mutant strain. However, the intensity was low and 
it could not be excluded that this compound is also present in the tdaE transposon 
mutant strain but below the detection limit. 
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Figure 3.20 Metabolome analysis dependent on TDA production. Shown are 
normalized peak areas of intracellularly detected metabolites by GC-MS analysis in 
the tdaE transposon mutant strain compared to the wild-type strain (A) and the Δ262-
kb mutant strain (B) at ½ ODmax. Peak areas are listed in table S11. Data were 
published in Will et al. (2017). 
The only noticeable difference between the wild-type and the TDA-free mutant 
strains is N-acetyl-serine which was only found in the wild-type strain (figure 3.20 A). 
In the previous analysis, homoserine was only detectable in the wild-type strain at 
ODmax (figure 3.2 C). Both metabolites might be connected to a production of N-acyl 
homoserine lactones (AHLs). These quorum sensing molecules were shown to induce 
TDA biosynthesis in P. inhibens DSM 17395 (Berger et al. 2011). 
3.2.2 Medium exchange between wild-type and TDA-free mutant strains 
A medium exchange experiment was performed in order to analyze whether costs for 
the TDA biosynthesis itself or the presence of TDA and consequently the antibacterial 
effect is crucial for the observed growth restriction. TDA-free mutant strains showed 
a drastic growth inhibition effect after transferring the cells into the sterile filtered, 
TDA containing medium of the wild-type strain (table 3.7). In presence of TDA, linear 
growth rates decreased about 68% (Δ262-kb) or 58% (tdaE) to approximately 
0.15 g L-1h-1. Additionally, a control experiment with a medium exchange between the 
Δ262-kb mutant and the tdaE mutant strains was performed to exclude growth 
inhibition effects due to the exchange procedure. Linear growth rates remained 
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similar for both strains underlying the assumption that the growth inhibition effect is 
directly connected to the presence of TDA (table 3.7). The growth rate of the wild-
type strain increased about 55% to an average of 0.17 g L-1h-1 with “TDA-free 
medium”. This is similar to the growth rate of the TDA-free mutant strains with TDA-
containing medium. As previously shown, TDA production per gCDW is similar at 
different growth phases (chapter 3.1.2, figure 3.7) assuming half-maximal TDA 
concentration at the time point of medium exchange. Thus, the presence of a half-
maximal TDA concentration led to the same growth inhibition effect as TDA 
production by the wild-type cells itself in a “TDA-free medium”. This means that 
growing cells are directly affected by the freshly produced TDA and, due to 
accumulation in the medium, growth inhibition is increasing leading to decreasing 
growth rates in the wild-type strain until reaching maximal TDA tolerance at CDWmax.  
Table 3.7 Linear growth rates (g L-1h-1) for the medium exchange. Shown are 
linear growth rates of the reference and the exchanged culture for the wild-type, the 
Δ262-kb mutant and the tdaE mutant strains, respectively. Growth rates were 
determined after the exchange procedure between the wild-type and TDA-free 
mutant strains. Furthermore, growth rates for the control experiment (exchange 
between the TDA-free mutant strains) were determined. For detailed cultivation 
procedure see chapter 2.4.2. Complete growth curves are shown in figure S1. Data 
were published in Will et al. (2017). 
Condition WT vs. Δ262 WT vs. tdaE Δ262 vs. tdaE 
WT reference 0.09 ± 0.01 0.06 ± 0.01 - 
WT exchange 0.20 ± 0.02 0.14 ± 0.02 - 
Δ262 reference 0.47 ± 0.05 - 0.43 ± 0.01 
Δ262 exchange 0.15 ± 0.05 - 0.53 ± 0.06 
tdaE reference - 0.33 ± 0.01 0.34 ± 0.03 
tdaE exchange - 0.14 ± 0.02 0.30 ± 0.01 
Growth of the tdaE transposon mutant strain was tested with TDA containing culture 
supernatant of the stationary growth phase to analyze the hypothesis that growth is 
not possible with the maximal reached TDA concentration. Casamino acid containing 
medium was supplemented with different dilutions of culture supernatant of the 
wild-type strain. Medium containing 20% and 40% of the wild-type supernatant did 
not influence the growth behavior compared to the reference (figure 3.21 A). Cultures 
with more TDA in the medium showed a prolonged lag phase and variable growth of 
the three biological replicates. No growth was observable after transfer of these cells 
into medium containing wild-type culture supernatant from a later time point (late 
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stationary growth phase) to increase TDA concentration (figure 3.21 B). The 
reference (TDA-free supernatant) showed normal growth behavior. Porsby et al. 
(2011) explained the inhibition effect of P. inhibens strain 24-7 by a not yet active TDA 
production when cells were tested. However, P. inhibens DSM 17395 wild-type cells 
from a fresh TDA-producing preculture were unable to grow in the TDA containing 
supernatant medium (figure 3.21 B), indicating that this effect is independent from a 
TDA production by the strain itself. An adaptation to TDA by selecting and transfer of 
more tolerant cells was not possible. Thus, the unsuccessful attempts by Porsby et al. 
(2011) to generate TDA tolerant or resistant strains were also transferable to 
P. inhibens DSM17398 as a TDA-producing strain.  
 
Figure 3.21 Analysis of TDA tolerance. (A) Shown are cultivations of the tdaE 
transposon mutant strain with casamino acid medium containing different dilutions 
of supernatant from wild-type cultivations (ODmax). Supernatant was diluted with salt 
water medium to obtain final TDA concentration of 80% (red), 40% (green), 20% 
(blue) and 0% (grey) of the initial concentration of the wild-type at ODmax. (B) 
Supposed TDA tolerant cells (closed red triangle) were transferred into fresh 
casamino acids medium with 80% of wild-type supernatant (red) and 80% of the tdaE 
transposon mutant supernatant (orange). Furthermore, 80% of the wild-type 
supernatant medium was inoculated with the wild-type strain from fresh precultures 
(black). 
Wilson et al. (2016) identified possible resistance genes located on the 262-kb 
plasmid in P. inhibens DSM 17395. However, no experimental evidence for a 
resistance mechanism is given so far. The presented data clearly show an inhibition 
effect by TDA under shaken culture conditions. Furthermore, the wild-type strain is 
not limited by carbon but enters stationary growth phase because maximal tolerable 
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TDA concentration is reached indicating insufficient energy supply by respiration due 
to the disruption of the proton gradient. 
3.2.3 TDA dependent respiratory activity 
In chapter 3.1.2 similar intracellular amounts of TDA per gCDW were detected at ½ 
ODmax and at ODmax. Here, TDA concentration in the supernatant was relatively 
determined by measurement of absorption at 302 nm (free TDA) and 398 nm (TDA-
iron complex). TDA concentration increased in the supernatant of the wild-type strain 
(figure 3.22). Both, TDA-iron complex and free TDA are correlated with the biomass 
but increase further when entering stationary growth phase indicating TDA 
production without a coupled biomass production at CDWmax. Thus, the respiratory 
metabolism is probably still active, but carbon is completely turned into TDA and CO2. 
 
Figure 3.22 Relative TDA concentration for cultivations with casamino acids. 
Shown are growth curves (red) and absorption measured in the culture supernatants 
at 302 nm (white bars, TDA) and 398 nm (blue bars, TDA-iron complex) for the wild-
type, the Δ262-kb mutant strain and the tdaE transposon mutant strain. Data were 
published in Will et al. (2017). 
To analyze the respiratory activity dependent on TDA production, dissolved oxygen 
(DO) was measured online in Erlenmeyer flasks cultivations to calculate oxygen 
uptake rates (figure S2, table S14). Specific oxygen uptake rates qO2  of approximately 
11.5 mmolO2gCDW-1 h-1 were similar and constant for all strains over the complete 
culture time (figure 3.23). For TDA-free mutant strains growth was mainly linear 
while the wild-type strain only showed a short linear growth around ½ ODmax. Thus, 
µ is decreasing over time for all strains with corresponding increasing oxygen 
consumption per gCDW due to a constant qO2. For the wild-type strain µ is decreasing 
to about 20% compared to ½ CDWmax while the TDA-free mutant strains only drop to 
about 50% of their µ at ½ CDWmax.  
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Figure 3.23 Oxygen consumption dependent on TDA presence. Shown are 
determined specific oxygen uptake rates qO2 and absolute oxygen consumption at 
different time points with corresponding logarithmized CDW. For detailed values see 
table S14. 
The absolute oxygen consumption at ½ ODmax were similar to those determined in 
process-controlled bioreactors (Trautwein et al. 2016). The overall oxygen 
consumption per gCDW is increasing with accumulation of TDA because the respiratory 
activity remains constant. The presence of TDA led to lower ATP yield due to the 
disruption of the proton gradient resulting in a less active ATP synthase. Thus, 
P. inhibens DSM 17395 is not able to increase respiratory activity to fully counteract 
the antibacterial effect of TDA. 
Taken together, the observed growth restriction of P. inhibens DSM 17395 by the 262-
kb plasmid is attributed to the disruption of the proton motive force by its own 
produced antibacterial compound TDA. This effect was observed for shaken cultures 
in Erlenmeyer flasks as well as for process-controlled bioreactor cultivations with 1% 
casamino acid containing defined salt water medium. Thus, the wild-type strain is not 
producing maximal possible biomass under the given conditions. Cultivations with 
single amino acids will be discussed in the following supported by simulations with 
the reconstructed metabolic model iPin571 to analyze energetic efficiency dependent 
on substrate and TDA production.   
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3.3 Metabolic model-based analyses of the TDA dependent growth 
restriction 
P. inhibens DSM 17395 was previously analyzed by Drüppel et al. (2014) with respect 
to reconstruction of degradation pathways for nine single amino acids. Growth 
physiology and morphology differed dependent on the amino acid. Further studies 
combining experimental data with metabolic model-based flux predictions were 
performed in order to analyze whether these differences are based on the inhibition 
effect by TDA or due to different growth efficiency (determined as biomass yield YX/C). 
Furthermore, in the study by Drüppel et al. (2014) cells were adapted to each amino 
acid by five consecutive transfers. The influence of the adaptation process on the 
growth behavior was included in the following analyses.  
3.3.1 The metabolic model iPin571 
The metabolic model iPin571 consists of 486 genes, 571 metabolic reactions (13 not 
sequenced based, 7 spontaneous), 17 biomass reactions, 35 transport reactions, 22 
exchange reactions and 564 metabolites. The model was analyzed for essential, non-
variable and variable reactions. Optimal FVAs were performed with glucose and 
casamino acids as theoretical carbon sources (Table 3.8). 53% (glucose) or 58% 
(casamino acids) of the reactions were identified as essential. 36 of the variable 
reactions were independent from the scenario. 4 variable reactions (threonine and 
proline biosynthesis) could be identified in the glucose scenario which had a flux of 
0 mmol gCDW
-1 h-1with casamino acids as substrate. 22 of the variable reactions were 
specific for the casamino acid scenario. These are mainly reactions of the citric acid 
cycle, gluconeogenesis and amino acid degradation steps via CoA intermediates.  
Table 3.8 Essential, non-variable and variable reactions for glucose and 
casamino acids.  Theoretical scenarios with glucose or casamino acids as carbon 
source were used for optimal FVA prediction; flux in mmol gCDW
-1 h-1. 
 
Glucose Casamino acids 
number % number % 
Essential (Flux ≠ 0) 368 53% 403 58% 
Non-variable 652 94% 634 92% 
Non-variable (Flux of 0 possible) 298 43% 256 37% 
Variable 40 6% 58 8% 
Variable (Flux of 0 possible) 25 4% 26 4% 
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P. inhibens DSM 17395 is able to grow with a variety of different carbon sources. The 
metabolic model iPin571 contains degradation pathways and transporter for 32 of 
them. 
3.3.2 Theoretical analyses of energetic efficiency of different carbon sources 
The 32 implemented carbon sources were analyzed for their energetic efficiency. In 
silico predictions of the theoretical maximal ATP yield without any biomass 
production showed a range from 2.8 molATP molC-1 (L-aspartate, L-asparagine, L-
methionine) up to 4.3 molATP molC-1 (L-isoleucine, L-lysine, mannitol, 4-
aminobutanoate, butanoate) (figure 3.24). Furthermore, the consumed oxygen was 
calculated and for sugars, L-alanine, L-threonine and acetate exactly 1 mol O2 was 
consumed per 1 mol carbon. The degradation of the aromatic amino acids L-
tryptophan, L-tyrosine and L-phenylalanine involve dioxygenase catalyzed reaction 
steps explaining the higher oxygen consumption observed for these three amino 
acids.  Except for these carbon sources, a tendency of a higher respiratory activity for 
higher ATP yields is observable. 
 
Figure 3.24 In silico predicted energetic efficiency for 32 carbon sources. Shown 
are theoretical maximal possible ATP yield (colored bars) and corresponding oxygen 
consumption (striped bars) without biomass production. Both values were referred 
to 1 mol carbon for better comparability. Sugar and sugar alcohols are marked in blue, 
amino acids in red and other short chain carboxylic acids in grey.  
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The branched chain amino acids (L-valine, L-leucine and L-isoleucine) belong to the 
six amino acids with the highest possible ATP yield but are not preferred by P. inhibens 
DSM 17395 with casamino acids as carbon source (chapter 3.1.2) (Zech et al. 2013b). 
In previous studies by Drüppel et al. (2014) growth with the branched chain amino 
acids as single carbon source was slower compared to e.g. L-threonine or succinate. 
These differences could indicate less efficient transporter for the branched chain 
amino acids, differences in maintenance energy or biomass composition. 
Furthermore, TDA production might be dependent on the respective carbon source 
and should be considered for comparison of theoretical and actual energetic 
efficiency.  
3.3.3 Growth characteristics with single amino acids as carbon source 
P. inhibens DSM 17395 was adapted by two consecutive transfers to each amino acid 
(L-alanine, L-threonine, L-phenylalanine, L-lysine or L-leucine) for determination of 
growth characteristics. Growth was similar for L-alanine and L-threonine with a 
longer lag phase observed for L-threonine (figure 3.25). The biomass yields YX/C of 
both substrates were only about 1-2 gCDW molC-1 lower compared to those determined 
in chapter 3.2.1 for the wild-type strain with casamino acids as carbon source 
(10 ± 0.9 gCDW molC-1). The similarity between L-alanine and L-threonine is in 
accordance with the similar possible ATP yields (figure 3.24). Cultures with L-
phenylalanine showed slightly decreased CDWmax and biomass yield YX/C. The highest 
growth efficiency under the given conditions was observed with L-leucine and the 
lowest with L-lysine as carbon source. The low growth efficiency observed for L-lysine 
is contrary to the predicted possible ATP yield which was similar to L-leucine. Thus, 
the low growth efficiency with L-lysine might be connected to the in chapter 3.1.4 
described pipecolate production which is probably not catabolized for energy and 
biomass generation.  
Cultures with L-leucine as carbon source showed only a weak yellow-brownish color 
(TDA-iron complex) in the late stage of growth while all other cultures already 
produced TDA at an early stage of growth. Thus, the lower biomass yield compared to 
L-leucine might be connected to the TDA production. However, it is not distinct if less 
carbon is available for biomass production due to the costs for TDA biosynthesis 
3 RESULTS AND DISCUSSION  73 
 
and/or due to the inhibitory effect by TDA because the available carbon source was 
completely depleted.  
 
Figure 3.25 Growth characteristic of the wild-type strain adapted to single 
amino acids. Shown are CDW over time and corresponding CDWmax and YX/C for the 
wild-type strain with L-alanine (grey), L-threonine (green), L-phenylalanine(red), L-
lysine (orange) and L-leucine (blue) as sole carbon source. Lag phases were corrected 
for L-threonine. 
Thus, L-phenylalanine as the TDA-precursor, L-alanine as an amino acid with 
immediate access to the central carbon metabolism and L-leucine as an amino acid 
with a more complex degradation pathway, slower growth and less TDA production 
were chosen for further experiments with TDA-free mutant strains. To exclude 
growth differences due to the adaptation process all cultivations were performed 
with only one preculture in the respective single amino acid. Without a functional TDA 
biosynthesis growth efficiency with L-alanine and L-leucine was similar to casamino 
acids (figure 3.26). Furthermore, with L-phenylalanine YX/C were slightly decreased 
compared to L-alanine and L-leucine for both TDA-free mutant strains. This could be 
explained by the less energetic efficiency determined by the maximal possible ATP 
yield (figure 3.24). The wild-type strain only reached about 55% (L-alanine and L-
leucine) or 30% (L-phenylalanine) of the YX/C of the TDA-free mutant strains. Only 
50% of the YX/C of the adapted L-phenylalanine cultures were reached without 
adaptation. The observed drawback in growth efficiency due to TDA production was 
analyzed in the context of energy requirements and carbon flux aided by in silico 
analyses with the metabolic model iPin571.  
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Figure 3.26 Growth characteristics of the wild-type, the Δ262-kb and tdaE 
mutant strains with single amino acids. Shown are cell dry weights (CDW) over 
time and corresponding CDWmax and YX/C with L-alanine (grey), L-phenylalanine(red) 
and L-leucine (blue) as sole carbon source. Cells were not adapted to the amino acids. 
3 RESULTS AND DISCUSSION  75 
 
3.3.4 Biomass composition 
In silico analyses of growth efficiency based on biomass production require reliable 
data for the biomass composition. Thus, experimental determination for the biomass 
composition was conducted as accurately as possible with the available analytics 
(figure 3.27). It was possible to determine DNA, RNA, lipids, protein and PHB content. 
Furthermore, the content of peptidoglycan was estimated to approximately 12% 
based on measurement of total diaminopimelate in samples with L-alanine, L-
phenylalanine and L-leucine as carbon sources. This estimated peptidoglycan content 
is unusual for Gram-negative bacteria and almost 5-fold higher compared to E. coli 
(Feist et al. 2007). A thicker murein layer could maintain a higher turgor pressure and 
might be a strategy of P. inhibens DSM 17395 to the higher salt concentrations. 
 
Figure 3.27 Determined biomass composition. Shown are experimentally 
determined biomass components as % of the complete CDW. For detailed values see 
table S15. 
Main differences between the substrates were observed in PHB content which was 
least abundant with L-alanine as carbon source. In contrast to the higher 
accumulation of PHB in the Δ262-kb mutant strain with casamino acids at ODmax 
(Trautwein et al. 2016) no differences related to the 262-kb plasmid could be 
observed for cultivations with single amino acids. The transposon mutant strain tdaE 
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produced more PHB with L-phenylalanine and L-leucine compared to the wild-type 
and Δ262-kb mutant strain. The difference is more distinct with L-phenylalanine as 
carbon source and might indicate a use of degradation products of the accumulating 
TDA biosynthesis intermediates for PHB production. The highest protein content was 
observed with L-lysine as carbon source. L-lysine was not included in the estimation 
of the peptidoglycan content and the content seems to be overestimated as 100% 
biomass is reached but the residual includes lipopolysaccharide (~3.4%) and soluble 
metabolites (~2%). The L-lysine degradation product pipecolate was already 
discussed as possible compatible solute in chapter 3.1.4. Thus, due to production of 
pipecolate a thinner murein layer might be possible. Furthermore, L-glutamate was 
implemented in the biomass composition (all carbon sources) for the metabolic 
model with about 4% based on quantification for D. shibae DFL12 (Kleist et al. 2016). 
RNA content is correlating with the growth rates. Thus, lowest RNA could be isolated 
with L-leucine as carbon source. 
3.3.5 Determination of GAM and NGAM 
Usually, growth-and non-growth-associated maintenance energy (GAM and NGAM) 
are determined by chemostat cultivations. Most metabolic models are reconstructed 
with GAM and NGAM values published for hardly related organisms. Here, the 
different observed growth rates for the different amino acids as carbon source were 
used instead of adjusted dilution rates in chemostat cultivations for the experimental 
determination of GAM and NGAM. As described in chapter 3.3.3, TDA-free cultures 
showed optimal growth while the wild-type strain is inhibited by TDA when grown 
on L-alanine or L-phenylalanine. Thus, only TDA-free cultures were included in the 
determination of GAM and NGAM. The y-intercept is representing NGAM costs while 
the slope can be used for determination of GAM. 
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Figure 3.28 Determination of NGAM (A) and GAM (B). (A) Specific uptake rates qS 
in mmolC gCDW-1 h-1 were plotted over the corresponding growth rates for L-alanine 
(blue), L-phenylalanine (red) and L-leucine (green) for the wild-type strain (squares), 
the Δ262-kb mutant strain (circle) and the tdaE transposon mutant strain (triangle). 
(B) Shown are experimental data from A (black line, stars) compared to predicted 
data in a range from 80-95 mmolATP gCDW-1  (blue dash lines). Predicted values for 85 mmolATP gCDW-1  (red line, circles) and 90 mmolATP gCDW-1  (green line, circles) are shown 
for each simulated data point. 
Transfer of the determined specific uptake rate qS at a growth rate of 0 h-1 yields 4.8 
(L-alanine), 4.5 (L-phenylalanine) and 5.0 (L-leucine) mmolATP gCDW-1 h-1 as NGAM 
values (figure 3.28 A, table 3.9). Thus, NGAM costs are higher compared to P. putida 
(3.96 mmolATP gCDW-1 h-1) but lower compared to E. coli (7.6 to 8.39 mmolATP gCDW-1 h-1) 
which were determined by chemostat cultivations (van Duuren et al. 2013; Feist et al. 
2007; Varma, Palsson 1994b).  
Table 3.9 Determination of NGAM. The determined specific uptake rate qS (mmolC gCDW-1 h-1) at a growth rate of 0 h-1 was transferred into mmolATP gCDW-1 h-1for L-alanine, 
L-phenylalanine and L-leucine.  
Amino acid mmolC gCDW-1 h-1 mmolS gCDW-1 h-1 mmolATP gCDW-1 h-1 
L-alanine 1.2 0.40 4.8 
L-phenylalanine 1.2 0.13 4.5 
L-leucine 1.2 0.20 5.0 
GAM was estimated by FBA with the respective experimentally determined specific 
substrate uptake rate qS. Different values for GAM within a range from 80 to 
95  mmolATP gCDW-1  were used for the simulations and the predicted growth rates were 
compared to the experimental data (figure 3.28 B). Changes in GAM have only a minor 
effect on the predictions with lower substrate uptake rates/growth rates and increase 
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with increasing growth rates and corresponding higher substrate uptake rates. 
Overall, a GAM value of 85 mmolATP gCDW-1  was chosen for further analyses and thus 
GAM is equal to the determined value of P. putida (van Duuren et al. 2013). GAM was 
estimated to 59.81 and 71 mmolATP gCDW-1  in chemostat cultivations for E. coli ( (Feist 
et al. 2007; Varma, Palsson 1994b). Thus, the maintenance for non-growth-associated 
processes are lower compared to E. coli but the growth-associated maintenance 
requirements are higher.  
Overall, the determination of GAM and NGAM for P. inhibens DSM 17395 with batch 
cultivations in Erlenmeyer flasks resulted in values which suit to literature data. This 
determination was possible with optimal growing (TDA-free) cultures with different 
growth rates achieved by combining amino acid overarching growth data. Wild-type 
strain cultivations with L-alanine and L-phenylalanine as carbon source could not be 
implemented in the determination of GAM and NGAM due to growth inhibition by TDA 
on both substrates (figure 3.25, figure 3.26). Thus, the drawback of TDA production 
on the growth efficiency will be analyzed aided by the metabolic model.  
3.3.6 Carbon flux and energy supply dependent on TDA production 
Experimental and theoretical biomass yield YX/C and oxygen consumption for 
cultivations with single amino acids were compared (figure 3.29). The TDA-free 
mutant strains showed optimal growth and experimental and theoretical biomass 
yields were similar, which was already observed in chapter 3.3.5 for determination of 
GAM and NGAM. The predicted oxygen consumption was least with L-alanine and 
increased with L-phenylalanine and highest were observed with L-leucine which is 
similar to the predictions for maximal possible ATP yields (figure 3.24). However, the 
experimentally determined oxygen consumption were about 20-30% higher with L-
alanine and L-leucine compared to the predicted values indicating a higher 
respiratory activity than theoretically necessary. The wild-type strain reached only 
67% (L-alanine), 42% (L-phenylalanine) or 77% (L-leucine) of the theoretically 
possible biomass yield. Experimentally determined oxygen consumptions were 
higher in the wild-type strain compared to the TDA-free mutant strains. The higher 
absolute oxygen consumption per gCDW with decreasing growth rates and almost 
constant specific oxygen uptake rates qO2 was already described in chapter 3.2.3 and 
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is explainable by the disruption of the proton motive force by TDA (Wilson et al. 
2016). 
 
Figure 3.29 Comparison of experimental and theoretical biomass yield and 
oxygen consumption for L-alanine, L-phenylalanine and L-leucine. Shown are 
experimental (grey) and predicted (blue) biomass yield YX/C and oxygen consumption 
for cultivations with L-alanine, L-phenylalanine and L-leucine as single carbon 
sources. Experimental qS from ½ CDWmax (growth curves shown in figure 3.26) were 
used for FBA analyses.  
Furthermore, observed biomass yield and oxygen consumption with L-alanine as 
carbon source were similar as with casamino acids (figure 3.23, table S14) indicating 
similar TDA production. With the TDA precursor L-phenylalanine, biomass yield 
decreased about 48% compared to L-alanine and oxygen consumption increased 
about 42% indicating a higher TDA production. The inhibition by TDA might be 
represented by a higher NGAM resulting in less available ATP for biomass production. 
This is only an approximation because the proton gradient is disrupted and thus, the 
ATP hydrolyzed in NGAM reaction is not actually produced. However, this is the 
easiest way to implement higher oxygen consumption into the model. With 
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experimental data from L-alanine and two L-phenylalanine cultivations (adapted 
cells) NGAM could be determined with the method described in chapter 3.3.5.  
 
Figure 3.30 Determination of NGAM for representing the inhibition effect by 
TDA. Specific uptake rates qS in mmolC g-1 h-1 were plotted over the corresponding 
growth rates for L-alanine (blue) and L-phenylalanine (red) for the wild-type strain. 
FBAs with the determined NGAM values and restricted biomass production predicted 
TDA production with L-alanine as carbon source of about 0.47 mmolTDA gCDW-1  which 
is corresponding to 170 µM TDA (table 3.10). In previous studies by Berger et al. 
(2011) approximately 400 µM TDA was maximally reached with MB medium. 
However, with L-phenylalanine the experimental µ of 0.035 h-1 could not be reached 
and no production of TDA was possible with this scenario. TDA production was 
observed for all cultivations with L-phenylalanine which is the precursor for TDA 
production. Thus, using an estimation of NGAM determined by specific uptake rates 
of the carbon sources is not possible. Furthermore, it indicates that the higher specific 
uptake rates are not entirely reflecting the higher energetic costs due to higher oxygen 
consumption and consequently higher CO2 production. In this experimental set-up, it 
might be considered that costs for the TDA biosynthesis itself reduces the available 
carbon.  
Table 3.10 Predicted oxygen consumption, CO2 and TDA production for the 
wild-type strain with higher NGAM costs. The upper bound of the biomass reaction 
was restricted to the experimentally determined growth rate and NGAM was set to 
20.8 (L-alanine) and 19.6 (L-phenylalanine) mmolATP gCDW-1 h-1. All simulations were 
performed with the respective experimental qS. 
Amino acid µ [h-1] mmolO2 gCDW-1  mmolCO2 gCDW-1  mmolTDA gCDW-1  
L-alanine 0.16 63 67 0.47 
L-phenylalanine 0.028 236 21 0 
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In casamino acid containing medium the variety and availability of carbon sources is 
high. Thus, probably only a minor effect of decreased biomass yield is attributed to 
less available carbon due to TDA production. However, for L-phenylalanine cultures, 
inoculated with growing cells from casamino acids cultures, mainly TDA production 
was observed and first considerably biomass production initiated at about 100 h 
(figure 3.31). After already one transfer lag phase was shortened to 30 h and CDWmax 
was almost doubled. Both cultivations showed a stationary growth phase while for 
adapted cells no transient and stationary phase could be observed. Overall, these 
results indicate the use of L-phenylalanine mainly as a TDA precursor in casamino 
acid cultures.  
 
Figure 3.31 Adaptation of the wild-type strain to L-phenylalanine as carbon 
source. Shown are growth curves from cultures directly inoculated with a casamino 
acid preculture (black), cultures inoculated with one preculture in L-phenylalanine 
(red) and two independent cultures with adapted glycerol-stocks (blue).   
To analyze this adaptation effect, the carbon flux distribution was calculated based on 
the experimentally determined specific substrate uptake rates and growth rates. The 
theoretically possible TDA production was predicted by restriction of the biomass 
reaction to the experimentally observed growth rate. Thus, excess carbon could be 
catabolized to TDA and CO2. The overall oxygen consumption and CO2 production 
increased with increasing TDA production (table 3.11). No TDA production for wild-
type cells adapted to L-leucine as substrate was possible. This is the only analyzed 
wild-type culture showing similar growth efficiency compared to the TDA-free 
mutant strains.  
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Table 3.11 Predicted oxygen consumption, CO2 and TDA production for the 
wild-type strain with restricted growth and normal NGAM costs. The upper 
bound of the biomass reaction was restricted to the experimentally determined 
growth rate and NGAM was set to the values determined in chapter 3.3.5. All 
simulations were performed with the respective experimental qS. a: adapted 
Amino acid strain mmolO2 gCDW-1  mmolCO2 gCDW-1  mmolTDA gCDW-1  mM TDA 
L-alanine 
WT 46 55 2.0 0.7 
Δ262-kb 33 36 0 0 
tdaE 31 34 0 0 
L-
phenylalanine 
WT 104 109 7.3 1.4 
WT-a1 81 84 5.1 1.5 
WT-a2 61 62 2.9 1.2 
Δ262-kb 43 40 0 0 
tdaE 47 43 0 0 
L-leucine 
WT 83 68 1.2 0.4 
WT-a 61 48 0 0 
Δ262-kb 52 40 0 0 
tdaE 50 39 0 0 
50% of the available carbon is used for biomass production and 50% is respired to 
CO2 in TDA-free mutant strains (table 3.12). For the wild-type strain slightly increased 
CO2 production is predicted with L-leucine as carbon source. If TDA production is 
active, CO2 production remained approximately at 50% but carbon incorporated into 
biomass decreased. The adaptation process of the wild-type strain to L-phenylalanine 
increased carbon flux to biomass from 19.1 to 31.6% with decreasing of TDA from 
28.2 to 18.9%. Thus, cells with already one preculture in L-phenylalanine had only 
19.1% of the carbon available for biomass production.  
A higher CO2 flux and less TDA production might be possible due to the disruption of 
the proton gradient. Thus, the method is restricted and absolute quantification of TDA 
would be necessary. However, TDA quantification is challenging due to the TDA-iron 
complex which is precipitated while extraction procedure and the available standard 
substance which showed a different behavior. 
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Table 3.12 Predicted carbon flux distribution dependent on TDA production. 
Listed are the theoretically carbon flux distributions for L-alanine, L-phenylalanine 
and L-leucine for the wild-type strain and TDA-free mutant strains. The flux values for 
CDW, CO2 and TDA were referred to the specific uptake rate qS (both values 
transferred into mmolC). a: adapted 
Amino acid strain % CDW % CO2 % TDA 
L-alanine 
WT 34.1 51.1 14.8 
Δ262-kb 51.0 49.0 0 
tdaE 52.5 47.5 0 
L-phenylalanine 
WT 19.1 52.7 28.2 
WT-a1 27.3 48.9 23.8 
WT-a2 31.6 49.5 18.9 
Δ262-kb 49.5 50.5 0 
tdaE 49.6 50.4 0 
L-leucine 
WT 28.3 62.8 8.9 
WT-a 45.5 54.5 0 
Δ262-kb 51.0 49.0 0 
tdaE 50.7 49.3 0 
Overall the presented metabolic model-based analyses showed a high growth 
efficiency of P. inhibens DSM 17395 for many different substrates if growth is not 
inhibited by TDA. Observed biomass yields were independent from the growth rate. 
Thus, with L-leucine similar biomass yield was observed as for L-alanine and L-
phenylalanine. Lipson (2015) already discussed the complex relationship between 
microbial growth rate and yield. One explanation for differences in growth rates and 
yields are different maintenance requirements. However, for the tested substrates the 
differences in NGAM were negligibly. Instead, L-leucine showed slower growth rates 
due to slower substrate uptake.  
P. inhibens DSM 17395 is highly adapted to its habitat with energetically efficient use 
of many substrates. Furthermore, within some days or hours this organism is able to 
adapt to carbon sources to improve efficiency. However, TDA production is a 
drawback on energy supply due to degradation of the proton gradient. This effect is 
probably lower in the marine environment due to higher dilution. Furthermore, 
P. inhibens DSM 17395 is producing less TDA in stagnant cultures (Berger et al. 2011) 
indicating less production when growing attached to marine algae.  
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4 Conclusion 
Extrachromosomal elements with a broad range of functions are widely spread 
amongst Rhodobacteraceae and enable optimal adaptation and survival in the natural 
habitat. For example, the 153-kb plasmid of D. shibae has an essential role in dealing 
with salinity extremes (Kleist et al. 2016) and the 65-kb (biofilm)plasmid of 
P. inhibens DSM 17395 is crucial for motility and colonization of the marine algal host 
(Frank et al. 2014).  
One metabolic role of the 262-kb plasmid is the uptake of glucose and xylose 
(Wiegmann et al. 2014). Deletion of the 262-kb plasmid resulted in enhanced growth 
with casamino acids as substrate. Metabolic analyses showed that this plasmid is not 
involved in the uptake and degradation of amino acids. Only minor changes in lysine 
catabolism could be attributed to the missing plasmid due to accumulation of 
pipecolate which is synthesized from L-lysine. The 262-kb plasmid encodes for a 
pipecolate oxidase which was shown to be necessary for further use of pipecolate with 
unknown final product. The main degradation pathway via cadaverine is crucial for 
biomass production from L-lysine. Pipecolate might originally function as compatible 
solute and with receipt of the 262-kb plasmid pipecolate is further degraded.  
The main function of the 262-kb plasmid is the biosynthesis of the antibacterial 
compound TDA. Based on the obtained data, it was possible to propose an updated 
biosynthetic pathway involving sulfur incorporation steps via an episulfide structure. 
Besides the TDA biosynthetic gene cluster on the 262-kb plasmid, further proteins 
encoded on the chromosome are crucial for TDA biosynthesis. Thus, P. inhibens DSM 
17395 developed a high specific and unusual biosynthetic pathway for a sulfur 
containing antibiotic. Recently, TDA was shown to be active as signaling molecule in 
global gene regulation (Beyersmann et al. 2017). Lacking the complete 262-kb 
plasmid resulted in various changes on transcriptomic level. Several of them could be 
related to the TDA biosynthesis and one methyltransferase was newly proposed to be 
involved in the conversion of “pre”-TDA to TDA.  
Furthermore, deletion of the 262-kb plasmid led to high expression levels of a 
putative lipoteichoic acid (LTA) biosynthetic gene cluster observed at maximally 
reached biomass. Possible components of this putative LTA could be identified and 
structures were proposed to include 3-hydroxybutanoate units originated from the 
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accumulated storage compound PHB. At the same time point expression levels of a 
gene cluster including phage relevant genes increased. Thus, starvation might trigger 
a phage and LTA is produced in return to counteract the phage. This observation is 
only indirectly connected to the 262-kb plasmid. The wild-type strain did not reach a 
starvation phase due to the immense growth restriction by TDA. 
It was shown that this observation is connected to an inhibitory effect of TDA on the 
wild-type strain due to disruption of the proton gradient. P. inhibens DSM 17395 is 
not able to fully counteract by higher respiratory activity to this effect. Furthermore, 
in silico analyses showed optimal growth efficiency for different substrates without 
an active TDA production. However, if TDA biosynthesis is active more oxygen is 
consumed per gCDW due to the inhibitory effect resulting in decreased biomass yield. 
L-phenylalanine, the precursor for TDA, was shown to be mainly used for TDA 
production if no adaptation to this carbon source for biomass production is ensued 
resulting in decreasing biomass yield due to less available carbon.  
Thus, despite the drawback on energetic level, TDA production and consequently 
carrying the 262-kb plasmid seem to provide benefits in the natural habitat.  For the 
more complex substrate range while algal bloom (represented in this work by 
casamino acids) only a minor effect of less available carbon due to TDA production is 
expected. Furthermore, less TDA is produced in stagnant cultures (Berger et al. 2011). 
Thus, the inhibitory effect could be lower when P. inhibens DSM 17395 is growing 
attached to the algae.  
Growth efficiency and nutritionally versatility combined with production of an 
antibacterial compound to inhibit competitors is the successful survival strategy of 
P. inhibens DSM 17395. Consequently, growth efficiency in extreme habitats is not 
represented by a high growth rate but a high biomass yield.  
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Supplementary material 
Table S1a Normalized peak areas of intracellularly detected metabolites of the 
wild-type and Δ262-kb mutant strain at ½ ODmax with casamino acids as carbon 
source (cultivation in process-controlled bioreactors). Normalized peak areas are 
listed with corresponding standard error for all identified metabolites detectable at 
least in one of both strains. n.d.: not detected. Cultivation and sampling were 
performed by the working group of Ralf Rabus (ICBM). 
Metabolite 
½ ODmax 
WT Δ262-kb 
2,4-diaminobutanoate 4.2x104 ± 8.3x102 5.7x104 ± 2.6x103 
2,6-diamino-pimelate 1.1x105 ± 4.5x103 1.4x105 ± 8.3x103 
2-aminoadipic-acid 7.4x104 ± 2.7x103 8.5x103 ± 1.3x103 
2-isopropylmalic acid 1.6x104 ± 8.8x102 8.1x103 ± 3.9x102 
2-oxoglutarate 1.5x104 ± 7.6x102 1.3x104 ± 4.8x102 
3-aminoisobutanoate 2.3x104 ± 2.1x103 2.6x104 ± 3.1x103 
3-hydroxybutanoate 3.7x104 ± 2.3x103 5.7x104 ± 2.6x103 
3-hydroxy-decanoate 1.3x104 ± 8.7x102 1.2x104 ± 7.1x102 
3-phosphoglycerate 2.6x104 ± 1.6x103 4.3x104 ± 1.4x103 
5-aminopentanoic-acid 4.9x106 ± 1.8x105 7.2x106 ± 5.8x105 
6-phospho-gluconate 7.0x103 ± 1.0x103 5.9x103 ± 3.1x102 
Adenine 1.2x105 ± 3.5x103 9.1x104 ± 2.4x103 
Alanine 7.1x106 ± 7.5x105 5.8x106 ± 7.1x105 
AMP 7.0x105 ± 2.2x104 7.0x105 ± 1.4x104 
Arginine 9.7x103 ± 3.4x102 1.3x104 ± 5.0x102 
Asparagine 1.8x104 ± 8.4x102 2.8x104 ± 1.5x103 
Aspartate 2.5x106 ± 1.4x105 3.0x106 ± 2.3x105 
Beta-alanine 5.5x104 ± 5.0x103 3.4x104 ± 4.5x103 
Cadaverine 1.0x105 ± 7.6x103 6.8x105 ± 1.8x105 
Cis-vaccenic acid 1.8x104 ± 1.9x103 1.8x104 ± 1.5x103 
Citrate 2.2x104 ± 1.1x103 3.5x104 ± 8.5x102 
Cysteine 1.0x104 ± 2.4x103 6.9x103 ± 1.4x103 
Cysteinylglycine 6.5x104 ± 5.2x103 5.9x104 ± 5.8x103 
Cytosine 1.6x105 ± 7.7x103 1.3x105 ± 6.0x103 
D200302_2009.31 n.d. 3.8x104 ± 2.4x103 
D-glucosaminate 2.2x104 ± 1.3x103 1.1x104 ± 9.3x102 
Ethanolamine 3.8x104 ± 1.9x103 7.2x104 ± 2.8x103 
Fructose-1,6-bisphosphate 5.5x104 ± 7.2x103 5.2x104 ± 6.6x103 
Fumarate 5.4x104 ± 7.7x102 4.4x104 ± 1.3x103 
Glucose 7.0x104 ± 1.7x103 5.3x104 ± 1.6x103 
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Table S1a continued 
Metabolite 
½ ODmax 
WT Δ262-kb 
Glucose-6-phosphate 1.5x104 ± 8.8x102 1.2x104 ± 5.1x102 
Glutamate 5.9x107 ± 1.0x106 5.7x107 ± 1.1x106 
Glutamine 3.9x106 ± 2.3x105 3.3x106 ± 2.9x105 
Glutarate 2.6x104 ± 1.1x103 2.1x104 ± 1.1x103 
Glycerol-3-phosphate 2.5x105 ± 1.2x104 3.0x105 ± 1.9x104 
Glycerophosphoglycerol 9.1x104 ± 4.2x103 9.9x104 ± 4.7x103 
Glycine 3.4x105 ± 1.7x104 3.2x105 ± 1.3x104 
Glycylglycine 1.2x105 ± 1.6x104 6.2x104 ± 1.1x104 
Glycylproline 6.3x103 ± 9.8x102 3.1x104 ± 6.5x103 
GMP 6.4x104 ± 1.5x103 6.9x104 ± 1.7x103 
Guanine 2.6x104 ± 9.6x102 2.4x104 ± 1.2x103 
Histidine 4.9x104 ± 2.0x103 7.4x104 ± 3.7x103 
Isoleucine 4.1x105 ± 1.2x104 3.5x105 ± 2.5x104 
Leucine 3.7x105 ± 2.4x104 2.9x105 ± 2.2x104 
Lysine 2.9x105 ± 9.1x103 3.4x105 ± 1.1x104 
Malate 7.0x104 ± 2.1x103 5.2x104 ± 1.1x103 
Methionine 1.5x105 ± 1.6x104 1.3x105 ± 1.7x104 
NA_1703.1 2.1x104 ± 1.5x103 4.6x104 ± 2.8x103 
NA_1705.1 1.3x104 ± 1.3x103 1.1x104 ± 6.5x103 
NA199017_1996.71 3.2x104 ± 1.3x103 2.5x104 ± 1.6x103 
NA261 1.0x105 ± 5.1x103 1.1x105 ± 5,2x103 
NA714 n.d. 2.4x105 ± 1.6x104 
N-acetyl-glutamate 9.7x103 ± 4.7x102 1.0x104 ± 7.2x102 
Nicotinamide 1.3x105 ± 3.0x103 1.1x105 ± 4.8x103 
Ornithine 3.3x104 ± 8.6x102 5.4x104 ± 4.9x103 
Phenylalanine 3.4x105 ± 1.4x104 3.7x105 ± 1.4x104 
Phosphate-monomethyl ester 3.4x104 ± 1.1x103 4.4x104 ± 1.0x103 
Phosphoenolpyruvate 4.9x103 ± 6.9x102 2.2x104 ± 1.1x103 
Pipecolate 9.3x105 ± 2.6x104 3.2x106 ± 7.6x104 
Proline 7.4x105 ± 5.7x104 5.8x105 ± 7.7x104 
Putrescine 6.5x104 ± 3.9x103 3.0x104 ± 3.6x103 
Pyroglutamate 7.1x106 ± 3.4x105 6.0x106 ± 2.3x105 
Serine 8.2x104 ± 3.6x103 2.2x105 ± 5.5x103 
Spermidine 2.7x104 ± 1.2x103 2.3x104 ± 1.1x103 
Succinate 6.8x104 ± 8.9x102 5.9x104 ± 1.3x103 
Threonine 2.0x105 ± 2.1x104 2.9x105 ± 2.7x104 
Thymine 3.3x104 ± 8.8x102 2.5x104 ± 6.2x102 
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Table S1a continued 
Metabolite 
½ ODmax 
WT Δ262-kb 
Tyrosine 1.4x106 ± 4.5x104 6.3x105 ± 3.0x104 
UMP 2.2x105 ± 1.2x104 1.8x105 ± 1.5x104 
Unknown#1169.8-pae-bth_013 7.4x104 ± 3.9x103 6.6x104 ± 2.9x103 
Unknown#1248.7-cgl-sst_008 1.2x105 ± 7.5x103 1.3x105 ± 1.2x104 
Unknown#1361.3-pin-mhe_010 2.9x104 ± 1.3x103 2.0x104 ± 1.0x103 
Unknown#1830.2-pin-mhe_038 1.6x104 ± 5.4x102 1.4x104 ± 8.4x102 
Unknown#2018.7-pin-mhe_028 4.0x104 ± 2.2x103 3.6x104 ± 1.3x103 
Unknown#2148.0-pin-mhe_047 1.5x104 ± 6.3x102 1.9x104 ± 1.3x103 
Unknown#2394.5-pin-mhe_056 1.7x104 ± 6.0x102 2.7x104 ± 7.5x102 
Unknown#2442.5-pin-mhe_059 n.d. 2.5x104 ± 1.7x103 
Unknown#2548.1-pin-mhe_066 1.2x104 ± 1.0x103 9.9x103 ± 1.1x103 
Uracil 5.2x104 ± 1.8x103 4.7x104 ± 1.7x103 
Uric acid 1.3x104 ± 6.9x102 5.7x103 ± 2.2x102 
Valine 4.3x106 ± 2.4x105 3.3x106 ± 2.9x105 
Xanthine 1.7x104 ± 1.1x103 1.4x104 ± 7.6x102 
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Table S1b Normalized peak areas of intracellularly detected metabolites of the 
wild-type and Δ262-kb mutant strain at ODmax with casamino acids as carbon 
source (cultivation in process-controlled bioreactors). Normalized peak areas are 
listed with corresponding standard error for all identified metabolites detectable at 
least in one of both strains. n.d.: not detected. Cultivation and sampling were 
performed by the working group of Ralf Rabus (ICBM). 
Metabolite 
ODmax 
WT Δ262-kb 
2,4-diaminobutanoate 5.3x104 ± 6.3x103 1.6x104 ± 3.8x103 
2,6-diamino-pimelate 1.7x105 ±2.3x104 3.6x104 ± 4.4x103 
2-aminoadipic-acid 1.4x105 ± 6.9x103 3.6x104 ± 2.3x103 
2-isopropylmalic acid 3.4x104 ± 3.6x103 5.2x103 ± 2.8x102 
2-oxoglutarate 8.4x103 ± 8.7x102 8.4x103 ± 6.4x102 
3-hydroxybutanoate 1.8x104 ± 2.8x103 4.1x104 ± 2.4x103 
3-hydroxy-decanoate 9.4x103 ± 7.8x102 8.4x103 ± 3.9x102 
5-aminopentanoic-acid 3.8x106 ± 5.9x105  1.1x106 ± 1.2x105 
Adenine 8.3x104 ± 5.4x103  6.1x104 ± 3.6x103 
Alanine 7.7x106 ± 7.1x105 2.9x106 ± 3.3x105 
Alanyl-alanine 4.0x105 ± 2.7x104 1.6x105 ± 7.5x103 
AMP 6.6x105 ± 3.1x104 5.1x105 ± 2.3x104 
Arginine 9.1x103 ± 6.3x102 1.1x104 ± 8.3x102 
Asparagine 1.4x104 ± 1.4x103 2.1x104 ± 1.3x103 
Aspartate 3.6x106 ± 7.6x105 1.0x106 ± 1.3x105 
Cadaverine 1.4x106 ± 3.4x105 8.1x105 ± 6.9x104 
Cis-vaccenic acid 2.0x104 ± 3.5x103 1.3x104 ± 9.9x102 
Citrate 3.7x104 ± 2.3x103 3.8x104 ± 4.4x103 
Cysteine 1.1x103 ± 1.1x103 1.8x104 ± 3.9x103 
Cysteinyl-glycine 1.0x105 ± 8.4x103 6.4x104 ± 3.0x103 
Cytosine 8.2x104 ± 5.3x103 6.3x104 ± 4.1x103 
D200302_2009.31 n.d. 5.1x104 ± 3.3x103 
Ethanolamine 2.9x104 ± 2.6x103 6.4x104 ± 6.6x103 
Fumarate 5.0x104 ± 4.1x103 3.6x104 ± 1.8x103 
Glucose 7.5x104 ± 3.2x103 4.2x104 ± 3.0x103 
Glutamate 3.3x107 ± 3.0x106 2.9x107 ± 2.0x106 
Glutamine 9.6x105 ± 1.1x105 4.9x105 ± 7.2x104 
Glutarate 2.6x104 ± 2.4x103 7.7x103 ± 5.3x102 
Glycerate 3.0x103 ± 3.0x102 4.7x103 ± 3.5x102 
Glycerol-3-phosphate 2.0x105 ± 2.1x104 2.1x105 ± 2.2x104 
Glycerophosphoglycerol 2.9x104 ± 4.1x103 4.2x104 ± 5.2x103 
Glycine 6.0x105 ± 8.7x104 4.4x105 ± 3.9x104 
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Table S1b continued 
Metabolite 
ODmax 
WT Δ262-kb 
Glycylglycine 1.6x104 ± 1.9x103 7.8x104 ± 1.5x104 
Glycyl-proline n.d. 7.0x104 ± 4.1x103 
GMP 5.0x104 ± 3.5x103 4.9x104 ± 2.7x103 
Guanine 1.8x104 ± 1.7x103 1.7x104 ± 8.8x102 
Histidine 3.7x104 ± 2.9x103 3.5x104 ± 4.8x103 
Homoserine 2.2x104 ± 4.3x103 n.d. 
Isoleucine 1.1x106 ± 1.1x105 1.6x105 ± 2.0x104 
Leucine 1.2x106 ± 9.8x104 2.0x105 ± 3.0x104 
Lysine 2.4x105 ± 1.7x104 5.8x105 ± 6.2x104 
Malate 7.0x104 ± 8.1x103 2.9x104 ± 1.8x103 
Methionine 1.4x105 ± 2.0x104 5.5x104 ± 6.9x103 
NA_1703.1 1.1x104 ± 1.1x103 3.2x104 ± 4.8x103 
NA199017_1996.71 4.8x104 ± 2.4x103 1.4x104 ± 2.3x103 
NA261 7.8x104 ± 1.1x104 8.5x104 ± 8.2x103 
NA714 n.d. 1.0x106 ± 6.0x104 
N-acetyl-glutamate 1.2x104 ± 5.2x102 1.3x104 ± 1.4x103 
Nicotinamide 1.5x105 ± 1.1x104 1.3x105 ± 1.0x104 
Octadecanoate 7.0x103 ± 5.5x102 6.3x103 ± 3.9x102 
Ornithine 4.0x104 ± 2.7x103 3.3x104 ± 2.5x103 
Phenylalanine 3.8x105 ± 3.6x104 1.1x105 ± 9.5x103 
Phosphate-monomethyl ester 2.9x104 ± 1.6x103 2.6x104 ± 2.9x103 
Pipecolate 1.7x106 ± 9.3x104 8.0x106 ± 4.5x105 
Proline 4.2x105 ± 1.4x104 1.8x105 ± 5.4x104 
Putrescine 2.3x104 ± 2.5x103 9.4x103 ± 8.0x102 
Pyroglutamate 4.3x106 ± 4.7x105 3.0x106 ± 2.4x105 
Pyruvate 5.5x103 ± 5.5x102 2.6x103 ± 8.2x102 
Serine 6.6x104 ± 6.1x103 2.3x104 ± 1.9x103 
Succinate 5.6x104 ± 3.4x103 4.4x104 ± 2.3x103 
Threonine 1.8x105 ± 1.8x104 2.4x105 ± 3.7x104 
Thymine 3.4x104 ± 1.8x103 2.5x104 ± 1.2x103 
Tyrosine 2.1x106 ± 1.1x105 5.1x105 ± 5.4x104 
UMP 2.1x105 ± 1.3x104 1.1x105 ± 8.8x103 
Unknown#1169.8-pae-bth_013 4.6x104 ± 4.9x103 4.6x104 ± 3.7x103 
Unknown#1248.7-cgl-sst_008 1.0x105 ± 1.2x104 8.2x104 ± 7.1x103 
Unknown#1830.2-pin-mhe_038 1.3x105 ± 9.1x103 9.0x104 ± 6.8x103 
Unknown#2148.0-pin-mhe_047 8.4x103 ± 8.0x102 1.5x104 ± 9.6x102 
Unknown#2260-cgl-sst_001 1.3x105 ± 1.3x104 n.d. 
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Table S1b continued 
Metabolite 
ODmax 
WT Δ262-kb 
Unknown#2394.5-pin-mhe_056 2.4x104 ± 1.4x103 3.1x104 ± 9.0x102 
Unknown#2442.5-pin-mhe_059 3.0x104 ± 2.2x103 4.9x104 ± 5.2x103 
Unknown#2548.1-pin-mhe_066 1.1x104 ± 1.5x103 1.4x104 ± 1.3x103 
Unknown#2557.6-pin-mhe_067 2.6x104 ± 4.5x103 1.7x105 ± 1.1x104 
Uracil 4.0x104 ± 2.5x103 3.6x104 ± 3.0x103 
Uric acid 7.5x103 ± 6.5x102 8.6x103 ± 8.0x102 
Valine 5.6x106 ± 5.7x105 4.6x106 ± 2.0x105 
Xanthine 1.2x104 ± 8.4x102 1.4x104 ± 1.7x103 
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Table S2a Normalized peak areas of extracellularly detected metabolites of the 
wild-type strain and of Δ262-kb mutant strain at ½ ODmax with casamino acids 
as carbon source (cultivation in process-controlled bioreactors). Normalized 
peak areas are listed with corresponding standard error for all identified metabolites 
detectable at least in one of both strains. n.d.: not detected 
Metabolite 
½ ODmax 
WT Δ262-kb 
2-amino-2-methylpropane-1,3-diol 3.2x105 ± 6.8x103 1.9x105 ± 1.5x104 
2-oxoisovaleric acid 6.4x103 ± 4.7x102 n.d. 
Alanine 6.4x106 ± 3.5x105 2.7x106 ± 3.3x105 
Arginine 3.8x104 ± 1.6x103 3.0x104 ± 2.2x103 
Aspartate 3.6x105 ± 1.2x104 7.6x103 ± 2.7x103 
Glutamate 3.0x106 ± 4.2x104 1.7x106 ± 2.0x105 
Glycerol 5.2x104 ± 2.7x104 n.d. 
Glycine 2.5x106 ± 1.5x105 7.5x103 ± 2.5x103 
Histidine 3.3x104 ± 8.3x102 1.1x104 ± 6.6x103 
Isoleucine 2.8x106 ± 8.8x104 1.8x106 ± 7.1x104 
Leucine 3.3x106 ± 1.4x105 2.0x106 ± 9.8x104 
Lysine 3.0x106 ± 3.3x104 2.6x106 ± 1.2x105 
Methionine 4.5x105 ± 9.7x103 3.0x105 ± 1.5x104 
N-acetyl-putrescine 3.4x104 ± 1.1x104 n.d. 
Phenylalanine 1.4x106 ± 1.7x104 9.3x105 ± 5.8x104 
Pipecolate n.d. 5.2x104 ± 4.4x103 
Proline 1.6x107 ± 5.0x105 9.1x106 ± 5.8x105 
Pyroglutamate 3.9x106 ± 9.1x104 3.0x106 ± 1.9x105 
Serine 3.9x105 ± 9.7x103 2.7x105 ± 1.4x104 
Threonine 2.4x105 ± 1.3x104 1.7x105 ± 3.9x103 
Tyrosine 3.4x106 ± 6.0x104 2.4x106 ± 1.3x105 
Urea 1.8x104 ± 5.1x102  1.6x104 ± 1.8x103 
Valine 4.5x106 ± 1.4x105 3.5x106 ± 8.0x104 
 
 
 
 
 
 
 
xviii  SUPPLEMENTARY MATERIAL 
 
Table S2b Normalized peak areas of extracellularly detected metabolites of the 
wild-type strain and of Δ262-kb mutant strain at ODmax with casamino acids as 
carbon source (cultivation in process-controlled bioreactors). Normalized peak 
areas are listed with corresponding standard error for all identified metabolites 
detectable at least in one of both strains. n.d.: not detected 
Metabolite 
ODmax 
WT Δ262-kb 
2-amino-2-methylpropane-1,3-diol 2.3x105 ± 1.4x104 5.4x104 ± 2.8x103 
2-isopropylmalic acid 2.9x104 ± 1.1x103 1.3x104 ± 1.6x102 
2-oxo-isocaproic-acid 1.8x104 ± 4.6x102 n.d. 
2-oxoisovaleric acid 1.8x104 ± 9.4x102 n.d. 
3-methyl-2-oxopentanoic-acid 1.5x104 ± 5.8x102 n.d. 
Alanine 4.7x106 ± 2.5x105 n.d. 
Arginine 2.9x104 ± 1.4x103 1.5x104 ± 8.0x102 
Aspartate 2.3x104 ± 3.2x103 n.d. 
Ethanolamine n.d. n.d. 
Glutamate 1.6x106 ± 1.8x105 1.3x104 ± 4.5x103 
Glycine 7.5x104 ± 3.9x104 n.d. 
Histidine 2.2x104 ± 2.6x103 n.d. 
Isoleucine 2.7x106 ± 6.4x104 3.9x105 ± 8.8x104 
Leucine 2.7x106 ± 7.6x104 4.9x105 ± 6.2x104 
Lysine 2.4x106 ± 6.7x104 1.3x106 ± 9.1x104 
Methionine 3.2x105 ± 7.9x103 3.5x104 ± 7.0x103 
N-acetyl-putrescine 4.6x104 ± 1.5x103 n.d. 
Phenylalanine 1.2x106 ± 4.1x104 2.3x105 ± 3.7x104 
Pipecolate 4.1x104 ± 2.6x103 1.9x105 ± 1.1x104 
Proline 1.2x107 ± 5.7x105 9.5x105 ± 3.5x105 
Pyroglutamate 3.3x106 ± 6.6x104 1.5x106 ± 7.8x104 
Serine 3.6x105 ± 7.8x103 n.d. 
Threonine 2.1x105 ± 6.9x103 5.0x104 ± 6.2x103 
Tyrosine 3.0x106 ± 4.9x104 6.9x105 ± 9.2x104 
Urea 5.4x104 ± 4.1x103 2.9x104 ± 2.3x103 
Valine 4.5x106 ± 8.3x104 1.3x106 ± 1.6x105 
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Table S2c Normalized peak areas of extracellularly detected compounds in the 
casamino acids medium (cultivation in process-controlled bioreactors). 
Normalized peak areas are listed with corresponding standard error for all identified 
compounds detected in the medium prior to inoculation. 
Metabolite medium 
2-amino-2-methylpropane-1,3-diol 3.6x105 ± 2.4x104 
Alanine 6.4x106 ± 8.3x105 
Arginine 4.1x104 ± 1.8x103 
Aspartate 4.8x105 ± 1.6x104 
Ethanolamine 2.4x104 ± 5.9x102 
Glutamate 3.5x106 ± 9.6x104 
Glycerol 2.4x105 ± 7.3x104 
Glycine 2.9x106 ± 6.0x104 
Histidine 5.4x104 ± 5.6x103 
Isoleucine 2.9x106 ± 4.6x104 
Leucine 3.7x106 ± 4.9x104 
Lysine 3.5x106 ± 4.3x104 
Methionine 5.5x105 ± 9.7x103 
Phenylalanine 1.5x106 ± 1.9x104 
Proline 1.8x107 ± 3.0x105 
Pyroglutamate 4.2x106 ± 6.4x104 
Serine 4.1x105 ± 4.9x103 
Threonine 2.6x105 ± 5.0x103 
Tyrosine 3.7x106 ± 4.3x104 
Valine 4.7x106 ± 5.1x104 
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Table S3 Fold changes of intracellularly detected metabolites of the Δ262-kb 
mutant strain compared to the wild-type strain at ½ ODmax and ODmax with 
casamino acids as carbon source (cultivation in process-controlled 
bioreactors). Fold changes were determined with normalized peak areas and are 
listed with corresponding standard error. Significance was calculated with Wilcoxon-
Mann-Whitney test. Metabolites only detected in the Δ262-kb mutant strain are listed 
with “+” and metabolites only detected in the wild-type strain with n.d. (not detected). 
Metabolites detected in none of both strains are listed with “-". 
Metabolite 
½ ODmax ODmax 
Fold change p-value Fold change p-value 
2,4-diaminobutanoate 1.37 ± 0.07 0.0001554 0.30 ± 0.08 0.0001554 
2,6-diamino-pimelate 1.31 ± 0.09 0.00109 0.21 ± 0.04 0.0001554 
2-aminoadipic-acid 0.12 ± 0.02 0.0001554 0.27 ± 0.02 0.0001554 
2-isopropylmalic acid 0.50 ± 0.04 0.0001554 0.15 ± 0.02 0.0001554 
2-oxoglutarate 0.91 ± 0.06 0.16053 1.00 ± 0.13 0.95913 
3-aminoisobutanoate 1.13 ± 0.17 0.57374 - - 
3-hydroxybutanoate 1.52 ± 0.12 0.0006216 2.27 ± 0.38 0.0001554 
3-hydroxy-decanoate 0.92 ± 0.08 0.64538 0.90 ± 0.09 0.38228 
3-phosphoglycerate 1.69 ± 0.12 0.0001554 - - 
5-aminopentanoic-acid 1.46 ± 0.13 0.0001554 0.28 ± 0.06 0.0006216 
6-phospho-gluconate 0.84 ± 0.13 0.13038 - - 
Adenine 0.77 ± 0.03 0.0001554 0.73 ± 0.06 0.03792 
Alanine 0.81 ± 0.13 0.06496 0.38 ± 0.06 0.0001554 
Alanylalanine - - 0.41 ± 0.03 0.0001554 
AMP 1.00 ± 0.04 0.64538 0.78 ± 0.05 0.00109 
Arginine 1.34 ± 0.07 0.0006216 1.16 ± 0.12 0.2345 
Asparagine 1.53 ± 0.11 0.0001554 1.47 ± 0.17 0.00466 
Aspartate 1.18 ± 0.11 0.13038 0.28 ± 0.07 0.00699 
Beta-alanine 0.61 ± 0.10 0.00699 - - 
Cadaverine 6.64 ± 1.87 0.0001554 0.57 ± 0.14 0.04988 
Cis-vaccenic acid 0.99 ± 0.13 0.95913 0.63 ± 0.12 0.27863 
Citrate 1.59 ± 0.09 0.0001554 1.04 ± 0.14 0.7209 
Cysteine 0.66 ± 0.20 0.27863 16.9 ± 17.3 0.0006216 
Cysteinylglycine 0.91 ± 0.11 0.4418 0.63 ± 0.06 0.00295 
Cytosine 0.85 ± 0.06 0.03792 0.77 ± 0.07 0.04988 
D200302_2009.31 + 0.0001554 + 0.0001554 
D-glucosaminate 0.52 ± 0.05 0.0001554 - - 
Ethanolamine 1.87 ± 0.12 0.0001554 2.20 ± 0.30 0.0006216 
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Table S3: continued 
Metabolite 
½ ODmax ODmax 
Fold change p-value Fold change p-value 
Fructose-1,6-bisphosphate 0.94 ± 0.17 0.7209 - - 
Fumarate 0.83 ± 0.03 0.0001554 0.72 ± 0.07 0.01041 
Glucose 0.76 ± 0.03 0.0001554 0.56 ± 0.05 0.0001554 
Glucose-6-phosphate 0.84 ± 0.06 0.06496 - - 
Glutamate 0.96 ± 0.02 0.19487 0.86 ± 0.10 0.4418 
Glutamine 0.85 ± 0.09 0.16053 0.51 ± 0.09 0.00699 
Glutarate 0.82 ± 0.05 0.02067 0.30 ± 0.03 0.0001554 
Glycerate - - 1.56 ± 0.19 0.00466 
Glycerol-3-phosphate 1.20 ± 0.10 0.19487 1.05 ± 0.16 0.87848 
Glycerophosphoglycerol 1.09 ± 0.07 0.04988 1.43 ± 0.27 0.04988 
Glycine 0.93 ± 0.06 0.2345 0.74 ± 0.12 0.08298 
Glycylglycine 0.52 ± 0.12 0.00466 4.90 ± 1.11 0.0001554 
Glycylproline 5.00 ± 1.30 0.0001554 + 0.0001554 
GMP 1.08 ± 0.04 0.04988 0.99 ± 0.09 0.79845 
Guanine 0.90 ± 0.06 0.2345 0.93 ± 0.10 0.64538 
Histidine 1.51 ± 0.10 0.0003108 0.95 ± 0.15 0.7209 
Homoserine - - n.d. 0.0001554 
Isoleucine 0.85 ± 0.07 0.03792 0.15 ± 0.03 0.0001554 
Leucine 0.78 ± 0.08 0.02813 0.17 ± 0.03 0.0001554 
Lysine 1.15 ± 0.05 0.00466 2.38 ± 0.31 0.0001554 
Malate 0.74 ± 0.03 0.0001554 0.42 ± 0.05 0.0001554 
Methionine 0.87 ± 0.15 0.32821 0.38 ± 0.07 0.00186 
NA_1703.1 2.22 ± 0.21 0.0001554 2.79 ± 0.50 0.00699 
NA_1705.1 0.85 ± 0.10 0.2345 - - 
NA199017_1996.71 0.79 ± 0.06 0.00466 0.29 ± 0.05 0.0001554 
NA261 1.11 ± 0.08 0.16053 1.09 ± 0.18 0.87848 
NA714 + 0.0001554 + 0.0001554 
N-acetyl-glutamate 1.02 ± 0.09 0.7209 1.12 ± 0.13 0.57374 
Nicotinamide 0.80 ± 0.04 0.00109 0.88 ± 0.09 0.16053 
Octadecanoate - - 0.90 ± 0.09 0.16053 
Ornithine 1.64 ± 0.15 0.0001554 0.82 ± 0.08 0.13038 
Phenylalanine 1.08 ± 0.06 0.38228 0.28 ± 0.04 0.0001554 
Phosphate-monomethyl 
ester 
1.28 ± 0.05 0.0003108 0.87 ± 0.11 0.50536 
Phosphoenolpyruvate 4.62 ± 0.69 0.0001554 - - 
Pipecolate 3.48 ± 0.13 0.0001554 4.86 ± 0.39 0.0001554 
Proline 0.78 ± 0.12 0.19487 0.44 ± 0.13 0.02067 
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Table S3: continued 
Metabolite 
½ ODmax ODmax 
Fold change p-value Fold change p-value 
Putrescine 0.46 ± 0.06 0.0001554 0.41 ± 0.06 0.0006216 
Pyroglutamate 0.85 ± 0.05 0.01476 0.71 ± 0.10 0.06496 
Pyruvate - - 0.47 ± 0.16 0.02036 
Serine 2.68 ± 0.13 0.0001554 0.35 ± 0.04 0.0001554 
Spermidine 0.83 ± 0.05 0.02067 - - 
Succinate 0.86 ± 0.02 0.0001554 0.78 ± 0.06 0.01041 
Threonine 1.43 ± 0.20 0.08298 1.34 ± 0.25 0.19487 
Thymine 0.78 ± 0.03 0.0001554 0.75 ± 0.05 0.00186 
Tyrosine 0.46 ± 0.03 0.0001554 0.25 ± 0.03 0.0001554 
UMP 0.86 ± 0.09 0.1049 0.51 ± 0.05 0.0001554 
Unknown#1169.8-pae-
bth_013 
0.89 ± 0.06 0.13038 1.01 ± 0.14 0.79845 
Unknown#1248.7-cgl-
sst_008 
1.13 ± 0.12 0.32821 0.81 ± 0.12 0.50536 
Unknown#1361.3-pin-
mhe_010 
0.67 ± 0.05 0.0003108 - - 
Unknown#1830.2-pin-
mhe_038 
0.86 ± 0.06 0.00699 0.69 ± 0.07 0.0006216 
Unknown#2018.7-pin-
mhe_028 
0.91 ± 0.06 0.19487 - - 
Unknown#2148.0-pin-
mhe_047 
1.25 ± 0.10 0.00699 1.80 ± 0.21 0.0001554 
Unknown#2260-cgl-
sst_001 
- - n.d. 0.0001554 
Unknown#2394.5-pin-
mhe_056 
1.55 ± 0.07 0.0001554 1.28 ± 0.08 0.00186 
Unknown#2442.5-pin-
mhe_059 
+ 0.0001554 1.63 ± 0.21 0.00186 
Unknown#2548.1-pin-
mhe_066 
0.82 ± 0.11 0.1049 1.34 ± 0.23 0.16053 
Unknown#2557.6-pin-
mhe_067 
- - 6.74 ± 1.26 0.0001554 
Uracil 0.91 ± 0.05 0.16053 0.90 ± 0.09 0.27863 
Uric acid 0.45 ± 0.03 0.0001554 1.16 ± 0.15 0.32821 
Valine 0.78 ± 0.08 0.1049 0.82 ± 0.09 0.16053 
Xanthine 0.82 ± 0.07 0.03792 1.21 ± 0.17 0.32821 
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Table S4 Expression levels of genes involved in dipeptide transport.  
Locus tag Enzyme function 
WT Δ262-kb 
½ 
ODmax 
ODmax 
½ 
ODmax 
ODmax 
PGA1_262p01000 
dipeptide transport ATP-
binding protein DppF 
72 36 0 0 
PGA1_262p01010 
dipeptide transport ATP-
binding protein DppD 
30 6 0 0 
PGA1_262p01020 
dipeptide transport system 
permease DppC 
31 6 0 0 
PGA1_262p01030 
dipeptide transport system 
permease DppB 
36 5 0 0 
PGA1_262p01040 
periplasmic dipeptide 
transport protein precursor 
(dipeptide-binding protein) 
319 8 0 0 
 
Table S5 Amino acid concentrations for the wild-type strain and the Δ262-kb 
mutant strain at ½ ODmax and ODmax in the casamino acid medium (cultivation 
in process-controlled bioreactors). Amino acid concentrations in mmol L-1 in 
medium prior to inoculation and at ½ ODmax and ODmax are listed with corresponding 
standard deviation. 
Amino acid medium 
WT Δ262-kb 
½ ODmax ODmax ½ ODmax ODmax 
Aspartate 2.19 ± 0.07 1.64 ± 0.02 0.03 ± 0.03 0.00 ± 0.00 0.00 ± 0.00 
Glutamate 7.55 ± 0.27 6.59 ± 0.12 3.74 ± 0.70 4.32 ± 0.40 0.01 ± 0.00 
Serine 1.49 ± 0.06 1.39 ± 0.03 1.30 ± 0.09 0.98 ± 0.07 0.04 ± 0.02 
Glycine 2.80 ± 0.09 2.31 ± 0.04 0.11 ± 0.10 0.00 ± 0.00 0.01 ± 0.00 
Threonine 1.87 ± 0.06 1.76 ± 0.04 1.67 ± 0.10 1.29 ± 0.08 0.32 ± 0.08 
Histidine 0.99 ± 0.03 0.94 ± 0.02 0.88 ± 0.06 0.76 ± 0.04 0.24 ± 0.04 
Alanine 8.33 ± 0.28 7.43 ± 0.17 6.20 ± 0.54 3.73 ± 0.69 0.01 ± 0.00 
Arginine 1.57 ± 0.06 1.34 ± 0.03 1.09 ± 0.09 1.24 ± 0.07 0.80 ± 0.03 
Tyrosine 1.92 ± 0.07 1.74 ± 0.03 1.72 ± 0.12 1.39 ± 0.09 0.53 ± 0.10 
Valine 4.36 ± 0.14 4.09 ± 0.10 4.20 ± 0.27 3.25 ± 0.18 1.24 ± 0.19 
Methionine 1.31 ± 0.05 1.09 ± 0.03 0.78 ± 0.06 0.75 ± 0.06 0.14 ± 0.04 
Isoleucine 2.31 ± 0.05 2.17 ± 0.06 2.24 ± 0.15 1.56 ± 0.19 0.38 ± 0.10 
Phenylalanine 2.04 ± 0.08 1.83 ± 0.04 1.66 ± 0.11 1.32 ± 0.10 0.35 ± 0.09 
Leucine 4.54 ± 0.15 4.00 ± 0.09 3.54 ± 0.25 2.71 ± 0.20 0.64 ± 0.12 
Lysine 3.66 ± 0.28 3.30 ± 0.22 2.77 ± 0.28 3.33 ± 0.25 2.03 ± 0.11 
Proline 9.62 ± 0.62 8.39 ± 0.52 6.63 ± 0.59 5.76 ± 0.64 0.74 ± 0.46 
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Table S8. Proposed sum formula for intracellularly detected unidentified 
compounds at ½ ODmax and ODmax for the wild-type strain and Δ262-kb mutant 
strain.  Predictions were performed with SmartFormula, implemented in 
DataAnalysis 4.0 
Compound 
m/z 
measured 
Ion 
Formula 
mSigma m/z 
Sum 
Formula 
[M]269.2_RT464 270.1554 C10H24NO7 14.6 270.1547 C10H23NO7 
[M]313.2_RT672 314.1820 C12H28NO8 7.1 314.1809 C12H27NO8 
[M]357.2_RT846 358.2072 C14H32NO9 8.6 358.2072 C14H31NO9 
[M]401.2_RT995 402.2332 C16H36NO10 4.7 402.2334 C16H35NO10 
[M]445.3_RT1127 446.259 C18H40NO11 6.4 446.2596 C18H39NO11 
[M]489.3_RT1244 490.285 C20H44NO12 2.3 490.2858 C20H43NO12 
[M]533.3_RT1347 534.3109 C22H48NO13 15.6 534.312 C22H47NO13 
[M]577.3_RT1428 578.3358 C24H52NO14 4.1 578.3382 C24H51NO14 
[M]621.4_RT1472 622.3624 C26H56NO15 3.4 622.3644 C26H55NO15 
[M]665.4_RT1501 666.3886 too less abundant C28H59NO16 
[M]371.2_RT489 372.1853 C14H30NO10 10.7 372.1864 C14H29NO10 
[M]415.2_RT667 416.212 C16H34NO11 13.6 416.2126 C16H33NO11 
[M]459.2_RT818 460.2378 C18H38NO12 10.9 460.2389 C18H37NO12 
[M]503.3_RT949 504.2629 C20H42NO13 6.7 504.2651 C20H41NO13 
[M]547.3_RT1066 548.2902 C22H46NO14 2 548.2913 C22H45NO14 
[M]591.3_RT1170 592.3136 C24H50NO15 9.5 592.3178 C24H49NO15 
[M]635.3_RT1268 636.3446 too less abundant C26H53NO16 
[M]679.4_RT1357 680.3709 too less abundant C28H57NO17 
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Table S11 Normalized peak areas of intracellularly detected metabolites of the 
wild-typ, the Δ262-kb mutant and the tdaE transposon mutant strains with 
casamino acids as carbon source. Normalized peak areas are listed with 
corresponding standard error for all identified metabolites detectable at least in one 
of both strains. n.d.: not detected. 
Metabolite WT Δ262-kb tdaE 
2,4-diaminobutanoate 2.5x105 ± 2x104 3.1x105 ± 1x104 2.3x105 ± 3x103 
2,6-diamino-pimelate 3.1x105 ± 2x104 2.0x105 ± 1x104 1.7x105 ± 6x103 
2-amino-2-deoxygalactose 1.0x105 ± 6x103 5.2x105 ± 2x104 2.3x105 ± 9x103 
2-amino-2-deoxy-gluconate 4.0x105 ± 2x104 2.0x105 ± 4x103 1.3x105 ± 4x103 
2-amino-2-deoxy-glucose 7.8x104 ± 7x103 3.6x105 ± 2x104 1.6x105 ± 8x103 
2-aminoadipic-acid 5.4x104 ± 2x103 n.d. 2.5x104 ± 1x103 
2-isopropylmalic acid 4.6x104 ± 5x103 1.1x104 ± 5x102 4.3x103 ± 1x103 
2-oxoglutarate 2.5x104 ± 3x103 3.3x104 ± 3x103 4.0x104 ± 4x103 
3-aminoisobutanoate 3.5x104 ± 1x103 2.8x105 ± 2x104 4.4x104 ± 2x103 
3-hydroxybutanoate 2.6x104 ± 3x103 1.5x104 ± 2x103 2.1x104 ± 1x103 
3-hydroxy-decanoate 1.3x104 ± 8x102 2.5x104 ± 6x102 1.6x104 ± 1x103 
3-phosphoglycerate 4.0x104 ± 2x103 4.4x104 ± 4x103 5.3x104 ± 4x103 
5-aminopentanoic-acid 6.9x106 ± 7x105 1.9x107 ± 1x106 5.0x106 ± 8x105 
6-phospho-gluconate 2.2x104 ± 8x103 1.1x104 ± 5x102 1.1x104 ± 1x103 
Adenine 8.5x104 ± 3x103 7.7x104 ± 2x103 7.3x104 ± 3x103 
Alanine 8.2x106 ± 6x105 1.0x107 ± 4x105 5.1x106 ± 2x105 
AMP 1.1x106 ± 6x104 1.1x106 ± 5x104 9.7x105 ± 4x104 
Arginine 2.0x104 ± 1x103 3.8x104 ± 1x103 2.4x104 ± 1x103 
Asparagine 2.4x104 ± 1x103 4.3x104 ± 2x103 2.1x104 ± 8x102 
Aspartate 1.2x107 ± 6x105 3.6x107 ± 2x106 1.3x107 ± 1x106 
Beta-Alanine 4.1x104 ± 1x103 8.7x104 ± 4x103 6.2x104 ± 2x103 
Cadaverine 4.7x105 ± 2x104 2.5x106 ± 4x105 4.7x105 ± 3x104 
Citrate 1.4x105 ± 4x103 4.8x104 ± 3x103 6.7x104 ± 3x103 
Cysteine 1.8x104 ± 6x102 7.4x103 ± 2x103 8.8x103 ± 1x103 
Cysteinyl-glycine 6.2x104 ± 8x103 1.9x105 ± 2x104 1.3x105 ± 1x104 
Cytosine 5.9x104 ± 5x103 1.2x105 ± 9x103 5.8x104 ± 2x103 
D200302 n.d.  2.8x104 ± 8x102 n.d. 
Ethanolamine 3.3x104 ± 4x103 3.9x104 ± 3x103 4.1x104 ± 3x103 
Fructose-1,6-bisphosphate 1.7x104 ± 1x103 4.5x104 ± 3x103 3.1x104 ± 2x103 
Fumarate 1.0x105 ± 3x103 6.6x104 ± 2x103 5.9x104 ± 2x103 
Glucose 7.5x103 ± 5x102 7.9x103 ± 5x102 6.0x103 ± 1x103 
Glucose-6-phosphate 1.5x104 ± 9x102 2.6x104 ± 1x103 2.2x104 ± 1x103 
Glutamate 1.1x108 ± 3x106 1.5x108 ± 2x107 1.4x108 ± 2x106 
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Table S11 continued 
Metabolite WT Δ262-kb tdaE 
Glutamine 2.0x106 ± 1x105 2.1x106 ± 2x105 4.6x106 ± 1x105 
Glycerol-3-phosphate 2.2x105 ± 2x104 9.8x104 ± 8x103 1.8x105 ± 8x103 
Glycerophosphoglycerol 1.2x105 ± 1x104 5.9x104 ± 5x103 9.3x104 ± 6x103 
Glycine 8.7x105 ± 8x104 1.5x106 ± 1x105 1.2x106 ± 6x104 
Guanine 1.7x104 ± 1x103 1.9x104 ± 1x103 1.8x104 ± 1x103 
Guanosine-5-
monophosphate 
6.0x104 ± 3x103 8.4x104 ± 3x103 5.9x104 ± 5x103 
Homoserine 6.0x104 ± 3x103 5.8x104 ± 2x103 4.1x104 ± 2x103 
Isoleucine 8.4x105 ± 4x104 1.1x106 ± 5x104 2.3x105 ± 9x103 
Leucine 8.7x105 ± 5x104 5.1x105 ± 3x104 1.5x105 ± 1x104 
Lysine 1.6x105 ± 8x103 4.3x105 ± 3x104 2.0x105 ± 8x103 
Malate 1.6x105 ± 8x103 1.1x105 ± 7x103 1.0x105 ± 6x103 
Methionine 2.2x105 ± 2x104 2.6x105 ± 2x104 1.4x105 ± 5x103 
N-acetyl-glutamate 4.9x104 ± 1x103 4.1x104 ± 1x103 4.4x104 ± 1x103 
N-acetyl-ornithine 5.1x104 ± 2x103 9.2x104 ± 5x103 8.9x104 ± 3x103 
N-acetyl-serine 7.3x104 ± 4x103 n.d. n.d. 
Nicotinamide 2.7x105 ± 2x104 1.9x105 ± 1x104 1.9x105 ± 2x104 
Ornithine 1.8x105 ± 8x103 2.9x105 ± 9x103 2.7x105 ± 1x104 
Phenylalanine 1.0x106 ± 3x104 3.4x105 ± 7x104 7.6x105 ± 7x104 
Phosphate-
monomethylester 
4.7x104 ± 2x103 7.3x104 ± 3x103 5.6x104 ± 1x103 
Pipecolate 7.4x105 ± 4x104 2.0x106 ± 1x105 3.6x105 ± 2x104 
Proline 1.4x106 ± 1x105 3.9x106 ± 3x105 1.6x106 ± 1x105 
Putrescine 2.7x104 ± 8x102 5.2x104 ± 2x103 9.5x104 ± 3x103 
Pyroglutamate 1.9x107 ± 8x105 4.8x107 ± 2x106 2.6x107 ± 2x106 
Serine 8.2x104 ± 2x103 3.6x105 ± 1x104 1.4x105 ± 2x103 
Threonine 3.2x105 ± 7x103 4.7x105 ± 2x104 2.3x105 ± 8x103 
Thymine 4.0x104 ± 1x103 4.1x104 ± 1x103 3.3x104 ± 1x103 
Tyrosine 2.6x106 ± 4x105 4.7x105 ± 4x104 6.3x105 ± 2x104 
Uric acid 1.5x104 ± 1x103 n.d. 8.1x103 ± 8x102 
Uridine 5'-monophosphate 1.1x105 ± 8x103 2.1x105 ± 1x104 1.1x105 ± 1x104 
Valine 6.1x106 ± 2x105 1.0x107 ± 7x105 1.7x106 ± 9x104 
Xanthine 1.4x104 ± 8x102 7.5x103 ± 3x102 1.9x104 ± 9x103 
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Table S13 Amino acid concentrations for the wild-type strain, the Δ262-kb and 
tdaE mutant strain at ½ ODmax with casamino acids as carbon source. Amino acid 
concentrations in mmol L-1 at ½ ODmax (harvesting point for metabolome analysis) 
are listed with corresponding standard deviation. 
Amino acid WT Δ262-kb tdaE 
Aspartate 2.05 ± 0.05 1.52 ± 0.09 2.10 ± 0.05 
Glutamate 3.12 ± 0.19 6.37 ± 0.18 6.11 ± 0.21 
Serine 2.35 ± 0.02 1.95 ± 0.08 2.23 ± 0.03 
Glycine 0.45 ± 0.01 0.14 ± 0.03 0.45 ± 0.04 
Threonine 1.31 ± 0.15 0.19 ± 0.09 0.60 ± 0.05 
Histidine 0.72 ± 0.02 0.64 ± 0.01 0.59 ± 0.02 
Alanine 1.01 ± 0.04 0.39 ± 0.08 0.98 ± 0.05 
Arginine 0.39 ± 0.01 0.57 ± 0.01 0.49 ± 0.01 
Tyrosine 0.15 ± 0.01 0.03 ± 0.01 0.06 ± 0.00 
Valine 1.60 ± 0.02 1.17 ± 0.11 1.44 ± 0.04 
Methionine 0.44 ± 0.00 0.45 ± 0.02 0.52 ± 0.01 
Isoleucine 0.91 ± 0.01 0.82 ± 0.03 0.91 ± 0.02 
Phenylalanine 0.54 ± 0.03 0.12 ± 0.05 0.28 ± 0.03 
Leucine 1.19 ± 0.02 1.07 ± 0.04 1.27 ± 0.03 
Lysine 1.10 ± 0.03 1.54 ± 0.07 1.38 ± 0.03 
Proline 1.36 ± 0.05 2.39 ± 0.14 2.73 ± 0.13 
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Table S14 Oxygen consumption dependent on TDA presence. Shown are 
determined oxygen uptake rates with corresponding growth physiology for the wild-
type, the Δ262-kb and tdaE mutant strains at ⅛ODmax, ¼ ODmax, ½ ODmax, ¾ ODmax and 
shortly before reaching ODmax for cultivation with casamino acids.  
  WT Δ262-kb tdaE 
⅛ ODmax 
Time [h] 9.5 ± 0.1 8.6 ± 0.1 11.1 ± 0.3 
CDW [g L-1 h-1] 0.18 ± 0.00 0.33± 0.00 0.28 ± 0.01 
µ [h-1] 0.15 ± 0.00 0.40 ± 0.00 0.33 ± 0.02 
OUR [mmolO2 L-1 h-1] 1.9 ± 0.3 4.0 ± 0.7 2.7 ± 0.7 
qO2 [mmolO2 g-1 h-1] 10.3 ± 1.5 12.2 ± 2.1 9.7 ± 2.5 
O2 consumption [mmolO2 g-1] 67 ± 10 30 ± 6 30 ± 9 
¼ ODmax 
Time [h] 13.6 ± 0.1 10.4 ± 0.1 13.4 ± 0.4 
CDW [g L-1 h-1] 0.36 ± 0.00 0.65 ± 0.00 0.55 ± 0.00 
µ [h-1] 0.18 ± 0.00 0.35 ± 0.00 0.29 ± 0.02 
OUR [mmolO2 L-1 h-1] 4.5 ± 0.6 7.4 ± 0.3 6.2 ± 1.0 
qO2 [mmolO2 g-1 h-1] 12.4 ± 1.5 11.4 ± 0.4 11.2 ± 1.9 
O2 consumption [mmolO2 g-1] 68 ± 10 32 ± 1 40 ± 9 
½ ODmax 
Time [h] 17.5 ± 0.3 12.5 ± 0.2 15.9 ± 0.6 
CDW [g L-1 h-1] 0.72 ± 0.00 1.29 ± 0.01 1.09 ± 0.01 
µ [h-1] 0.13 ± 0.01 0.27 ± 0.00 0.22 ± 0.02 
OUR [mmolO2 L-1 h-1] 8.3 ± 0.8 14.3 ± 0.7 13.2 ± 1.7 
qO2 [mmolO2 g-1 h-1] 11.5 ± 1.1 11.1 ± 0.6 12.1 ± 1.7 
O2 consumption [mmolO2 g-1] 91 ± 14 40 ± 2 55 ± 11 
¾ ODmax 
Time [h] 20.9 ± 0.5 14.2 ± 0.2 17.9 ± 0.7 
CDW [g L-1 h-1] 1.03 ± 0.00 1.94 ± 0.01 1.65 ± 0.00 
µ [h-1] 0.07 ± 0.01 0.20 ± 0.00 0.16 ± 0.01 
OUR [mmolO2 L-1 h-1] 11.7 ± 1.2 22.4 ± 0.3 19.9 ± 0.8 
qO2 [mmolO2 g-1 h-1] 11.3 ± 1.2 11.5 ± 0.1 12.1 ± 1.7 
O2 consumption [mmolO2 g-1] 169 ± 37 59 ± 1 78 ± 15 
~ ODmax 
Time [h] 25.6 ± 1.6 15.2 ± 0.2 19.2 ± 0.9 
CDW [g L-1 h-1] 1.24 ± 0.01 2.34 ± 0.02 1.99 ± 0.01 
µ [h-1] 0.03 ± 0.01 0.14 ± 0.00 0.11 ± 0.01 
OUR [mmolO2 L-1 h-1] 13.2 ± 1.2 22.7 ± 3.6 23.1 ± 2.4 
qO2 [mmolO2 g-1 h-1] 10.6 ± 1.1 9.7 ± 1.5 11.6 ± 1.2 
O2 consumption [mmolO2 g-1] 446 ± 156 68 ± 12 107 ± 18.5 
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Model iPin571 
# model: iPin571     
# organism: Phaeobacter inhibens 
# strain: DSM 17395     
# updated: 171213    
# modeler: swi      
 
 
# EMP 
glycolysis_2.7.1.2_GLUCOKIN-RXN: 1 ATP + 1 beta-D-glucose --> 1 ADP + 1 H+ + 1 beta-D-glucose-6-
phosphate   
glycolysis_5.3.1.9_PGLUCISOM-RXN: 1 beta-D-glucose-6-phosphate <=> 1 D-fructose-6-phosphate   
glycolysis_4.1.2.13_F16ALDOLASE-RXN: 1 fructose-1,6-bisphosphate <=> 1 
dihydroxyacetone_phosphate + 1 D-glyceraldehyde-3-phosphate   
glycolysis_5.3.1.1_TRIOSEPISOMERIZATION-RXN: 1 D-glyceraldehyde-3-phosphate <=> 1 
dihydroxyacetone_phosphate   
~no-pathway_1.2.1.12_GAPDHSYNEC-RXN_NAD: 1 NAD+ + 1 D-glyceraldehyde-3-phosphate + 1 
phosphate <=> 1 1,3-bisphospho-D-glycerate + 1 NADH + 1 H+   
glycolysis_2.7.2.3_PHOSGLYPHOS-RXN: 1 ATP + 1 3-phospho-D-glycerate <=> 1 1,3-bisphospho-D-
glycerate + 1 ADP   
glycolysis_5.4.2.12_3PGAREARR-RXN: 1 3-phospho-D-glycerate <=> 1 2-phospho-D-glycerate   
glycolysis_4.2.1.11_2PGADEHYDRAT-RXN: 1 2-phospho-D-glycerate <=> 1 phosphoenolpyruvate + 1 
H2O   
glycolysis_2.7.1.40_PEPDEPHOS-RXN: 1 ATP + 1 pyruvate <-- 1 H+ + 1 phosphoenolpyruvate + 1 ADP  
 
# gluconeogenesis 
~no-pathway_1.1.1.39_1.1.1.39-RXN: 1 NAD+ + 1 (S)-malate --> 1 NADH + 1 pyruvate + 1 CO2   
gluconeogenesis_C4-photosynthetic-carbon-assimilation-cycle_1.1.1.39_1.1.1.40_MALIC-NADP-RXN: 
1 (S)-malate + 1 NADP+ --> 1 pyruvate + 1 NADPH + 1 CO2   
superpathway-of-glyoxylate-cycle_gluconeogenesis_4.1.1.49_PEPCARBOXYKIN-RXN: 1 ATP + 1 
oxaloacetate --> 1 CO2 + 1 ADP + 1 phosphoenolpyruvate   
C4_photosynthetic_carbon_assimilation_cycle-2.7.9.1-PYRUVATEORTHOPHOSPHATE-DIKINASE-
RXN: 1 ATP + 1 phosphate + 1 pyruvate --> 1 AMP + 1 phosphoenolpyruvate + 1 diphosphate + 1 H+  
Calvin-Benson-Bassham-cycle_1.2.1.59_1.2.1.13-RXN: 1 NADP+ + 1 D-glyceraldehyde-3-phosphate + 
1 phosphate <-- 1 NADPH + 1 H+ + 1 1,3-bisphospho-D-glycerate   
glycolysis_3.1.3.11_F16BDEPHOS-RXN: 1 fructose-1,6-bisphosphate + 1 H2O --> 1 phosphate + 1 D-
fructose-6-phosphate  
 
# EDP 
~multiple-pathways_1.1.1.49_GLU6PDEHYDROG-RXN: 1 beta-D-glucose-6-phosphate + 1 NADP+ <=> 
1 6-phospho-D-glucono-1,5-lactone + 1 NADPH + 1 H+   
~multiple-pathways_3.1.1.31_6PGLUCONOLACT-RXN: 1 H2O + 1 6-phospho-D-glucono-1,5-lactone --
> 1 H+ + 1 6-phospho-D-gluconate   
Entner-Doudoroff-pathway-I_4.2.1.12_PGLUCONDEHYDRAT-RXN: 1 6-phospho-D-gluconate --> 1 
H2O + 1 2-dehydro-3-deoxy-D-gluconate-6-phosphate  
Entner-Doudoroff-pathway_4.1.2.14_KDPGALDOL-RXN: 1 2-dehydro-3-deoxy-D-gluconate-6-
phosphate --> 1 D-glyceraldehyde-3-phosphate + 1 pyruvate   
 
# PPP 
~multiple-pathways_5.1.3.1_RIBULP3EPIM-RXN: 1 D-ribulose-5-phosphate <=> 1 D-xylulose-5-
phosphate   
~multiple-pathways_5.3.1.6_RIB5PISOM-RXN: 1 D-ribose-5-phosphate <=> 1 D-ribulose-5-phosphate  
~multiple-pathways_2.2.1.1_1TRANSKETO-RXN: 1 D-sedoheptulose-7-phosphate + 1 D-
glyceraldehyde-3-phosphate <=> 1 D-xylulose-5-phosphate + 1 D-ribose-5-phosphate  
xliv   MODEL iPIN571 
 
~multiple-pathways_2.2.1.1_2TRANSKETO-RXN: 1 D-xylulose-5-phosphate + 1 D-erythrose-4-
phosphate <=> 1 D-glyceraldehyde-3-phosphate + 1 D-fructose-6-phosphate   
~multiple-pathways_2.2.1.2_TRANSALDOL-RXN: 1 D-sedoheptulose-7-phosphate + 1 D-
glyceraldehyde-3-phosphate <=> 1 D-fructose-6-phosphate + 1 D-erythrose-4-phosphate  
 
# PDH comnplex 
acetyl-CoA-biosynthesis-(from-pyruvate)_1.2.4.1_RXN0-1134 : 1 lipoamide + 1 pyruvate + 1 H+ --> 1 
S-acetyldihydrolipoamide + 1 CO2   
glycine-cleavage-complex_1.8.1.4_RXN-8629: 1 NAD+ + 1 dihydrolipoamide --> 1 NADH + 1 lipoamide 
+ 1 H+   
~no-pathway_2.3.1.12_DIHYDLIPACETRANS-RXN: 1 acetyl-CoA + 1 dihydrolipoamide <=> 1 S-
acetyldihydrolipoamide + 1 coenzyme_A   
 
# CAC 
TCA-cycle_2.3.3.1_CITSYN-RXN: 1 H2O + 1 acetyl-CoA + 1 oxaloacetate --> 1 H+ + 1 coenzyme_A + 1 
citrate   
TCA-cycle_4.2.1.3_ACONITATEDEHYDR-RXN: 1 citrate <=> 1 cis-aconitate + 1 H2O  
TCA-cycle_4.2.1.3_ACONITATEHYDR-RXN: 1 cis-aconitate + 1 H2O <=> 1 D-threo-isocitrate   
reductive-TCA-cycle_1.1.1.42_ISOCITDEH-RXN : 1 D-threo-isocitrate + 1 NADP+ --> 1 CO2 + 1 NADPH 
+ 1 2-oxoglutarate   
2-ketoglutarate-dehydrogenase-complex_2.3.1.61_RXN0-1147: 1 H+ + 1 dihydrolipoamide + 1 
succinyl-CoA <=> 1 |Oxo-glutarate-dehydro-suc-DH-lipoyl| + 1 coenzyme_A   
2-ketoglutarate-dehydrogenase-complex_1.2.4.2_2OXOGLUTDECARB-RXN: 1 2-oxoglutarate + 1 
lipoamide + 2 H+ --> 1 |Oxo-glutarate-dehydro-suc-DH-lipoyl| + 1 CO2   
TCA-cycle_6.2.1.5_SUCCCOASYN-RXN: 1 coenzyme_A + 1 ATP + 1 succinate <=> 1 ADP + 1 succinyl-
CoA + 1 phosphate   
TCA-cycle_1.3.5.1_SUCCINATE-DEHYDROGENASE-UBIQUINONE-RXN: 1 succinate + 1 ubiquinone-10 
--> 1 fumarate + 1 ubiquinol-10  
TCA-cycle_4.2.1.2_FUMHYDR-RXN: 1 (S)-malate <=> 1 fumarate + 1 H2O   
TCA-cycle_1.1.1.37_MALATE-DEH-RXN: 1 (S)-malate + 1 NAD+ <=> 1 H+ + 1 oxaloacetate + 1 NADH   
TCA-cycle-variation_2.3.3.9_MALSYN-RXN: 1 acetyl-CoA + 1 H2O + 1 glyoxylate --> 1 H+ + 1 (S)-
malate + 1 coenzyme_A  
anapleurotic_synthesis_of_oxalacetate-6.4.1.1-PYRUVATE-CARBOXYLASE-RXN: 1 ATP + 1 
bicarbonate + 1 pyruvate --> 1 ADP + 1 oxaloacetate + 1 phosphate + 1 H+  
 
# pyruvate metabolism 
~multiple-pathways_2.3.1.8_PHOSACETYLTRANS-RXN: 1 phosphate + 1 acetyl-CoA <=> 1 
coenzyme_A + 1 acetylphosphate   
~multiple-pathways_2.7.2.1_ACETATEKIN-RXN: 1 ATP + 1 acetate --> 1 ADP + 1 acetylphosphate   
~multiple-pathways_6.2.1.1_ACETATE--COA-LIGASE-RXN: 1 acetate + 1 ATP + 1 coenzyme_A --> 1 
acetyl-CoA + 1 diphosphate + 1 AMP   
oxidative-ethanol-degradation_1.2.1.3_RXN66-3: 1 H2O + 1 NAD+ + 1 acetaldehyde --> 1 NADH + 2 
H+ + 1 acetate   
 
# oxidative phosphorylation 
~multiple-pathways_1.6.5.3_NADH-DEHYDROG-A-RXN: 1 NADH + 5 H+ + 1 ubiquinone-10 <=> 1 
NAD+ + 1 ubiquinol-10 + 4 H+_rc  
aerobic-respiration----electron-donor-II_1.10.2.2_1.10.2.2-RXN: 2 |Cytochromes-C-Oxidized| + 1 
ubiquinol-10 + 2 H+  <=> 2 |Cytochromes-C-Reduced| + 1 ubiquinone-10 + 2 H+_rc  
aerobic-respiration----electron-donor-II_1.9.3.1_CYTOCHROME-C-OXIDASE-RXN: 1 oxygen + 4 
|Cytochromes-C-Reduced| + 4 H+ --> 2 H2O + 4 |Cytochromes-C-Oxidized| + 4 H+_rc   
~no-pathway_1.6.99.5_NADH-DEHYDROGENASE-RXN: 1 NADH + 1 H+ + 1 ubiquinone-10 --> 1 
ubiquinol-10 + 1 NAD+  
oxidative_phosphorylation-3.6.3.27-3.6.3.27-RXN: 1 ATP + 1 phosphate_ex + 1 H2O --> 1 ADP + 2 
phosphate + 1 H+  
~no-pathway_3.6.1.1_INORGPYROPHOSPHAT-RXN: 1 diphosphate + 1 H2O --> 1 H+ + 2 phosphate  
oxidative_phosphorylation-3.6.3.14-ATPSYN-RXN: 1 ATP + 3 H+ + 1 H2O <=> 1 ADP + 1 phosphate + 
4 H+_rc  
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# shikimate pathway 
~no-pathway_2.5.1.54_DAHPSYN-RXN: 1 H2O + 1 D-erythrose-4-phosphate + 1 
phosphoenolpyruvate --> 1 phosphate + 1 3-deoxy-D-arabino-heptulosonate-7-phosphate   
~no-pathway_4.2.3.4_3-DEHYDROQUINATE-SYNTHASE-RXN: 1 3-deoxy-D-arabino-heptulosonate-7-
phosphate --> 1 3-dehydroquinate + 1 phosphate   
quinate-degradation_4.2.1.10_3-DEHYDROQUINATE-DEHYDRATASE-RXN: 1 3-dehydroquinate <=> 1 
H2O + 1 3-dehydroshikimate  
~no-pathway_1.1.1.25_RXN-7968_NADP: 1 NADP+ + 1 shikimate <-- 1 3-dehydroshikimate + 1 
NADPH + 1 H+   
~no-pathway_2.7.1.71_SHIKIMATE-KINASE-RXN: 1 shikimate + 1 ATP --> 1 shikimate-3-phosphate + 
1 H+ + 1 ADP   
~no-pathway_2.5.1.19_2.5.1.19-RXN: 1 phosphoenolpyruvate + 1 shikimate-3-phosphate <=> 1 5-
enolpyruvyl-shikimate-3-phosphate + 1 phosphate   
~no-pathway_4.2.3.5_CHORISMATE-SYNTHASE-RXN: 1 5-enolpyruvyl-shikimate-3-phosphate --> 1 
chorismate + 1 phosphate  
 
# ethylmalonyl-CoA pathway   
~multiple-pathways_2.3.1.9_ACETYL-COA-ACETYLTRANSFER-RXN: 2 acetyl-CoA <=> 1 coenzyme_A 
+ 1 acetoacetyl-CoA   
acetyl-CoA-fermentation-to-butyrate_glutaryl-CoA-degradation_1.1.1.35_RXN-11662: 1 NAD+ + 1 (S)-
3-hydroxybutanoyl-CoA <=> 1 NADH + 1 H+ + 1 acetoacetyl-CoA  
~multiple-pathways_1.1.1.36_RXN-5901: 1 (R)-3-hydroxybutanoyl-CoA + 1 NADP+ <-- 1 H+ + 1 
NADPH + 1 acetoacetyl-CoA  
acetyl-CoA-fermentation-to-butyrate_ethylmalonyl-pathway_4.2.1.55_1.1.1.36_4.2.1.17_3-
HYDROXBUTYRYL-COA-DEHYDRATASE-RXN: 1 (R)-3-hydroxybutanoyl-CoA --> 1 H2O + 1 crotonyl-
CoA 
~multiple-pathways_4.2.1.55_4.2.1.17_RXN-11667: 1 (S)-3-hydroxybutanoyl-CoA <=> 1 crotonyl-CoA 
+ 1 H2O   
~no-pathway_5.1.2.3_5.1.2.3-RXN: 1 (S)-3-hydroxybutanoyl-CoA <=> 1 (R)-3-hydroxybutanoyl-CoA 
ethylmalonyl-pathway_1.3.1.85_RXN-8957: 1 NADP+ + 1 (2S)-ethylmalonyl-CoA <=> 1 NADPH + 1 
crotonyl-CoA + 1 CO2   
ethylmalonyl-pathway_5.4.99.2_RXN-8958: 1 (2S)-ethylmalonyl-CoA --> 1 methylsuccinyl-CoA   
ethylmalonyl-CoA_pathway-RXN-8959: 1 methylsuccinyl-CoA --> 1 mesaconyl-CoA + 2 H+ 
ethylmalonyl-CoA_pathway-RXN-8960 : 1 mesaconyl-CoA + 1 H2O <=> 1 beta-methylmalyl-CoA  
glyoxylate-assimilation_ethylmalonyl-pathway_4.1.3.24_RXN-8961: 1 beta-methylmalyl-CoA <=> 1 
glyoxylate + 1 propanoyl-CoA   
3-hydroxypropionate-cycle_methylmalonyl-pathway_6.4.1.3_PROPIONYL-COA-CARBOXY-RXN: 1 ATP 
+ 1 propanoyl-CoA + 1 bicarbonate --> 1 H+ + 1 (S)-methylmalonyl-CoA + 1 ADP + 1 phosphate   
~multiple-pathways_5.1.99.1_METHYLMALONYL-COA-EPIM-RXN: 1 (R)-methylmalonyl-CoA <=> 1 
(S)-methylmalonyl-CoA   
~multiple-pathways_5.4.99.2_METHYLMALONYL-COA-MUT-RXN: 1 (R)-methylmalonyl-CoA <=> 1 
succinyl-CoA  
 
# PHB  
PHB_biosynthesis-PhaC-2.3.1.-RXN: 1 (R)-3-hydroxybutanoyl-CoA --> 1 [PHB] + 1 coenzyme_A  
PHB_degradation-3.1.1.75-3.1.1.75-RXN: 1 [PHB] + 1 H2O --> 1 (R)-3-hydroxybutanoate  
-no_pathway-1.1.1.30-3-HYDROXYBUTYRATE-DEHYDROGENASE-RXN: 1 (R)-3-hydroxybutanoate + 
1 NAD+ <=> 1 acetoacetate + 1 NADH + 1 H+  
 
################################################################# 
 
# fatty acid biosynthesis 
 
# starter molecule 
~multiple-pathways_6.4.1.2_ACETYL-COA-CARBOXYLTRANSFER-RXN: 1 bicarbonate + 1 ATP + 1 
acetyl-CoA --> 1 malonyl-CoA + 1 H+ + 1 phosphate + 1 ADP   
fatty-acid-biosynthesis-initiation_fatty-acid-biosynthesis_2.3.1.39_MALONYL-COA-ACP-TRANSACYL-
RXN : 1 ACP + 1 malonyl-CoA <=> 1 malonyl-[ACP] + 1 coenzyme_A   
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fatty-acid-biosynthesis-initiation-I_2.3.1.180_2.3.1.180-RXN    : 1 malonyl-[ACP] + 1 acetyl-CoA + 1 H+ 
--> 1 Acetoacetyl-[ACP] + 1 CO2 + 1 coenzyme_A   
 
# octanoic acid  
palmitate-biosynthesis_1.1.1.100_RXN-9514   : 1 Acetoacetyl-[ACP]+ 1 NADPH + 1 H+ --> 1 (R)-3-
hydroxy-butanoyl-[ACP] + 1 NADP+  
palmitate-biosynthesis_4.2.1.59_4.2.1.58-RXN  : 1 (R)-3-hydroxy-butanoyl-[ACP] --> 1 trans-D2-
butenoyl-[ACP] + 1 H2O   
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9657 : 1 NAD+ + 1 Butanoyl-[ACP] <-- 1 
trans-D2-butenoyl-[ACP] + 1 H+ + 1 NADH   
palmitate-biosynthesis-II-(bacteria-and-plants)_2.3.1.180_2.3.1.41_RXN-9516    : 1 Butanoyl-[ACP] + 
1 malonyl-[ACP] + 1 H+ --> 1 CO2 + 1 ACP + 1 3-oxo-hexanoyl-[ACP]   
palmitate-biosynthesis_1.1.1.100_RXN-9518    : 1 (R)-3-hydroxy-hexanoyl-[ACP] + 1 NADP+ <-- 1 3-
oxo-hexanoyl-[ACP] + 1 H+ + 1 NADPH   
palmitate-biosynthesis_4.2.1.59_RXN-9520  : 1 (R)-3-hydroxy-hexanoyl-[ACP] --> 1 trans-D2-
hexenoyl-[ACP] + 1 H2O   
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9658  : 1 NAD+ + 1 Hexanoyl-[ACP] <-- 1 
H+ + 1 trans-D2-hexenoyl-[ACP] + 1 NADH 
palmitate-biosynthesis-II-(bacteria-and-plants)_2.3.1.180_2.3.1.41_RXN-9523  : 1 Hexanoyl-[ACP] + 1 
malonyl-[ACP] + 1 H+ --> 1 ACP + 1 CO2 + 1 3-oxo-octanoyl-[ACP]  
palmitate-biosynthesis_1.1.1.100_RXN-9524 : 1 NADP+ + 1 (R)-3-hydroxy-octanoyl-[ACP] <-- 1 
NADPH + 1 H+ + 1 3-oxo-octanoyl-[ACP]   
palmitate-biosynthesis_4.2.1.59_4.2.1.59-RXN   : 1 (R)-3-hydroxy-octanoyl-[ACP] --> 1 trans-D2-
octenoyl-[ACP] + 1 H2O   
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9659    : 1 NAD+ + 1 Octanoyl-[ACP] <-- 
1 trans-D2-octenoyl-[ACP] + 1 NADH + 1 H+   
 
# decanoic acid  
palmitate-biosynthesis-II-(bacteria-and-plants)_2.3.1.180_2.3.1.41_RXN-9527    : 1 Octanoyl-[ACP] + 
1 malonyl-[ACP] + 1 H+ --> 1 ACP + 1 3-oxo-decanoyl-[ACP] + 1 CO2  
palmitate-biosynthesis_1.1.1.100_RXN-9528   : 1 NADP+ + 1 (R)-3-hydroxy-decanoyl-[ACP] <-- 1 H+ + 
1 3-oxo-decanoyl-[ACP] + 1 NADPH  
cis-dodecenoyl-biosynthesis_palmitate-biosynthesis_4.2.1.59_RXN-9655  : 1 (R)-3-hydroxy-decanoyl-
[ACP] --> 1 trans-D2-decenoyl-[ACP] + 1 H2O  
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9660: 1 NAD+ + 1 Decanoyl-[ACP] <-- 1 
H+ + 1 NADH + 1 trans-D2-decenoyl-[ACP] 
 
# dodecanoic acid  
palmitate-biosynthesis-II-(bacteria-and-plants)_2.3.1.180_2.3.1.41_RXN-9531   : 1 Decanoyl-[ACP] + 1 
malonyl-[ACP] + 1 H+ --> 1 ACP + 1 CO2 + 1 3-oxo-dodecanoyl-[ACP]   
palmitate-biosynthesis_1.1.1.100_RXN-9532    : 1 NADP+ + 1 (R)-3-hydroxy-dodecanoyl-[ACP] <-- 1 
NADPH + 1 3-oxo-dodecanoyl-[ACP] + 1 H+   
palmitate-biosynthesis_4.2.1.59_RXN-9533      : 1 (R)-3-hydroxy-dodecanoyl-[ACP] --> 1 H2O + 1 
trans-D2-dodecenoyl-[ACP]   
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9661   : 1 NAD+ + 1 Dodecanoyl-[ACP] 
<-- 1 H+ + 1 trans-D2-dodecenoyl-[ACP] + 1 NADH  
# tetradecanoic acid  
palmitate-biosynthesis-II-(bacteria-and-plants)_2.3.1.180_2.3.1.41_RXN-9535    : 1 Dodecanoyl-[ACP] 
+ 1 malonyl-[ACP] + 1 H+ --> 1 ACP + 1 CO2 + 1 3-oxo-tetradecanoyl-[ACP]   
palmitate-biosynthesis_1.1.1.100_RXN-9536   : 1 NADP+ + 1 (R)-3-hydroxy-tetradecanoyl-[ACP] <-- 1 
NADPH + 1 3-oxo-tetradecanoyl-[ACP] + 1 H+   
palmitate-biosynthesis_4.2.1.59_RXN-9537  : 1 (R)-3-hydroxy-tetradecanoyl-[ACP] --> 1 H2O + 1 
trans-D2-tetradecenoyl-[ACP]   
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9662  : 1 NAD+ + 1 Tetradecanoyl-[ACP] 
<-- 1 H+ + 1 trans-D2-tetradecenoyl-[ACP] + 1 NADH 
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# hexadecanoic acid  
palmitate-biosynthesis-II-(bacteria-and-plants)_2.3.1.41_RXN-9539   : 1 Tetradecanoyl-[ACP] + 1 
malonyl-[ACP] + 1 H+ --> 1 ACP + 1 CO2 + 1 3-oxo-hexadecanoyl-[ACP]   
palmitate-biosynthesis_1.1.1.100_RXN-9540     : 1 NADP+ + 1 (R)-3-hydroxy-hexadecanoyl-[ACP] <-- 
1 NADPH + 1 3-oxo-hexadecanoyl-[ACP] + 1 H+   
palmitate-biosynthesis_4.2.1.59_4.2.1.61-RXN : 1 (R)-3-hydroxy-hexadecanoyl-[ACP] --> 1 H2O + 1 
trans-D2-hexadecenoyl-[ACP]   
palmitate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9663  : 1 NAD+ + 1 Hexadecanoyl-[ACP] 
<-- 1 H+ + 1 trans-D2-hexadecenoyl-[ACP] + 1 NADH 
 
# octadecanoic acid  
stearate-biosynthesis-II-(bacteria-and-plants)_2.3.1.41_RXN-9632    : 1 Hexadecanoyl-[ACP] + 1 
malonyl-[ACP] + 1 H+ --> 1 ACP + 1 CO2 + 1 3-oxo-octadecanoyl-[ACP]   
stearate-biosynthesis_1.1.1.100_RXN-9633  : 1 NADP+ + 1 (R)-3-hydroxy-octadecanoyl-[ACP] <-- 1 
NADPH + 1 3-oxo-octadecanoyl-[ACP] + 1 H+   
stearate-biosynthesis_4.2.1.59_RXN-9634   : 1 (R)-3-hydroxy-octadecanoyl-[ACP] --> 1 H2O + 1 trans-
D2-octadecenoyl-[ACP]   
stearate-biosynthesis-II-(bacteria-and-plants)_1.3.1.9_RXN-9635  : 1 NAD+ + 1 Octadecanoyl-[ACP] <-
- 1 H+ + 1 trans-D2-octadecenoyl-[ACP] + 1 NADH 
 
# cis-D5-dodecenoyl-[ACP]  
cis-dodecenoyl-biosynthesis_5.3.3.14_5.3.3.14-RXN  : 1 trans-D2-decenoyl-[ACP] --> 1 cis-D3-
decenoyl-[ACP] 
cis-dodecenoyl-biosynthesis_fabB_RXN   : 1 cis-D3-decenoyl-[ACP] + 1 malonyl-[ACP] --> 1 3-oxo-cis-
D5-dodecenoyl-[ACP] + ACP + CO2  
cis-dodecenoyl-biosynthesis_1.1.1.100_RXN0-2142      : 1 (3R)-hydroxy-cis-D5-dodecenoyl-[ACP] + 1 
NADP+ <-- 1 H+ + 1 3-oxo-cis-D5-dodecenoyl-[ACP] + 1 NADPH   
cis-dodecenoyl-biosynthesis_4.2.1.59_RXN0-2144   : 1 (3R)-hydroxy-cis-D5-dodecenoyl-[ACP] --> 1 
H2O + 1 trans-D3-cis-D5-dodecenoyl-[ACP]   
cis-dodecenoyl-biosynthesis_1.3.1.9_RXN0-2145  : 1 cis-D5-dodecenoyl-[ACP] + 1 NAD+ <-- 1 H+ + 1 
trans-D3-cis-D5-dodecenoyl-[ACP] + 1 NADH  
 
# Palmitoleoyl-[ACP] ((Z)-hexadec-11-enoyl-[ACP])  
palmitoleate-biosynthesis-I_2.3.1.41_RXN-10654     : 1 cis-D5-dodecenoyl-[ACP] + 1 malonyl-[ACP] + 
1 H+ --> 1 ACP + 1 CO2 + 1 3-oxo-cis-D7-tetradecenoyl-[ACP] 
palmitoleate-biosynthesis-I_1.1.1.100_RXN-10655   : 1 NADP+ + 1 (3R)-hydroxy-cis-D7-
tetradecenoyl-[ACP] <-- 1 3-oxo-cis-D7-tetradecenoyl-[ACP] + 1 NADPH + 1 H+  
palmitoleate-biosynthesis-I_4.2.1.59_RXN-10656     : 1 (3R)-hydroxy-cis-D7-tetradecenoyl-[ACP] --> 1 
trans-D3-cis-D7-tetradecenoyl-[ACP] + 1 H2O    
palmitoleate-biosynthesis-I_1.3.1.9_RXN-10657    : 1 cis-D7-tetradecenoyl-[ACP] + 1 NAD+ <-- 1 
trans-D3-cis-D7-tetradecenoyl-[ACP] + 1 H+ + 1 NADH  
palmitoleate-biosynthesis-I_2.3.1.41_RXN-10658   : 1 cis-D7-tetradecenoyl-[ACP] + 1 malonyl-[ACP] + 
1 H+ --> 1 CO2 + 1 3-oxo-cis-D9-hexadecenoyl-[ACP] + 1 ACP 
palmitoleate-biosynthesis-I_1.1.1.100_RXN-10659   : 1 NADP+ + 1 (3R)-hydroxy-cis-D9-hexaecenoyl-
[ACP] <-- 1 3-oxo-cis-D9-hexadecenoyl-[ACP] + 1 H+ + 1 NADPH 
palmitoleate-biosynthesis-I_4.2.1.59_RXN-10660   : 1 (3R)-hydroxy-cis-D9-hexaecenoyl-[ACP] --> 1 
H2O + 1 trans-D3-cis-D9-hexadecenoyl-[ACP] 
palmitoleate-biosynthesis-I_1.3.1.9_RXN-10661  : 1 Palmitoleoyl-[ACP] + 1 NAD+ <-- 1 H+ + 1 trans-
D3-cis-D9-hexadecenoyl-[ACP] + 1 NADH  
 
# cis-vaccenic acid ((Z)-octadec-11-enoic acid)  
cis-vaccenate-biosynthesis_2.3.1.179_2.3.1.179-RXN    : 1 Palmitoleoyl-[ACP] + 1 malonyl-[ACP] + 1 
H+ --> 1 3-oxo-cis-vaccenoyl-[ACP] + 1 CO2 + 1 ACP  
cis-vaccenate-biosynthesis_1.1.1.100_RXN-9556     : 1 (R)-3-hydroxy-cis-vaccenoyl-[ACP] + 1 NADP+ 
<-- 1 3-oxo-cis-vaccenoyl-[ACP] + 1 H+ + 1 NADPH  
cis-vaccenate-biosynthesis_4.2.1.59_RXN-9557  : 1 (R)-3-hydroxy-cis-vaccenoyl-[ACP] --> 1 H2O + 1 
cis-vaccen-2-enoyl-[ACP] 
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cis-vaccenate-biosynthesis_1.3.1.9_RXN-9558   : 1 NADH + 1 H+ + 1 cis-vaccen-2-enoyl-[ACP] --> 1 
NAD+ + 1 cis-vaccenoyl-[ACP]  
 
################################################################# 
 
# phospholipids 
 
# phosphatidylglycerol  
CDP-diacylglycerol-biosynthesis_1.1.1.94_GLYC3PDEHYDROGBIOSYN-RXN_NAD  : 1 NAD+ + 1 sn-
glycerol_3-phosphate <-- 1 dihydroxyacetone_phosphate + 1 NADH + 1 H+  
CDP-diacylglycerol-biosynthesis_1.1.1.94_GLYC3PDEHYDROGBIOSYN-RXN_NADP  : 1 sn-glycerol_3-
phosphate + 1 NADP+ <-- 1 NADPH + 1 dihydroxyacetone_phosphate + 1 H+  
CDP-diacylglycerol-biosynthesis-II_2.3.1.15_RXN-10462   : 1 cis-vaccenoyl-[ACP] + 1 sn-glycerol_3-
phosphate --> 1 cis-vaccenoyl-sn-glycerol-3-phosphate + 1 ACP 
CDP-diacylglycerol-biosynthesis_2.3.1.51_1-ACYLGLYCEROL-3-P-ACYLTRANSFER-RXN : 1 cis-
vaccenoyl-sn-glycerol-3-phosphate + 1 cis-vaccenoyl-[ACP] --> 1 1,2-di-cis-vaccenoyl-sn-glycerol-3-
phosphate + 1 ACP  
~no-pathway_2.7.7.41_RXN0-5515    : 1 CTP + 1 1,2-di-cis-vaccenoyl-sn-glycerol-3-phosphate + 1 H+ 
--> 1 diphosphate + 1 CDP-1,2-di-cis-vaccenoylglycerol  
PG_I-2.7.8.5-PHOSPHAGLYPSYN-RXN    : 1 CDP-1,2-di-cis-vaccenoylglycerol + 1 sn-glycerol_3-
phosphate --> 1 H+ + 1 CMP + 1 L-1-phosphatidylglycerol-phosphate 
~no-pathway_3.1.3.27_RXN-13313 : 1 L-1-phosphatidylglycerol-phosphate + 1 H2O --> 1 L-1-
phosphatidylglycerol + 1 phosphate  
 
# phosphatidylethanolamine  
PE_2.7.8.8_RXN  : 1 CDP-1,2-di-cis-vaccenoylglycerol + 1 L-serine --> 1 H+ + 1 CMP + 1 L-1-
phosphatidylserine  
phosphatidylethanolamine-biosynthesis-I_4.1.1.65_PHOSPHASERDECARB-RXN   : 1 L-1-
phosphatidylserine + 1 H+ --> 1 CO2 + 1 L-1-phosphatidylethanolamine 
 
# phosphatidylcholine 
phosphatidylcholine-biosynthesis-V_2.1.1.17_2.1.1.17-RXN : 1 L-1-phosphatidylethanolamine + 1 S-
adenosyl-L-methionine --> 1 phosphatidyl-N-methylethanolamine + 1 S-adenosyl-L-homocysteine + 1 
H+  
phosphatidylcholine-biosynthesis_2.1.1.71_2.1.1.71-RXN  : 1 phosphatidyl-N-methylethanolamine + 1 
S-adenosyl-L-methionine --> 1 H+ + 1 phosphatidyl-N-dimethylethanolamine + 1 S-adenosyl-L-
homocysteine   
phosphatidylcholine-biosynthesis_2.1.1.17_2.1.1.71_RXN4FS-2   : 1 phosphatidyl-N-
dimethylethanolamine + 1 S-adenosyl-L-methionine --> 1 phosphatidylcholine + 1 H+ + 1 S-adenosyl-
L-homocysteine 
 
# cardiolipin 
cardiolipin-biosynthesis-I_2.7.8.-_CARDIOLIPSYN-RXN   : L-1-phosphatidylglycerol + CDP-1,2-di-cis-
vaccenoylglycerol --> 1 cardiolipin + 1 CMP + H+  
 
################################################################# 
 
 
# amino acids biosynthesis 
 
# aspartate and asparagine biosynthesis 
~multiple-pathways_2.6.1.1_ASPAMINOTRANS-RXN    : 1 2-oxoglutarate + 1 L-aspartate <=> 1 
oxaloacetate + 1 L-glutamate   
~metabolism-of-asparagine_3.5.1.1_ASPARAGHYD-RXN : 1 L-asparagine + 1 H2O --> 1 L-aspartate + 
1 ammonia + 1 H+   
~no-pathway_6.1.1.-_RXN490-3616   : 1 L-aspartate + 1 |ASN-tRNAs| + 1 ATP --> 1 diphosphate + 1 
|L-aspartyl-tRNAAsn| + 1 AMP   
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~no-pathway_6.3.5.6_6.3.5.6-RXN    : 1 L-glutamine + 1 |L-aspartyl-tRNAAsn| + 1 H2O + 1 ATP --> 1 L-
glutamate + 1 |Charged-ASN-tRNAs| + 2 H+ + 1 phosphate + 1 ADP   
~no-pathway_3.1.1.29_RXN-12460  : 1 |Charged-ASN-tRNAs| + 1 H2O --> 2 H+ + 1 |ASN-tRNAs| + 1 L-
asparagine   
 
# glutamate and glutamine biosynthesis 
~multiple-pathways_1.4.1.3_GLUTAMATE-DEHYDROGENASE-NADP+-RXN_NAD       : 1 L-glutamate + 
1 H2O + 1 NAD+ <=> 1 2-oxoglutarate + 1 NADH + 2 H+ + 1 ammonia  
~multiple-pathways_1.4.1.3_GLUTAMATE-DEHYDROGENASE-NADP+-RXN_NADP      : 1 L-glutamate + 
1 H2O + 1 NADP+ <-- 1 ammonia + 1 NADPH + 1 2-oxoglutarate + 2 H+  
glutamate-biosynthesis_glutamine-degradation_1.4.1.13_GLUTAMATESYN-RXN : 1 NADP+ + 2 L-
glutamate <-- 1 H+ + 1 2-oxoglutarate + 1 NADPH + 1 L-glutamine   
glutamine-biosynthesis_nitrate-reduction_6.3.1.2_GLUTAMINESYN-RXN : 1 ATP + 1 ammonia + 1 L-
glutamate --> 1 ADP + 1 phosphate + 1 L-glutamine  
 
# proline biosynthesis 
proline-biosynthesis_citrulline-biosynthesis_2.7.2.11_GLUTKIN-RXN  : 1 ATP + 1 L-glutamate --> 1 
ADP + 1 L-glutamate-5-phosphate   
proline-biosynthesis_citrulline-biosynthesis_1.2.1.41_GLUTSEMIALDEHYDROG-RXN   : 1 NADP+ + 1 
L-glutamate-5-semialdehyde + 1 phosphate <-- 1 NADPH + 1 L-glutamate-5-phosphate + 1 H+   
proline-biosynthesis_arginine-degradation_1.5.1.2_PYRROLINECARBREDUCT-RXN_NAD  : 1 NAD+ + 
1 L-proline <-- 1 (S)-1-pyrroline-5-carboxylate + 1 NADH + 2 H+   
proline-biosynthesis_arginine-degradation_1.5.1.2_PYRROLINECARBREDUCT-RXN_NADP : 1 NADP+ 
+ 1 L-proline <-- 2 H+ + 1 NADPH + 1 (S)-1-pyrroline-5-carboxylate    
 
# arginine biosynthesis 
ornithine-biosynthesis_arginine-biosynthesis_2.3.1.1_N-ACETYLTRANSFER-RXN   : 1 acetyl-CoA + 1 
L-glutamate --> 1 H+ + 1 coenzyme_A + 1 N-acetyl-L-glutamate   
arginine-biosynthesis-II-(acetyl-cycle)_2.3.1.35_GLUTAMATE-N-ACETYLTRANSFERASE-RXN           : 1 
N-acetyl-L-ornithine + 1 L-glutamate --> 1 L-ornithine + 1 N-acetyl-L-glutamate   
ornithine-biosynthesis_arginine-biosynthesis_2.7.2.8_ACETYLGLUTKIN-RXN   : 1 ATP + 1 N-acetyl-L-
glutamate --> 1 N-acetylglutamyl-phosphate + 1 ADP   
ornithine-biosynthesis_arginine-biosynthesis_1.2.1.38_N-ACETYLGLUTPREDUCT-RXN   : 1 NADP+ + 1 
N-acetyl-L-glutamate_5-semialdehyde + 1 phosphate <=> 1 H+ + 1 N-acetylglutamyl-phosphate + 1 
NADPH   
ornithine-biosynthesis_arginine-biosynthesis_2.6.1.11_ACETYLORNTRANSAM-RXN                   : 1 2-
oxoglutarate + 1 N-acetyl-L-ornithine <=> 1 L-glutamate + 1 N-acetyl-L-glutamate_5-semialdehyde   
ornithine-biosynthesis_3.5.1.16_ACETYLORNDEACET-RXN   : 1 N-acetyl-L-ornithine + 1 H2O --> 1 
acetate + 1 L-ornithine   
~multiple-pathways_2.1.3.3_ORNCARBAMTRANSFER-RXN   : 1 carbamoyl-phosphate + 1 L-ornithine 
<=> 1 H+ + 1 L-citrulline + 1 phosphate   
~multiple-pathways_6.3.4.5_ARGSUCCINSYN-RXN    : 1 L-aspartate + 1 L-citrulline + 1 ATP --> 1 
diphosphate + 1 L-arginino-succinate + 1 H+ + 1 AMP  
~multiple-pathways_4.3.2.1_ARGSUCCINLYA-RXN  : 1 L-arginino-succinate <=> 1 fumarate + 1 L-
arginine   
de-novo-biosynthesis-of-uridine-5'-monophosphate_arginine-biosynthesis_6.3.5.5_CARBPSYN-RXN  : 
2 ATP + 1 L-glutamine + 1 H2O + 1 bicarbonate --> 1 phosphate + 2 ADP + 2 H+ + 1 L-glutamate + 1 
carbamoyl-phosphate   
 
# valine biosynthesis 
valine-biosynthesis_2.2.1.6_ACETOLACTSYN-RXN : 2 pyruvate + 1 H+ --> 1 CO2 + 1 (S)-2-acetolactate   
valine-biosynthesis_1.1.1.86_ACETOLACTREDUCTOISOM-RXN   : 1 NADP+ + 1 (R)-2,3-dihydroxy-3-
methylbutanoate <=> 1 NADPH + 1 H+ + 1 (S)-2-acetolactate   
valine-biosynthesis_4.2.1.9_DIHYDROXYISOVALDEHYDRAT-RXN  : 1 (R)-2,3-dihydroxy-3-
methylbutanoate --> 1 H2O + 1 2-oxoisovalerate   
~multiple-pathways_2.6.1.42_BRANCHED-CHAINAMINOTRANSFERVAL-RXN : 1 2-oxoglutarate + 1 
L-valine <=> 1 L-glutamate + 1 2-oxoisovalerate   
 
l   MODEL iPIN571 
 
# leucine biosynthesis 
leucine-biosynthesis_2.3.3.13_2-ISOPROPYLMALATESYN-RXN   : 1 acetyl-CoA + 1 H2O + 1 2-
oxoisovalerate --> 1 coenzyme_A + 1 H+ + 1 (2S)-2-isopropylmalate   
leucine-biosynthesis_4.2.1.33_3-ISOPROPYLMALISOM-RXN   : 1 (2S)-2-isopropylmalate --> 1 2-
isopropylmaleate + 1 H2O   
leucine_metabolism-4.2.1.33-RXN-8991  : 1 (2R,3S)-3-isopropylmalate <-- 1 2-isopropylmaleate + 1 
H2O  
leucine-biosynthesis_1.1.1.85_3-ISOPROPYLMALDEHYDROG-RXN   : 1 (2R,3S)-3-isopropylmalate + 1 
NAD+ <=> 1 H+ + 1 NADH + 1 (2S)-2-isopropyl-3-oxosuccinate   
leucine-biosynthesis_1.1.1.85_RXN-7800  : 1 (2S)-2-isopropyl-3-oxosuccinate + 1 H+ --> 1 CO2 + 1 4-
methyl-2-oxopentanoate   
leucine-biosynthesis_2.6.1.42_BRANCHED-CHAINAMINOTRANSFERLEU-RXN  : 1 2-oxoglutarate + 1 
L-leucine <=> 1 L-glutamate + 1 4-methyl-2-oxopentanoate   
 
# isoleucine biosynthesis 
isoleucine-biosynthesis-from-threonine_isoleucine-biosynthesis_2.2.1.6_ACETOOHBUTSYN-RXN: 1 
H+ + 1 2-oxobutanoate + 1 pyruvate --> 1 CO2 + 1 2-aceto-2-hydroxy-butanoate   
isoleucine-biosynthesis-from-threonine_isoleucine-
biosynthesis_1.1.1.86_ACETOOHBUTREDUCTOISOM-RXN  : 1 NADP+ + 1 2,3-dihydroxy-3-
methylvalerate <=> 1 H+ + 1 NADPH + 1 2-aceto-2-hydroxy-butanoate   
isoleucine-biosynthesis-from-threonine_isoleucine-
biosynthesis_4.2.1.9_DIHYDROXYMETVALDEHYDRAT-RXN : 1 2,3-dihydroxy-3-methylvalerate --> 1 
H2O + 1 2-keto-3-methyl-valerate   
~metabolism-of-isoleucine_2.6.1.42_BRANCHED-CHAINAMINOTRANSFERILEU-RXN    : 1 2-
oxoglutarate + 1 L-isoleucine <=> 1 L-glutamate + 1 2-keto-3-methyl-valerate   
isoleucine-biosynthesis-from-threonine_threonine-degradation_4.3.1.19_THREDEHYD-RXN   : 1 L-
threonine --> 1 H+ + 1 2-oxobutanoate + 1 ammonia   
 
# threonine biosynthesis 
~metabolism-of-biosynthesis_2.7.2.4_ASPARTATEKIN-RXN   : 1 ATP + 1 L-aspartate --> 1 L-aspartyl-
4-phosphate + 1 ADP   
~metabolism-of-biosynthesis_1.2.1.11_ASPARTATE-SEMIALDEHYDE-DEHYDROGENASE-RXN          : 1 
phosphate + 1 NADP+ + 1 L-aspartate-semialdehyde <=> 1 NADPH + 1 L-aspartyl-4-phosphate + 1 H+   
homoserine-biosynthesis_1.1.1.3_HOMOSERDEHYDROG-RXN_NAD    : 1 NAD+ + 1 L-homoserine <-- 1 
L-aspartate-semialdehyde + 1 NADH + 1 H+   
homoserine-biosynthesis_1.1.1.3_HOMOSERDEHYDROG-RXN_NADP   : 1 L-homoserine + 1 NADP+ <-- 
1 H+ + 1 NADPH + 1 L-aspartate-semialdehyde   
methionine-biosynthesis_threonine-biosynthesis-from-homoserine_2.7.1.39_HOMOSERKIN-RXN : 1 
L-homoserine + 1 ATP --> 1 H+ + 1 O-phospho-L-homoserine + 1 ADP   
threonine-biosynthesis-from-homoserine_4.2.3.1_THRESYN-RXN     : 1 O-phospho-L-homoserine + 1 
H2O --> 1 L-threonine + 1 phosphate   
 
# methionine biosynthesis 
methionine-biosynthesis-I_2.3.1.46_HOMSUCTRAN-RXN   : 1 L-homoserine + 1 succinyl-CoA --> 1 
coenzyme_A + 1 O-succinyl-L-homoserine   
methionine-biosynthesis-I_2.5.1.48_O-SUCCHOMOSERLYASE-RXN   : 1 L-cysteine + 1 O-succinyl-L-
homoserine --> 1 L-cystathionine + 1 succinate + 1 H+   
methionine-biosynthesis_homocysteine-and-cysteine-interconversion_4.4.1.8_CYSTATHIONINE-
BETA-LYASE-RXN : 1 H2O + 1 L-cystathionine --> 1 L-homocysteine + 1 ammonia + 1 H+ + 1 pyruvate  
~multiple-pathways_2.1.1.13_HOMOCYSMETB12-RXN   : 1 5-methyl-tetrahydrofolate + 1 L-
homocysteine --> 1 tetrahydrofolate + 1 L-methionine   
S-adenosyl-L-methionine-cycle_methionine-biosynthesis_2.1.1.14_HOMOCYSMET-RXN  : 1 5-
methyltetrahydropteroyltri-L-glutamate + 1 L-homocysteine <=> 1 L-methionine + 1 
tetrahydropteroyl_tri-L-glutamate   
~multiple-pathways_2.5.1.6_S-ADENMETSYN-RXN  : 1 L-methionine + 1 ATP + 1 H2O --> 1 phosphate 
+ 1 diphosphate + 1 S-adenosyl-L-methionine  
S-adenosyl-L-methionine-cycle_methionine-degradation_3.3.1.1_ADENOSYLHOMOCYSTEINASE-RXN: 
1 S-adenosyl-L-homocysteine + 1 H2O <=> 1 L-homocysteine + 1 adenosine  
MODEL iPIN571  li 
 
S-methyl-5-thio-alpha-D-ribose-1-phosphate-degradation-II_2.5.1.49_O-ACETYLHOMOSERINE-
THIOL-LYASE-RXN  : 1 O-acetyl-L-homoserine + 1 methanethiol --> 1 acetate + 1 H+ + 1 L-methionine 
homocysteine-biosynthesis_2.5.1.49_ACETYLHOMOSER-CYS-RXN : 1 O-acetyl-L-homoserine + 1 
hydrogen_sulfide <=> 1 H+ + 1 acetate + 1 L-homocysteine 
 
# lysine biosynthesis 
lysine-biosynthesis_4.3.3.7_DIHYDRODIPICSYN-RXN : 1 L-aspartate-semialdehyde + 1 pyruvate --> 1 
H2O + 1 H+ + 1 (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate  
~no-pathway_1.17.1.8_RXN-14014  : 1 NADP+ + 1 H2O + 1 (S)-2,3,4,5-tetrahydrodipicolinate <-- 1 H+ 
+ 1 (2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + 1 NADPH   
lysine-biosynthesis-I_2.3.1.117_TETHYDPICSUCC-RXN   : 1 (S)-2,3,4,5-tetrahydrodipicolinate + 1 
succinyl-CoA + 1 H2O --> 1 coenzyme_A + 1 N-succinyl-2-amino-6-ketopimelate   
lysine-biosynthesis-I_2.6.1.17_SUCCINYLDIAMINOPIMTRANS-RXN : 1 2-oxoglutarate + 1 N-succinyl-
L,L-2,6-diaminopimelate <=> 1 N-succinyl-2-amino-6-ketopimelate + 1 L-glutamate   
lysine-biosynthesis-I_3.5.1.18_SUCCDIAMINOPIMDESUCC-RXN  : 1 N-succinyl-L,L-2,6-
diaminopimelate + 1 H2O --> 1 succinate + 1 L,L-diaminopimelate   
lysine-biosynthesis_5.1.1.7_DIAMINOPIMEPIM-RXN : 1 L,L-diaminopimelate <=> 1 meso-
diaminopimelate   
lysine-biosynthesis_4.1.1.20_DIAMINOPIMDECARB-RXN  : 1 meso-diaminopimelate + 1 H+ --> 1 L-
lysine + 1 CO2   
 
# serine and glycine biosynthesis 
serine-biosynthesis_1.1.1.95_PGLYCDEHYDROG-RXN : 1 3-phospho-D-glycerate + 1 NAD+ <=> 1 H+ + 
1 NADH + 1 3-phospho-hydroxypyruvate   
serine-biosynthesis_2.6.1.52_PSERTRANSAM-RXN   : 1 3-phospho-L-serine + 1 2-oxoglutarate <=> 1 
L-glutamate + 1 3-phospho-hydroxypyruvate   
serine-biosynthesis_3.1.3.3_RXN0-5114  : 1 3-phospho-L-serine + 1 H2O --> 1 phosphate + 1 L-serine   
~multiple-pathways_2.1.2.1_GLYOHMETRANS-RXN   : 1 L-serine + 1 tetrahydrofolate <=> 1 H2O + 1 
5,10-methylenetetrahydrofolate + 1 glycine   
 
# cysteine and alanine biosynthesis 
cysteine-biosynthesis-I_2.3.1.30_SERINE-O-ACETTRAN-RXN : 1 L-serine + 1 acetyl-CoA <=> 1 
coenzyme_A + 1 O-acetyl-L-serine   
cysteine-biosynthesis-I_2.5.1.47_ACSERLY-RXN : 1 O-acetyl-L-serine + 1 hydrogen_sulfide <=> 1 L-
cysteine + 1 H+ + 1 acetate   
alanine-biosynthesis-III_2.8.1.7_RXN0-308  : 1 L-cysteine + 1 |L-Cysteine-Desulfurases| --> 1 
|Persulfurated-L-cysteine-desulfurases| + 1 L-alanine  
 
# tyrosine and phenylalanine biosynthesis 
phenylalanine-biosynthesis_tyrosine-biosynthesis_5.4.99.5_CHORISMATEMUT-RXN  : 1 chorismate 
<=> 1 prephenate   
tyrosine-biosynthesis-I_1.3.1.12_PREPHENATEDEHYDROG-RXN  : 1 NAD+ + 1 prephenate --> 1 NADH 
+ 1 4-hydroxyphenylpyruvate + 1 CO2   
~multiple-pathways_2.6.1.57_TYROSINE-AMINOTRANSFERASE-RXN  : 1 2-oxoglutarate + 1 L-
tyrosine <=> 1 L-glutamate + 1 4-hydroxyphenylpyruvate   
phenylalanine-biosynthesis-I_4.2.1.51_PREPHENATEDEHYDRAT-RXN  : 1 prephenate + 1 H+ --> 1 
keto-phenylpyruvate + 1 CO2 + 1 H2O   
phenylalanine-biosynthesis_2.6.1.57_PHEAMINOTRANS-RXN  : 1 L-glutamate + 1 keto-
phenylpyruvate <=> 1 L-phenylalanine + 1 2-oxoglutarate   
 
# tryptophan biosynthesis 
tryptophan-biosynthesis_4.1.3.27_ANTHRANSYN-RXN  : 1 chorismate + 1 L-glutamine <=> 1 H+ + 1 
pyruvate + 1 L-glutamate + 1 anthranilate   
tryptophan-biosynthesis_2.4.2.18_PRTRANS-RXN : 1 N-(5'-phosphoribosyl)-anthranilate + 1 
diphosphate <-- 1 5-phospho-alpha-D-ribose_1-diphosphate + 1 anthranilate   
tryptophan-biosynthesis_5.3.1.24_PRAISOM-RXN  : 1 N-(5'-phosphoribosyl)-anthranilate --> 1 1-(o-
carboxyphenylamino)-1'-deoxyribulose-5'-phosphate   
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tryptophan-biosynthesis_4.1.1.48_IGPSYN-RXN   : 1 H+ + 1 1-(o-carboxyphenylamino)-1'-
deoxyribulose-5'-phosphate --> 1 (1S,2R)-1-C-(indol-3-yl)glycerol_3-phosphate + 1 H2O + 1 CO2   
IAA-biosynthesis_tryptophan-biosynthesis_4.2.1.20_RXN0-2381 : 1 (1S,2R)-1-C-(indol-3-
yl)glycerol_3-phosphate <=> 1 D-glyceraldehyde-3-phosphate + 1 indole   
tryptophan-biosynthesis_4.2.1.20_RXN0-2382   : 1 indole + 1 L-serine --> 1 L-tryptophan + 1 H2O   
 
# histidine biosynthesis 
PRPP-biosynthesis-II_5.4.2.7_PPENTOMUT-RXN  : 1 alpha-D-ribose-1-phosphate <=> 1 D-ribose-5-
phosphate 
PRPP-biosynthesis-I_2.7.6.1_PRPPSYN-RXN   : 1 ATP + 1 D-ribose-5-phosphate <=> 1 5-phospho-
alpha-D-ribose_1-diphosphate + 1 H+ + 1 AMP   
histidine-biosynthesis-I_2.4.2.17_ATPPHOSPHORIBOSYLTRANS-RXN : 1 phosphoribosyl-ATP + 1 
diphosphate <-- 1 5-phospho-alpha-D-ribose_1-diphosphate + 1 ATP   
histidine-biosynthesis-I_3.6.1.31_HISTPRATPHYD-RXN   : 1 phosphoribosyl-ATP + 1 H2O --> 1 H+ + 1 
diphosphate + 1 1-(5-phospho-D-ribosyl)-AMP  
histidine-biosynthesis-I_3.5.4.19_HISTCYCLOHYD-RXN  : 1 1-(5-phospho-D-ribosyl)-AMP + 1 H2O --> 
1 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino]imidazole-4-carboxamide   
histidine-biosynthesis-I_5.3.1.16_PRIBFAICARPISOM-RXN   : 1 1-(5-phosphoribosyl)-5-[(5-
phosphoribosylamino)methylideneamino]imidazole-4-carboxamide --> 1 
phosphoribulosylformimino-AICAR-P  
histidine-biosynthesis-I_4.1.3.-_2.4.2.-_GLUTAMIDOTRANS-RXN  : 1 phosphoribulosylformimino-
AICAR-P + 1 L-glutamine --> 1 D-erythro-imidazole-glycerol-phosphate + 1 L-glutamate + 1 H+ + 1 
aminoimidazole_carboxamide_ribonucleotide  
histidine-biosynthesis-I_4.2.1.19_IMIDPHOSDEHYD-RXN  : 1 D-erythro-imidazole-glycerol-phosphate 
--> 1 H2O + 1 imidazole_acetol-phosphate   
histidine-biosynthesis-I_2.6.1.9_HISTAMINOTRANS-RXN  : 1 L-glutamate + 1 imidazole_acetol-
phosphate <=> 1 2-oxoglutarate + 1 L-histidinol-phosphate   
histidine-biosynthesis-I_3.1.3.15_HISTIDPHOS-RXN : 1 L-histidinol-phosphate + 1 H2O --> 1 
phosphate + 1 histidinol   
histidine-biosynthesis-I_1.1.1.23_HISTOLDEHYD-RXN : 1 histidinol + 1 NAD+ --> 1 histidinal + 1 H+ + 
1 NADH   
histidine-biosynthesis-I_1.1.1.23_HISTALDEHYD-RXN : 1 H2O + 1 NAD+ + 1 histidinal --> 1 NADH + 2 
H+ + 1 L-histidine  
 
 
# beta-alanine biosynthesis 
beta-alanine-biosynthesis-II_1.3.8.-_PROPCOASYN-RXN : 1 FAD + 1 propanoyl-CoA --> 1 FADH2 + 1 
acryloyl-CoA  
~multiple-pathways_4.2.1.116_RXN-6383  : 1 3-hydroxypropanoyl-CoA <=> 1 H2O + 1 acryloyl-CoA   
beta-alanine-biosynthesis-II_3.1.2.4_RXN-6384  : 1 3-hydroxypropanoyl-CoA + 1 H2O --> 1 
coenzyme_A + 1 3-hydroxypropionate + 1 H+  
acrylate-degradation_beta-alanine-biosynthesis_1.1.1.59_3-HYDROXYPROPIONATE-
DEHYDROGENASE-RXN : 1 3-hydroxypropionate + 1 NAD+ --> 1 H+ + 1 malonate_semialdehyde + 1 
NADH 
beta-alanine-degradation_beta-alanine-biosynthesis_2.6.1.18_2.6.1.18-RXN: 1 L-alanine + 1 
malonate_semialdehyde <=> 1 beta-alanine + 1 pyruvate  
~multiple-pathways_2.6.1.19_BS353590 : 1 2-oxoglutarate + 1 beta-alanine <=> 1 L-glutamate + 1 
malonate_semialdehyde  
 
################################################################# 
 
# purine metabolism 
~no-pathway_2.4.2.14_PRPPAMIDOTRANS-RXN : 1 L-glutamate + 1 diphosphate + 1 5-phospho-beta-
D-ribosyl-amine <-- 1 L-glutamine + 1 5-phospho-alpha-D-ribose_1-diphosphate + 1 H2O  
~no-pathway_6.3.4.13_GLYRIBONUCSYN-RXN : 1 glycine + 1 5-phospho-beta-D-ribosyl-amine + 1 
ATP --> 1 ADP + 1 H+ + 1 5-phospho-ribosyl-glycineamide + 1 phosphate 
MODEL iPIN571  liii 
 
~no-pathway_6.3.5.3_FGAMSYN-RXN : 1 ATP + 1 L-glutamine + 1 5'-phosphoribosyl-N-
formylglycineamide + 1 H2O --> 1 H+ + 1 ADP + 1 phosphate + 1 5-phosphoribosyl-N-
formylglycineamidine + 1 L-glutamate 
~no-pathway_6.3.3.1_AIRS-RXN : 1 ATP + 1 5-phosphoribosyl-N-formylglycineamidine --> 1 H+ + 1 
phosphate + 1 ADP + 1 5-amino-1-(5-phospho-D-ribosyl)imidazole 
~no-pathway_6.3.4.18_RXN0-742  : 1 ATP + 1 5-amino-1-(5-phospho-D-ribosyl)imidazole + 1 
bicarbonate --> 2 H+ + 1 phosphate + 1 N5-carboxyaminoimidazole_ribonucleotide + 1 ADP   
~no-pathway_5.4.99.18_RXN0-743  : 1 N5-carboxyaminoimidazole_ribonucleotide --> 1 5-amino-1-
(5-phospho-D-ribosyl)imidazole-4-carboxylate  
~no-pathway_6.3.2.6_SAICARSYN-RXN  : 1 ATP + 1 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-
carboxylate + 1 L-aspartate --> 1 H+ + 1 ADP + 1 phosphate + 1 5'-phosphoribosyl-4-(N-
succinocarboxamide)-5-aminoimidazole   
~no-pathway_4.3.2.2_AICARSYN-RXN  : 1 5'-phosphoribosyl-4-(N-succinocarboxamide)-5-
aminoimidazole <=> 1 aminoimidazole_carboxamide_ribonucleotide + 1 fumarate  
~no-pathway_2.1.2.3_AICARTRANSFORM-RXN : 1 10-formyl-tetrahydrofolate + 1 
aminoimidazole_carboxamide_ribonucleotide <=> 1 phosphoribosyl-formamido-carboxamide + 1 
tetrahydrofolate 
~no-pathway_3.5.4.10_2.1.2.3_IMPCYCLOHYDROLASE-RXN  : 1 IMP + 1 H2O <=> 1 phosphoribosyl-
formamido-carboxamide   
purine-nucleotides-de-novo-biosynthesis-II_6.3.4.4_ADENYLOSUCCINATE-SYNTHASE-RXN : 1 L-
aspartate + 1 GTP + 1 IMP --> 1 GDP + 1 phosphate + 2 H+ + 1 adenylo-succinate  
purine-nucleotides-de-novo-biosynthesis-II_4.3.2.2_AMPSYN-RXN  : 1 adenylo-succinate <=> 1 
fumarate + 1 AMP   
salvage-pathways-of-purine-and-pyrimidine-nucleotides_2.7.4.3_ADENYL-KIN-RXN   : 1 AMP + 1 ATP 
<=> 2 ADP 
~no-pathway_1.17.4.1_ADPREDUCT-RXN    : 1 dADP + 1 H2O + 1 |Ox-Thioredoxin| <-- 1 |Red-
Thioredoxin| + 1 ADP  
~no-pathway_2.7.4.6_DADPKIN-RXN     : 1 dADP + 1 ATP --> 1 dATP + 1 ADP  
purine-nucleotides-de-novo-biosynthesis_urate-biosynthesis_1.1.1.205_IMP-DEHYDROG-RXN  : 1 
NAD+ + 1 H2O + 1 IMP <=> 1 NADH + 1 H+ + 1 XMP  
purine-nucleotides-de-novo-biosynthesis-II_6.3.5.2_GMP-SYN-GLUT-RXN   : 1 XMP + 1 H2O + 1 ATP + 
1 L-glutamine --> 1 L-glutamate + 1 diphosphate + 1 AMP + 2 H+ + 1 GMP 
salvage-pathways-of-purine-and-pyrimidine-nucleotides_2.7.4.8_GUANYL-KIN-RXN   : 1 ATP + 1 GMP 
--> 1 GDP + 1 ADP  
~no-pathway_2.7.4.8_GMKALT-RXN    : 1 ATP + 1 dGMP --> 1 dGDP + 1 ADP  
~no-pathway_1.17.4.1_GDPREDUCT-RXN   : 1 H2O + 1 dGDP + 1 |Ox-Thioredoxin| <-- 1 |Red-
Thioredoxin| + 1 GDP   
~no-pathway_2.7.4.6_DGDPKIN-RXN    : 1 ATP + 1 dGDP --> 1 dGTP + 1 ADP 
ppGpp-biosynthesis_2.7.4.6_GDPKIN-RXN   : 1 GDP + 1 ATP --> 1 GTP + 1 ADP 
salvage-pathways-of-adenine,-hypoxanthine,-and-their-nucleosides_3.1.3.5_AMP-
DEPHOSPHORYLATION-RXN : 1 H2O + 1 AMP --> 1 phosphate + 1 adenosine   
~no-pathway_3.1.3.5_RXN-7609 : 1 H2O + 1 GMP --> 1 phosphate + 1 guanosine  
urate-biosynthesis_3.1.3.5_XMPXAN-RXN     : 1 H2O + 1 XMP --> 1 xanthosine + 1 phosphate 
~no-pathway_3.1.3.5_RXN-7607     : 1 IMP + 1 H2O --> 1 phosphate + 1 inosine 
~no-pathway_3.1.3.5_RXN-14142   : 1 dGMP + 1 H2O --> 1 phosphate + 1 deoxyguanosine  
~no-pathway_3.1.3.5_RXN-14161     : 1 H2O + 1 dAMP --> 1 phosphate + 1 deoxyadenosine  
purine-deoxyribonucleosides-degradation_2.4.2.1_DEOXYADENPHOSPHOR-RXN : 1 deoxyadenosine 
+ 1 phosphate <=> 1 adenine + 1 2-deoxy-alpha-D-ribose_1-phosphate   
purine-deoxyribonucleosides-degradation_2.4.2.1_DEOXYGUANPHOSPHOR-RXN    : 1 phosphate + 1 
deoxyguanosine <=> 1 guanine + 1 2-deoxy-alpha-D-ribose_1-phosphate   
purine-deoxyribonucleosides-degradation_2.4.2.1_DEOXYINOPHOSPHOR-RXN  : 1 deoxyinosine + 1 
phosphate <=> 1 hypoxanthine + 1 2-deoxy-alpha-D-ribose_1-phosphate   
~metabolism-of-purine_2.4.2.1_ADENPHOSPHOR-RXN : 1 adenosine + 1 phosphate <=> 1 alpha-D-
ribose-1-phosphate + 1 adenine   
~multiple-pathways_2.4.2.1_INOPHOSPHOR-RXN  : 1 phosphate + 1 inosine <=> 1 alpha-D-ribose-1-
phosphate + 1 hypoxanthine   
~metabolism-of-purine_2.4.2.1_RXN0-5199     : 1 guanosine + 1 phosphate <=> 1 alpha-D-ribose-1-
phosphate + 1 guanine   
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~multiple-pathways_2.4.2.1_XANTHOSINEPHOSPHORY-RXN  : 1 xanthosine + 1 phosphate <=> 1 
xanthine + 1 alpha-D-ribose-1-phosphate   
~no-pathway_3.5.4.2_ADENINE-DEAMINASE-RXN  : 1 adenine + 1 H2O --> 1 ammonia + 1 
hypoxanthine  
purine-degradation_3.5.4.3_GUANINE-DEAMINASE-RXN : 1 guanine + 1 H2O --> 1 xanthine + 1 
ammonia  
~metabolism-of-salvage-pathways-purine_2.4.2.7_ADENPRIBOSYLTRAN-RXN: 1 AMP + 1 
diphosphate <-- 1 5-phospho-alpha-D-ribose_1-diphosphate + 1 adenine   
~no-pathway_2.4.2.8_HYPOXANPRIBOSYLTRAN-RXN : 1 diphosphate + 1 IMP <-- 1 5-phospho-alpha-
D-ribose_1-diphosphate + 1 hypoxanthine   
salvage-pathways-of-purine-and-pyrimidine-nucleotides_2.4.2.8_2.4.2.22_GUANPRIBOSYLTRAN-RXN        
: 1 GMP + 1 diphosphate <-- 1 5-phospho-alpha-D-ribose_1-diphosphate + 1 guanine   
salvage-pathways-of-guanine,-xanthine,-and-their-nucleosides_2.4.2.8_2.4.2.22_XANPRIBOSYLTRAN-
RXN  : 1 diphosphate + 1 XMP <-- 1 xanthine + 1 5-phospho-alpha-D-ribose_1-diphosphate 
~multiple-pathways_1.17.1.4_RXN0-901: 1 NAD+ + 1 H2O + 1 xanthine <=> 1 H+ + 1 urate + 1 NADH   
~multiple-pathways_1.17.1.4_RXN-7682: 1 hypoxanthine + 1 NAD+ + 1 H2O --> 1 NADH + 1 H+ + 1 
xanthine   
~no-pathway_3.6.1.19_RXN0-1603     : 1 XTP + 1 H2O --> 1 H+ + 1 XMP + 1 diphosphate   
~no-pathway_3.6.1.19_RXN0-6382    : 1 ITP + 1 H2O --> 1 H+ + 1 diphosphate + 1 IMP   
~no-pathway_3.6.1.19_RXN-14140   : 1 GTP + 1 H2O --> 1 diphosphate + 1 H+ + 1 GMP   
~no-pathway_3.6.1.19_RXN0-385  : 1 dGTP + 1 H2O --> 1 H+ + 1 diphosphate + 1 dGMP 
~no-pathway_3.6.1.19_RXN0-384    : 1 dATP + 1 H2O --> 1 H+ + 1 diphosphate + 1 dAMP  
~no-pathway_3.1.5.1_DGTPTRIPHYDRO-RXN  : 1 dGTP + 1 H2O --> 1 H+ + 1 PPPi + 1 deoxyguanosine 
ppGpp-biosynthesis_3.1.7.2_PPGPPSYN-RXN    : 1 ppGpp + 1 H2O --> 1 H+ + 1 diphosphate + 1 GDP   
ppGpp-biosynthesis_3.1.7.2_RXN0-6427    : 1 H2O + 1 pppGpp --> 1 diphosphate + 1 H+ + 1 GTP 
ppGpp-biosynthesis_2.7.6.5_GDPPYPHOSKIN-RXN    : 1 GDP + 1 ATP --> 1 ppGpp + 1 AMP   
ppGpp-biosynthesis_2.7.6.5_GTPPYPHOSKIN-RXN    : 1 GTP + 1 ATP --> 1 pppGpp + 1 AMP  
ppGpp-biosynthesis_3.6.1.11_3.6.1.40_PPPGPPHYDRO-RXN    : 1 H2O + 1 pppGpp --> 1 H+ + 1 
phosphate + 1 ppGpp 
 
 
# pyrimidine metabolism 
de-novo-biosynthesis-of-uridine-5'-monophosphate_2.1.3.2_ASPCARBTRANS-RXN   : 1 carbamoyl-
phosphate + 1 L-aspartate <=> 1 H+ + 1 N-carbamoyl-L-aspartate + 1 phosphate   
de-novo-biosynthesis-of-uridine-5'-monophosphate_3.5.2.3_DIHYDROOROT-RXN   : 1 (S)-
dihydroorotate + 1 H2O <=> 1 H+ + 1 N-carbamoyl-L-aspartate  
de-novo-biosynthesis-of-uridine-5'-monophosphate_1.3.5.2_RXN0-6491   : 1 ubiquinone-10 + 1 (S)-
dihydroorotate --> 1 ubiquinol-10 + 1 orotate  
de-novo-biosynthesis-of-uridine-5'-monophosphate_2.4.2.10_OROPRIBTRANS-RXN    : 1 orotidine-5'-
phosphate + 1 diphosphate <=> 1 5-phospho-alpha-D-ribose_1-diphosphate + 1 orotate  
de-novo-biosynthesis-of-uridine-5'-monophosphate_4.1.1.23_OROTPDECARB-RXN    : 1 orotidine-5'-
phosphate + 1 H+ --> 1 CO2 + 1 UMP  
de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_2.7.4.6_DCDPKIN-RXN  : 1 ATP + 1 dCDP -
-> 1 dCTP + 1 ADP   
de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_2.7.4.6_DTDPKIN-RXN : 1 dTDP + 1 ATP --
> 1 dTTP + 1 ADP   
de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_2.7.4.6_DUDPKIN-RXN  : 1 dUDP + 1 ATP -
-> 1 dUTP + 1 ADP   
pyrimidine-ribonucleotides-interconversion_2.7.4.6_UDPKIN-RXN  : 1 ATP + 1 UDP --> 1 UTP + 1 ADP   
~metabolism-of-ribonucleotides-pyrimidine_2.7.4.6_CDPKIN-RXN : 1 ATP + 1 CDP <=> 1 CTP + 1 ADP  
~no-pathway_2.7.4.22_2.7.4.25_RXN-12002  : 1 UMP + 1 ATP --> 1 UDP + 1  
pyrimidine-ribonucleotides-interconversion_6.3.4.2_CTPSYN-RXN  : 1 H2O + 1 ATP + 1 UTP + 1 L-
glutamine --> 2 H+ + 1 ADP + 1 CTP + 1 L-glutamate + 1 phosphate 
thioredoxin-pathway_1.8.1.9_THIOREDOXIN-REDUCT-NADPH-RXN  : 1 |Red-Thioredoxin| + 1 NADP+ 
<-- 1 |Ox-Thioredoxin| + 1 H+ + 1 NADPH  
de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_1.17.4.1_CDPREDUCT-RXN  : 1 H2O + 1 
dCDP + 1 |Ox-Thioredoxin| <-- 1 |Red-Thioredoxin| + 1 CDP   
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de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_1.17.4.1_UDPREDUCT-RXN : 1 H2O + 1 
dUDP + 1 |Ox-Thioredoxin| <-- 1 UDP + 1 |Red-Thioredoxin| 
de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_3.5.4.13_DCTP-DEAM-RXN  : 1 H2O + 1 
dCTP --> 1 dUTP + 1 ammonia   
~no-pathway_3.5.4.13_3.5.4.5_RXN-14118   : 1 CTP + 1 H+ + 1 H2O --> 1 UTP + 1 ammonium   
~no-pathway_3.6.1.19_DCTP-PYROPHOSPHATASE-RXN  : 1 H2O + 1 dCTP --> 1 diphosphate + 1 H+ + 
1 dCMP   
~no-pathway_3.6.1.19_RXN0-383     : 1 CTP + 1 H2O --> 1 CMP + 1 diphosphate + 1 H+   
~no-pathway_3.6.1.19_RXN0-5107   : 1 dTTP + 1 H2O --> 1 H+ + 1 dTMP + 1 diphosphate 
de-novo-biosynthesis-of-pyrimidine-deoxyribonucleotides_3.6.1.19_3.6.1.23_DUTP-PYROP-RXN : 1 
dUTP + 1 H2O --> 1 H+ + 1 diphosphate + 1 dUMP 
~metabolism-of-pyrimidine_2.7.4.9_DTMPKI-RXN    : 1 ATP + 1 dTMP --> 1 ADP + 1 dTDP  
~no-pathway_2.7.4.22_2.7.4.9_2.7.4.25_RXN-14122    : 1 dUMP + 1 ATP --> 1 dUDP + 1 ADP  
~metabolism-of-salvage-pathways-pyrimidine_2.7.4.25_RXN-11832  : 1 CMP + 1 ATP --> 1 CDP + 1 
ADP   
~no-pathway_2.7.4.25_RXN-7913     : 1 dCMP + 1 ATP --> 1 dCDP + 1 ADP  
~no-pathway_3.1.3.5_THYMIDYLATE-5-PHOSPHATASE-RXN   : 1 dTMP + 1 H2O --> 1 thymidine + 1 
phosphate 
~no-pathway_3.1.3.5_RXN-14026 : 1 H2O + 1 CMP --> 1 phosphate + 1 cytidine   
~no-pathway_3.1.3.5_RXN-14025  : 1 H2O + 1 UMP --> 1 phosphate + 1 uridine   
~no-pathway_3.1.3.5_RXN0-5292   : 1 dCMP + 1 H2O --> 1 phosphate + 1 deoxycytidine 
~metabolism-of-pyrimidine_3.5.4.5_CYTIDEAM-RXN  : 1 deoxycytidine + 1 H2O --> 1 ammonia + 1 
deoxyuridine 
~metabolism-of-pyrimidine_3.5.4.5_CYTIDEAM2-RXN  : 1 H2O + 1 cytidine --> 1 uridine + 1 ammonia 
salvage-pathways-of-pyrimidine-deoxyribonucleotides_2.7.1.21_DURIDKI-RXN    : 1 deoxyuridine + 1 
ATP --> 1 H+ + 1 dUMP + 1 ADP  
~metabolism-of-salvage-pathways-pyrimidine_2.7.1.21_THYKI-RXN  : 1 thymidine + 1 ATP --> 1 
dTMP + 1 H+ + 1 ADP  
~metabolism-of-pyrimidine_2.4.2.1_2.4.2.4_URA-PHOSPH-RXN   : 1 phosphate + 1 deoxyuridine <=> 
1 uracil + 1 2-deoxy-alpha-D-ribose_1-phosphate  
~metabolism-of-pyrimidine_2.4.2.4_THYM-PHOSPH-RXN   : 1 phosphate + 1 thymidine <=> 1 
thymine + 1 2-deoxy-alpha-D-ribose_1-phosphate  
~metabolism-of-salvage-pathways-pyrimidine_2.4.2.9_URACIL-PRIBOSYLTRANS-RXN    : 1 
diphosphate + 1 UMP <=> 1 uracil + 1 5-phospho-alpha-D-ribose_1-diphosphate   
 
################################################################# 
 
# methylerythritol phosphate pathway 
~multiple-pathways_2.2.1.7_DXS-RXN   : 1 pyruvate + 1 D-glyceraldehyde-3-phosphate + 1 H+ --> 1 
CO2 + 1 1-deoxy-D-xylulose_5-phosphate  
methylerythritol-phosphate-pathway_1.1.1.267_DXPREDISOM-RXN : 1 NADP+ + 1 2-C-methyl-D-
erythritol_4-phosphate <=> 1 H+ + 1 NADPH + 1 1-deoxy-D-xylulose_5-phosphate 
methylerythritol-phosphate-pathway_2.7.7.60_2.7.7.60-RXN   : 1 2-C-methyl-D-erythritol_4-
phosphate + 1 H+ + 1 CTP --> 1 4-(cytidine_5'-diphospho)-2-C-methyl-D-erythritol + 1 diphosphate 
methylerythritol-phosphate-pathway_2.7.1.148_2.7.1.148-RXN  : 1 4-(cytidine_5'-diphospho)-2-C-
methyl-D-erythritol + 1 ATP --> 1 H+ + 1 2-phospho-4-(cytidine_5'-diphospho)-2-C-methyl-D-
erythritol + 1 ADP 
methylerythritol-phosphate-pathway_4.6.1.12_RXN0-302    : 1 2-phospho-4-(cytidine_5'-diphospho)-
2-C-methyl-D-erythritol --> 1 CMP + 1 2-C-methyl-D-erythritol-2,4-cyclodiphosphate  
methylerythritol-phosphate-pathway_1.17.7.1_RXN0-882    : 1 1-hydroxy-2-methyl-2-(E)-butenyl_4-
diphosphate + 2 |Oxidized-flavodoxins| + 1 H2O <-- 1 H+ + 1 2-C-methyl-D-erythritol-2,4-
cyclodiphosphate + 2 |Reduced-flavodoxins|  
methylerythritol-phosphate-pathway_1.17.1.2_ISPH2-RXN_NAD   : 1 NAD+ + 1 H2O + 1 
isopentenyl_diphosphate <-- 1 H+ + 1 1-hydroxy-2-methyl-2-(E)-butenyl_4-diphosphate + 1 NADH   
methylerythritol-phosphate-pathway_1.17.1.2_ISPH2-RXN_NADP  : 1 H2O + 1 
isopentenyl_diphosphate + 1 NADP+ <-- 1 H+ + 1 1-hydroxy-2-methyl-2-(E)-butenyl_4-diphosphate + 
1 NADPH   
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methylerythritol-phosphate-pathway_1.17.1.2_RXN0-884_NAD    : 1 H2O + 1 NAD+ + 1 
dimethylallyl_diphosphate <-- 1 NADH + 1 H+ + 1 1-hydroxy-2-methyl-2-(E)-butenyl_4-diphosphate   
methylerythritol-phosphate-pathway_1.17.1.2_RXN0-884_NADP   : 1 NADP+ + 1 H2O + 1 
dimethylallyl_diphosphate <-- 1 H+ + 1 1-hydroxy-2-methyl-2-(E)-butenyl_4-diphosphate + 1 NADPH 
~multiple-pathways_5.3.3.2_IPPISOM-RXN  : 1 isopentenyl_diphosphate <=> 1 
dimethylallyl_diphosphate  
~no-pathway_1.18.1.2_FLAVONADPREDUCT-RXN   : 1 H+ + 1 NADPH + 1 |Oxidized-flavodoxins| <=> 
1 |Reduced-flavodoxins| + 1 NADP+  
 
################################################################# 
 
# tetrahydrofolate biosynthesis 
~multiple-pathways_2.1.1.45_THYMIDYLATESYN-RXN   : 1 dUMP + 1 5,10-
methylenetetrahydrofolate --> 1 dTMP + 1 7,8-dihydrofolate  
~multiple-pathways_3.5.4.9_METHENYLTHFCYCLOHYDRO-RXN    : 1 5,10-methenyltetrahydrofolate 
+ 1 H2O <=> 1 H+ + 1 10-formyl-tetrahydrofolate   
~no-pathway_2.1.2.2_GART-RXN  : 1 5-phospho-ribosyl-glycineamide + 1 10-formyl-tetrahydrofolate 
<=> 1 H+ + 1 tetrahydrofolate + 1 5'-phosphoribosyl-N-formylglycineamide  
~no-pathway_2.6.1.85_PABASYN-RXN   : 1 chorismate + 1 L-glutamine <=> 1 L-glutamate + 1 4-
amino-4-deoxychorismate   
~no-pathway_4.1.3.38_ADCLY-RXN   : 1 4-amino-4-deoxychorismate <=> 1 pyruvate + 1 4-
aminobenzoate + 1 H+   
~no-pathway_2.5.1.15_H2PTEROATESYNTH-RXN      : 1 6-hydroxymethyl-dihydropterin_diphosphate 
+ 1 4-aminobenzoate --> 1 diphosphate + 1 7,8-dihydropteroate   
formylTHF-biosynthesis-I_6.3.2.12_DIHYDROFOLATESYNTH-RXN   : 1 L-glutamate + 1 ATP + 1 7,8-
dihydropteroate --> 1 ADP + 1 H+ + 1 phosphate + 1 7,8-dihydrofolate  
formylTHF-biosynthesis_1.5.1.3_DIHYDROFOLATEREDUCT-RXN     : 1 tetrahydrofolate + 1 NADP+ <-- 
1 NADPH + 1 H+ + 1 7,8-dihydrofolate 
tetrahydrobioprein-biosynthesis_3.5.4.16_GTP-CYCLOHYDRO-I-RXN  : 1 H2O + 1 GTP --> 1 H+ + 1 
formate + 1 7,8-dihydroneopterin_triphosphate   
~no-pathway_3.6.1.-_DIHYDRONEOPTERIN-MONO-P-DEPHOS-RXN   : 1 7,8-dihydroneopterin_3'-
phosphate + 1 H2O --> 1 phosphate + 1 7,8-dihydro-D-neopterin   
~no-pathway_3.6.1.-_H2NEOPTERINP3PYROPHOSPHOHYDRO-RXN   : 1 7,8-
dihydroneopterin_triphosphate + 1 H2O --> 1 diphosphate + 1 7,8-dihydroneopterin_3'-phosphate + 
1 H+   
~no-pathway_4.1.2.25_H2NEOPTERINALDOL-RXN    : 1 7,8-dihydro-D-neopterin --> 1 6-
hydroxymethyl-7,8-dihydropterin + 1 glycolaldehyde   
~no-pathway_2.7.6.3_H2PTERIDINEPYROPHOSPHOKIN-RXN    : 1 ATP + 1 6-hydroxymethyl-7,8-
dihydropterin --> 1 H+ + 1 6-hydroxymethyl-dihydropterin_diphosphate + 1 AMP   
~multiple-pathways_6.3.4.3_FORMATETHFLIG-RXN   : 1 tetrahydrofolate + 1 formate + 1 ATP --> 1 
10-formyl-tetrahydrofolate + 1 ADP + 1 phosphate   
~multiple-pathways_1.5.1.5_METHYLENETHFDEHYDROG-NADP-RXN     : 1 5,10-
methylenetetrahydrofolate + 1 NADP+ <=> 1 NADPH + 1 5,10-methenyltetrahydrofolate  
formylTHF-biosynthesis_folate-transformations_1.5.1.20_1.5.1.20-RXN  : 1 5-methyl-tetrahydrofolate 
+ 1 NAD+ <=> 1 NADH + 1 5,10-methylenetetrahydrofolate + 1 H+  
D-arabinose-degradation_ethylene-glycol-degradation_1.2.1.21_GLYCOLALD-DEHYDROG-RXN : 1 
H2O + 1 glycolaldehyde + 1 NAD+ --> 1 glycolate + 2 H+ + 1 NADH  
~metabolism-of-degradation_1.1.1.26_BR29285   : 1 glycolate + 1 NAD+ <=> 1 H+ + 1 NADH + 1 
glyoxylate  
 
# flavin biosynthesis 
flavin-biosynthesis_3.5.4.25_GTP-CYCLOHYDRO-II-RXN    : 3 H2O + 1 GTP --> 1 2,5-diamino-6-(5-
phospho-D-ribosylamino)pyrimidin-4(3H)-one + 2 H+ + 1 formate + 1 diphosphate 
flavin-biosynthesis_4.1.99.12_DIOHBUTANONEPSYN-RXN  : 1 D-ribulose-5-phosphate --> 1 1-deoxy-
L-glycero-tetrulose_4-phosphate + 1 H+ + 1 formate  
flavin-biosynthesis_3.5.4.26_RIBOFLAVINSYNDEAM-RXN  : 1 2,5-diamino-6-(5-phospho-D-
ribosylamino)pyrimidin-4(3H)-one + 1 H2O --> 1 ammonia + 1 5-amino-6-(5-phospho-D-
ribosylamino)uracil   
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flavin-biosynthesis_1.1.1.193_RIBOFLAVINSYNREDUC-RXN: 1 5-amino-6-(5-phospho-D-
ribitylamino)uracil + 1 NADP+ <-- 1 NADPH + 1 H+ + 1 5-amino-6-(5-phospho-D-ribosylamino)uracil  
flavin_biosynthesis-RIBOPHOSPHAT-RXN  : 1 5-amino-6-(5-phospho-D-ribitylamino)uracil + 1 H2O --
> 1 5-amino-6-(D-ribitylamino)uracil + 1 phosphate  
flavin-biosynthesis_2.5.1.78_LUMAZINESYN-RXN  : 1 5-amino-6-(D-ribitylamino)uracil + 1 1-deoxy-
L-glycero-tetrulose_4-phosphate --> 1 H+ + 1 6,7-dimethyl-8-(1-D-ribityl)lumazine + 1 phosphate + 2 
H2O   
flavin-biosynthesis_2.5.1.9_RIBOFLAVIN-SYN-RXN  : 2 6,7-dimethyl-8-(1-D-ribityl)lumazine + 1 H+ --
> 1 riboflavin + 1 5-amino-6-(D-ribitylamino)uracil   
flavin-biosynthesis_5,6-dimethylbenzimidazole-biosynthesis_2.7.1.26_RIBOFLAVINKIN-RXN : 1 
riboflavin + 1 ATP --> 1 H+ + 1 FMN + 1 ADP   
flavin-biosynthesis_2.7.7.2_FADSYN-RXN   : 1 ATP + 2 H+ + 1 FMN --> 1 FAD + 1 diphosphate  
 
# NAD biosynthesis 
NAD-biosynthesis-I-(from-aspartate)_1.4.3.16_L-ASPARTATE-OXID-RXN    : 1 L-aspartate + 1 oxygen -
-> 1 H+ + 1 hydrogen_peroxide + 1 alpha-iminosuccinate 
NAD-biosynthesis-I-(from-aspartate)_2.5.1.72_QUINOLINATE-SYNTHA-RXN  : 1 
dihydroxyacetone_phosphate + 1 alpha-iminosuccinate --> 2 H2O + 1 phosphate + 1 quinolinate  
NAD-biosynthesis-from-2-amino-3-carboxymuconate-semialdehyde_NAD-
biosynthesis_2.4.2.19_QUINOPRIBOTRANS-RXN : 2 H+ + 1 5-phospho-alpha-D-ribose_1-diphosphate 
+ 1 quinolinate --> 1 diphosphate + 1 CO2 + 1 nicotinate_D-ribonucleotide 
~multiple-pathways_2.7.7.18_NICONUCADENYLYLTRAN-RXN    : 1 ATP + 1 nicotinate_D-
ribonucleotide + 1 H+ --> 1 nicotinate_adenine_dinucleotide + 1 diphosphate   
~multiple-pathways_6.3.5.1_NAD-SYNTH-GLN-RXN      : 1 H2O + 1 nicotinate_adenine_dinucleotide + 
1 ATP + 1 L-glutamine --> 1 L-glutamate + 1 NAD+ + 1 AMP + 1 H+ + 1 diphosphate   
~metabolism-of-phosphorylation-dephosphorylation_2.7.1.23_NAD-KIN-RXN  : 1 ATP + 1 NAD+ --> 1 
H+ + 1 ADP + 1 NADP+ 
NAD_NADP-1.6.1.2-RXN      : 1 NAD+ + 1 NADPH + 1 H+ <-- 1 NADH + 1 NADP+ + 1 H+_ex  
 
 
# ubiquinol-10 biosynthesis 
~metabolism-of-biosynthesis_2.5.1.1_GPPSYN-RXN   : 1 dimethylallyl_diphosphate + 1 
isopentenyl_diphosphate <=> 1 diphosphate + 1 geranyl_diphosphate 
~metabolism-of-biosynthesis_2.5.1.10_FPPSYN-RXN  : 1 isopentenyl_diphosphate + 1 
geranyl_diphosphate <=> 1 diphosphate + 1 (2E,6E)-farnesyl_diphosphate  
all-trans-decaprenyl-diphosphate-biosynthesis_2.5.1.91_RXN-9106   : 7 isopentenyl_diphosphate + 1 
(2E,6E)-farnesyl_diphosphate <=> 1 all-trans-decaprenyl_diphosphate + 7 diphosphate 
ubiquinol-8-biosynthesis_4-hydroxybenzoate-biosynthesis_4.1.3.40_CHORPYRLY-RXN : 1 chorismate 
--> 1 pyruvate + 1 4-hydroxybenzoate  
ubiquinol-10-biosynthesis_2.5.1.39_RXN-9230    : 1 4-hydroxybenzoate + 1 all-trans-
decaprenyl_diphosphate --> 1 diphosphate + 1 3-decaprenyl-4-hydroxybenzoate 
ubiquinol-10-biosynthesis-(prokaryotic)_4.1.1.-_RXN-9231  : 1 3-decaprenyl-4-hydroxybenzoate + 1 
H+ --> 1 2-decaprenylphenol + 1 CO2  
ubiquinol-10-biosynthesis-(prokaryotic)_1.14.13.-_RXN-9232   : 1 oxygen + 1 NADPH + 1 H+ + 1 2-
decaprenylphenol --> 1 NADP+ + 1 3-(all-trans-decaprenyl)benzene-1,2-diol + 1 H2O   
ubiquinol-10-biosynthesis-(prokaryotic)_2.1.1.222_RXN-9233    : 1 S-adenosyl-L-methionine + 1 3-
(all-trans-decaprenyl)benzene-1,2-diol --> 1 2-methoxy-6-(all-trans-decaprenyl)phenol + 1 H+ + 1 S-
adenosyl-L-homocysteine   
ubiquinol-10-biosynthesis_1.14.13.-_RXN-9234      : 1 NADPH + 1 2-methoxy-6-(all-trans-
decaprenyl)phenol + 1 H+ + 1 oxygen --> 1 H2O + 1 NADP+ + 1 2-methoxy-6-all_trans-decaprenyl-2-
methoxy-1,4-benzoquinol   
ubiquinol-10-biosynthesis_2.1.1.201_RXN-9235     : 1 2-methoxy-6-all_trans-decaprenyl-2-methoxy-
1,4-benzoquinol + 1 S-adenosyl-L-methionine --> 1 H+ + 1 6-methoxy-3-methyl-2-all-trans-
decaprenyl-1,4-benzoquinol + 1 S-adenosyl-L-homocysteine  
ubiquinol-10-biosynthesis_1.14.-.-_RXN-9236    : 1 oxygen + 1 NADPH + H+ + 1 6-methoxy-3-methyl-
2-all-trans-decaprenyl-1,4-benzoquinol --> 1 3-demethylubiquinol-10 + 1 H2O + 1 NADP+  
ubiquinol-10-biosynthesis_2.1.1.64_RXN-9237   : 1 S-adenosyl-L-methionine + 1 3-
demethylubiquinol-10 --> 1 ubiquinol-10 + 1 H+ + 1 S-adenosyl-L-homocysteine 
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# pantothenate biosynthesis 
phosphopantothenate-biosynthesis_2.1.2.11_3-CH3-2-OXOBUTANOATE-OH-CH3-XFER-RXN : 1 2-
oxoisovalerate + 1 5,10-methylenetetrahydrofolate + 1 H2O <=> 1 2-dehydropantoate + 1 
tetrahydrofolate  
phosphopantothenate-biosynthesis_1.1.1.169_2-DEHYDROPANTOATE-REDUCT-RXN   : 1 (R)-
pantoate + 1 NADP+ <-- 1 H+ + 1 NADPH + 1 2-dehydropantoate   
phosphopantothenate-biosynthesis-I_6.3.2.1_PANTOATE-BETA-ALANINE-LIG-RXN   : 1 ATP + 1 (R)-
pantoate + 1 beta-alanine --> 1 (R)-pantothenate + 1 diphosphate + 1 AMP + 1 H+  
 
# coenzyme A biosynthesis 
phosphopantothenate-biosynthesis_2.7.1.33_PANTOTHENATE-KIN-RXN  : 1 (R)-pantothenate + 1 
ATP --> 1 ADP + 1 H+ + 1 D-4'-phosphopantothenate 
coenzyme-A-biosynthesis_6.3.2.5_P-PANTOCYSLIG-RXN    : 1 L-cysteine + 1 D-4'-
phosphopantothenate + 1 CTP --> 1 diphosphate + 1 H+ + 1 R-4'-phosphopantothenoyl-L-cysteine + 1 
CMP  
coenzyme-A-biosynthesis_4.1.1.36_P-PANTOCYSDECARB-RXN   : 1 H+ + 1 R-4'-
phosphopantothenoyl-L-cysteine --> 1 4'-phosphopantetheine + 1 CO2  
coenzyme-A-biosynthesis_2.7.7.3_PANTEPADENYLYLTRAN-RXN   : 1 ATP + 1 H+ + 1 4'-
phosphopantetheine --> 1 3'-dephospho-CoA + 1 diphosphate 
coenzyme-A-biosynthesis_2.7.1.24_DEPHOSPHOCOAKIN-RXN  : 1 3'-dephospho-CoA + 1 ATP --> 1 H+ 
+ 1 coenzyme_A + 1 ADP 
 
################################################################# 
 
# N-acetyl-glucosamine 
CMP-legionaminate-biosynthesis_UDP-N-acetyl-D-glucosamine-biosynthesis_2.6.1.16_L-GLN-FRUCT-
6-P-AMINOTRANS-RXN : 1 D-fructose-6-phosphate + 1 L-glutamine <=> 1 L-glutamate + 1 alpha-D-
glucosamine_6-phosphate  
CMP-legionaminate-biosynthesis_UDP-N-acetyl-D-glucosamine-biosynthesis_5.4.2.10_5.4.2.10-RXN                   
: 1 D-glucosamine_1-phosphate <=> 1 alpha-D-glucosamine_6-phosphate 
UDP-N-acetyl-D-glucosamine-biosynthesis-I_2.3.1.157_2.3.1.157-RXN    : 1 acetyl-CoA + 1 D-
glucosamine_1-phosphate --> 1 H+ + 1 N-acetyl-alpha-D-glucosamine_1-phosphate + 1 coenzyme_A 
~metabolism-of-biosynthesis_2.7.7.23_NAG1P-URIDYLTRANS-RXN    : 1 N-acetyl-alpha-D-
glucosamine_1-phosphate + 1 UTP + 1 H+ --> 1 UDP-N-acetyl-alpha-D-glucosamine + 1 diphosphate  
 
# peptidoglycan biosynthesis 
UDP-N-acetylmuramoyl-pentapeptide-
biosynthesis_2.5.1.7_UDPNACETYLGLUCOSAMENOLPYRTRANS-RXN   : 1 phosphoenolpyruvate + 1 
UDP-N-acetyl-alpha-D-glucosamine --> 1 UDP-N-acetyl-alpha-D-glucosamine-enolpyruvate + 1 
phosphate  
UDP-N-acetylmuramoyl-pentapeptide-biosynthesis_1.3.1.98_UDPNACETYLMURAMATEDEHYDROG-
RXN   : 1 NADP+ + 1 UDP-N-alpha-D-acetylmuramate <-- 1 H+ + 1 NADPH + 1 UDP-N-acetyl-alpha-D-
glucosamine-enolpyruvate 
UDP-N-acetylmuramoyl-pentapeptide-biosynthesis_6.3.2.8_UDP-NACMUR-ALA-LIG-RXN  : 1 UDP-N-
alpha-D-acetylmuramate + 1 L-alanine + 1 ATP --> 1 H+ + 1 phosphate + 1 ADP + 1 UDP-N-
acetylmuramoyl-L-alanine 
UDP-N-acetylmuramoyl-pentapeptide-biosynthesis_5.1.1.3_GLUTRACE-RXN   : 1 L-glutamate <=> 1 
D-glutamate 
UDP-N-acetylmuramoyl-pentapeptide-biosynthesis_6.3.2.9_UDP-NACMURALA-GLU-LIG-RXN: 1 UDP-
N-acetylmuramoyl-L-alanine + 1 ATP + 1 D-glutamate --> 1 H+ + 1 phosphate + 1 ADP + 1 UDP-N-
acetylmuramoyl-L-alanyl--D-glutamate 
UDP-N-acetylmuramoyl-pentapeptide-biosynthesis-III-(meso-DAP-containing)_6.3.2.13_UDP-
NACMURALGLDAPLIG-RXN   : 1 ATP + 1 meso-diaminopimelate + 1 UDP-N-acetylmuramoyl-L-alanyl-
-D-glutamate --> 1 phosphate + 1 ADP + 1 UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-
meso-2,6-diaminopimelate + 1 H+ 
alanine-degradation_alanine-biosynthesis_5.1.1.1_ALARACECAT-RXN   : 1 L-alanine <=> 1 D-alanine 
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UDP-N-acetylmuramoyl-pentapeptide-biosynthesis_6.3.2.4_DALADALALIG-RXN   : 1 ATP + 2 D-
alanine --> 1 phosphate + 1 H+ + 1 ADP + 1 D-alanyl-D-alanine   
UDP-N-acetylmuramoyl-pentapeptide-biosynthesis-III-(meso-DAP-containing)_6.3.2.10_UDP-
NACMURALGLDAPAALIG-RXN : 1 ATP + 1 UDP-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-
meso-2,6-diaminopimelate + 1 D-alanyl-D-alanine --> 1 ADP + 1 UDP-N-acetylmuramoyl-L-alanyl-
gamma-D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine + 1 H+ + 1 phosphate 
di-trans,poly-cis-undecaprenyl-phosphate-biosynthesis_2.5.1.31_RXN-8999                                      : 8 
isopentenyl_diphosphate + 1 (2E,6E)-farnesyl_diphosphate <=> 8 diphosphate + 1 di-trans,octa-cis-
undecaprenyl_diphosphate 
~no-pathway_3.6.1.27_UNDECAPRENYL-DIPHOSPHATASE-RXN  : 1 H2O + 1 di-trans,octa-cis-
undecaprenyl_diphosphate --> 1 H+ + 1 phosphate + 1 di-trans,octa-cis-undecaprenyl_phosphate 
peptidoglycan-biosynthesis-I-(meso-diaminopimelate-
containing)_2.7.8.13_PHOSNACMURPENTATRANS-RXN   : 1 UDP-N-acetylmuramoyl-L-alanyl-gamma-
D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine + 1 di-trans,octa-cis-
undecaprenyl_phosphate --> 1 UMP + 1 undecaprenyldiphospho-N-acetylmuramoyl-L-alanyl-gamma-
D-glutamyl-meso-2,6-diaminopimelyl-D-alanyl-D-alanine 
peptidoglycan-biosynthesis-I-(meso-diaminopimelate-containing)_2.4.1.227_NACGLCTRANS-RXN                     
: 1 undecaprenyldiphospho-N-acetylmuramoyl-L-alanyl-gamma-D-glutamyl-meso-2,6-
diaminopimelyl-D-alanyl-D-alanine + 1 UDP-N-acetyl-alpha-D-glucosamine <=> 1 UDP + 1 H+ + 1 
undecaprenyldiphospho-N-acetyl-(N-acetylglucosaminyl)muramoyl-L-alanyl-gamma-D-glutamyl-
meso-2,6-diaminopimelyl-D-alanyl-D-alanine  
peptidoglycan-biosynthesis-I-(meso-diaminopimelate-containing)_2.4.1.129_RXN0-5405                           
: 2 undecaprenyldiphospho-N-acetyl-(N-acetylglucosaminyl)muramoyl-L-alanyl-gamma-D-glutamyl-
meso-2,6-diaminopimelyl-D-alanyl-D-alanine --> 1 a_peptidoglycan_dimer_(meso-
diaminopimelate_containing) + 1 di-trans,octa-cis-undecaprenyl_diphosphate + 1 H+ 
peptidoglycan-biosynthesis-I-(meso-diaminopimelate-containing)_3.4.16.4_RXN-11302                            
: 2 a_peptidoglycan_dimer_(meso-diaminopimelate_containing) --> 1 
a_peptidoglycan_with_D,D_cross-links_(meso-diaminopimelate_containing) + 1 D-alanine 
 
# KDO-lipidA 
CMP-KDO-biosynthesis-I_5.3.1.13_DARAB5PISOM-RXN : 1 D-arabinose_5-phosphate <=> 1 D-
ribulose-5-phosphate 
CMP-KDO-biosynthesis_2.5.1.55_KDO-8PSYNTH-RXN   : 1 phosphoenolpyruvate + 1 D-arabinose_5-
phosphate + 1 H2O --> 1 phosphate + 1 3-deoxy-D-manno-octulosonate_8-phosphate  
CMP-KDO-biosynthesis_3.1.3.45_KDO-8PPHOSPHAT-RXN   : 1 3-deoxy-D-manno-octulosonate_8-
phosphate + 1 H2O --> 1 3-deoxy-D-manno-octulosonate + 1 phosphate 
CMP-KDO-biosynthesis_2.7.7.38_CPM-KDOSYNTH-RXN   : 1 3-deoxy-D-manno-octulosonate + 1 CTP -
-> 1 diphosphate + 1 CMP-3-deoxy-D-manno-octulosonate 
lipid-IVA-biosynthesis_2.3.1.129_UDPNACETYLGLUCOSAMACYLTRANS-RXN                                      : 1 
(R)-3-hydroxy-tetradecanoyl-[ACP] + 1 UDP-N-acetyl-alpha-D-glucosamine --> 1 UDP-3-O-[(3R)-3-
hydroxymyristoyl]-N-acetyl-alpha-D-glucosamine + ACP   
lipid-IVA-biosynthesis_3.5.1.108_UDPACYLGLCNACDEACETYL-RXN    : 1 UDP-3-O-[(3R)-3-
hydroxymyristoyl]-N-acetyl-alpha-D-glucosamine + 1 H2O --> 1 UDP-3-O-(3-hydroxymyristoyl)-
alpha-D-glucosamine + 1 acetate  
lipid-IVA-biosynthesis_2.3.1.191_UDPHYDROXYMYRGLUCOSAMNACETYLTRANS-RXN                                
: 1 UDP-3-O-(3-hydroxymyristoyl)-alpha-D-glucosamine + 1 (R)-3-hydroxy-tetradecanoyl-[ACP] --> 1 
ACP + 1 H+ + 1 UDP-2,3-bis[O-(3R)-3-hydroxymyristoyl]-alpha-D-glucosamine   
lipid-IVA-biosynthesis_3.6.1.54_LIPIDXSYNTHESIS-RXN   : 1 H2O + 1 UDP-2,3-bis[O-(3R)-3-
hydroxymyristoyl]-alpha-D-glucosamine --> 2 H+ + 1 UMP + 1 2,3-bis[(3R)-3-hydroxymyristoyl]-
alpha-D-glucosaminyl_1-phosphate 
lipid-IVA-biosynthesis_2.4.1.182_LIPIDADISACCHARIDESYNTH-RXN   : 1 2,3-bis[(3R)-3-
hydroxymyristoyl]-alpha-D-glucosaminyl_1-phosphate + 1 UDP-2,3-bis[O-(3R)-3-hydroxymyristoyl]-
alpha-D-glucosamine --> 1 UDP + 1 lipid_A_disaccharide + 1 H+  
lipid-IVA-biosynthesis_2.7.1.130_TETRAACYLDISACC4KIN-RXN    : 1 lipid_A_disaccharide + 1 ATP --> 
1 lipid_IVA + 1 H+ + 1 ADP  
KDO-transfer-to-lipid-IVA-I_2.4.99.12_2.4.99.13_KDOTRANS-RXN   : 1 CMP-3-deoxy-D-manno-
octulosonate + 1 lipid_IVA --> 1 H+ + 1 alpha-Kdo-(2rarr6)-lipid_IVA + 1 CMP 
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KDO-transfer-to-lipid-IVA-I_2.4.99.13_KDOTRANS2-RXN  : 1 CMP-3-deoxy-D-manno-octulosonate + 1 
alpha-Kdo-(2rarr6)-lipid_IVA --> 1 alpha-Kdo-(2->4)-alpha-Kdo-(2->6)-lipid_IVA + 1 H+ + 1 CMP 
superpathway-of-(KDO)2-lipid-A-biosynthesis_(KDO)2-lipid-A-biosynthesis_2.3.1.-
_LAUROYLACYLTRAN-RXN   : 1 alpha-Kdo-(2->4)-alpha-Kdo-(2->6)-lipid_IVA + 1 Dodecanoyl-[ACP] -
-> 1 ACP + 1 (KDO)2-(lauroyl)-lipid_IVA 
superpathway-of-(KDO)2-lipid-A-biosynthesis_(KDO)2-lipid-A-biosynthesis_2.3.1.-
_MYRISTOYLACYLTRAN-RXN : 1 (KDO)2-(lauroyl)-lipid_IVA + 1 Tetradecanoyl-[ACP] --> 1 (KDO)2-
lipid_A + 1 ACP 
~multiple-pathways_5.4.2.2_PHOSPHOGLUCMUT-RXN   : 1 alpha-D-glucose_1-phosphate <=> 1 
alpha-D-glucose_6-phosphate 
~multiple-pathways_2.7.7.9_GLUC1PURIDYLTRANS-RXN  : 1 H+ + 1 alpha-D-glucose_1-phosphate + 1 
UTP <=> 1 UDP-alpha-D-glucose + 1 diphosphate 
 
################################################################# 
 
# SECONDARY METABOLITES 
 
# TDA biosynthesis (based on Brock et al 2014) 
TDA_biosynthesis-RXN : 3-oxo-5,6-dehydrosuberyl-CoA_semialdehyde + 2 L-cysteine + 2 H2O + 4 
NAD+ --> 1 TDA + 2 L-serine + 1 coenzyme_A + 4 NADH + 4 H+  
 
################################################################# 
 
# detoxification 
methanol-oxidation-to-formaldehyde_superoxide-radicals-degradation_1.11.1.21_CATAL-RXN : 2 
hydrogen_peroxide --> 1 oxygen + 2 H2O  
~no-pathway_1.14.12.17_R621-RXN_NAD   : 1 NADH + 2 nitric_oxide + 2 oxygen --> 1 NAD+ + 2 
nitrate + 1 H+  
~no-pathway_1.14.12.17_R621-RXN_NADP: 2 nitric_oxide + 2 oxygen + 1 NADPH --> 2 nitrate + 1 
NADP+ + 1 H+  
~multiple-pathways_1.7.2.1_NITRITE-REDUCTASE-CYTOCHROME-RXN   : 1 nitric_oxide + 1 H2O + 1 
|Cytochromes-C-Oxidized| <=> 1 |Cytochromes-C-Reduced| + 1 nitrite + 2 H+  
nitrate-reduction_nitrifier-denitrification_1.7.2.5_NITRIC-OXIDE-REDUCTASE-RXN  : 1 nitrous_oxide 
+ 2 |Cytochromes-C-Oxidized| + 1 H2O <=> 2 |Cytochromes-C-Reduced| + 2 H+ + 2 nitric_oxide  
 
################################################################# 
 
# sulfate assimilation 
sulfate-reduction-I-(assimilatory)_1.8.1.2_SULFITE-REDUCT-RXN: 3 NADP+ + 3 H2O + 1 
hydrogen_sulfide <=> 5 H+ + 3 NADPH + 1 sulfite  
thiosulfate-disproportionation-III-(rhodanese)_2.8.1.1_THIOSULFATE-SULFURTRANSFERASE-RXN : 
1 hydrogen_cyanide + 1 thiosulfate <=> 1 sulfite + 2 H+ + 1 thiocyanate (E.coli) 
~multiple-pathways_2.7.7.4_SULFATE-ADENYLYLTRANS-RXN  : 1 ATP + 1 sulfate + 1 H+ <=> 1 
diphosphate + 1 adenosine_5'-phosphosulfate   
sulfate-activation-for-sulfonation_2.7.1.25_ADENYLYLSULFKIN-RXN   : 1 adenosine_5'-
phosphosulfate + 1 ATP --> 1 phosphoadenosine-5'-phosphosulfate + 1 H+ + 1 ADP   
sulfate-reduction-I-(assimilatory)_1.8.4.8_1.8.4.8-RXN  : 1 |Ox-Thioredoxin| + 2 H+ + 1 
adenosine_3',5'-bisphosphate + 1 sulfite <=> 1 |Red-Thioredoxin| + 1 phosphoadenosine-5'-
phosphosulfate   
~no-pathway_3.1.3.7_325-BISPHOSPHATE-NUCLEOTIDASE-RXN   : 1 adenosine_3',5'-bisphosphate + 
1 H2O --> 1 phosphate + 1 AMP  
 
################################################################# 
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# DEGRADATION PATHWAYS 
 
# amino acid degradation 
 
# tryptophan degradation 
~metabolism-of-tryptophan-degradation_1.13.11.11_RXN-8665  : 1 oxygen + 2 H+ + 1 L-tryptophan -
-> 1 N-formylkynurenine 
~metabolism-of-tryptophan-degradation_3.5.1.9_ARYLFORMAMIDASE-RXN  : 1 N-formylkynurenine 
+ 1 H2O --> 1 formate + 3 H+ + 1 L-kynurenine 
tryptophan-degradation_3.7.1.3_KYNURENINASE-RXN : 1 L-kynurenine + 1 H2O --> 1 L-alanine + 1 
H+ + 1 anthranilate 
alanine-degradation-IV_1.4.1.1_ALANINE-DEHYDROGENASE-RXN  : 1 H2O + 1 L-alanine + 1 NAD+ 
<=> 1 H+ + 1 NADH + 1 ammonium + 1 pyruvate 
~multiple-pathways_6.2.1.32_AMINOBENZCOALIG-RXN  : 1 ATP + 1 anthranilate + 1 coenzyme_A --> 
1 diphosphate + 1 2-aminobenzoyl-CoA + 1 AMP 
anthranilate-degradation-II-(aerobic)_1.14.13.40_ANTHRANILOYL-COA-MONOOXYGENASE-
RXN_NAD  : 2 NADH + 2 H+ + 1 oxygen + 1 2-aminobenzoyl-CoA --> 1 2-amino-5-oxocyclohex-1-
enecarboxyl-CoA + 1 H2O + 2 NAD+   
anthranilate-degradation-II-(aerobic)_1.14.13.40_ANTHRANILOYL-COA-MONOOXYGENASE-
RXN_NADP : 2 H+ + 2 NADPH + 1 oxygen + 1 2-aminobenzoyl-CoA --> 1 2-amino-5-oxocyclohex-1-
enecarboxyl-CoA + 2 NADP+ + 1 H2O   
#tryptophan-degradation1_RXN : 1 2-amino-5-oxocyclohex-1-enecarboxyl-CoA + 1 NADPH + 3 H+ + 2 
oxygen --> 1 3-oxoadipate + 1 NADPH + 1 ammonia + 1 coenzyme_A + CO2 
#tryptophan-degradation2_RXN  : 1 2-amino-5-oxocyclohex-1-enecarboxyl-CoA + 1 NADP+ + 1 
aspartate + 1 H+ + 2 oxygen --> 1 3-oxoadipate + 1 NADPH + 1 asparagine + 1 coenzyme_A + CO2 
#tryptophan-degra_2.8.3.5_RXN  : 1 3-oxoadipate + 1 succinyl-CoA <=> 1 3-oxoadipyl-CoA + 1 
succinate 
tryptophan-degra-grob-RXN : 1 2-amino-5-oxocyclohex-1-enecarboxyl-CoA + 1 coenzyme_A  + 2 
oxygen + 2 H+ + 1 NADPH --> 1 succinyl-CoA + 1 acetyl-CoA + 1 CO2 + 1 ammonium + 1 NADP+ 
 
# phenylalanine degradation 
phenylalanine-degradation_2.6.1.57_PHEAMINOTRANS-RXN  : 1 L-glutamate + 1 keto-
phenylpyruvate <=> 1 L-phenylalanine + 1 2-oxoglutarate 
phenylalanine_degra_1.2.7.8_-RXN   : 1 |Oxidized-ferredoxins| + 1 keto-phenylpyruvate + 1 
coenzyme_A --> 1 phenylacetyl-CoA + 1 CO2 + 1 |Reduced-ferredoxins|   
phenylacetate-degradation-I-(aerobic)_1.14.13.149_RXN0-2042    : 1 phenylacetyl-CoA + 1 H+ + 1 
oxygen + 1 NADPH --> 1 H2O + 1 2-(1,2-epoxy-1,2-dihydrophenyl)acetyl-CoA + 1 NADP+  
phenylacetate-degradation-I-(aerobic)_5.3.3.18_RXN0-6510  : 1 2-(1,2-epoxy-1,2-
dihydrophenyl)acetyl-CoA <=> 1 2-oxepin-2(3H)-ylideneacetyl-CoA 
phenylacetate-degradation-I-(aerobic)_3.3.2.12_RXNMETA-12671  : 1 2-oxepin-2(3H)-ylideneacetyl-
CoA + 1 H2O --> 1 3-oxo-5,6-dehydrosuberyl-CoA_semialdehyde  
phenylacetate-degradation-I-(aerobic)_1.17.1.7_RXNMETA-12672   : 1 H2O + 1 3-oxo-5,6-
dehydrosuberyl-CoA_semialdehyde + 1 NADP+ --> 1 NADPH + 2 H+ + 1 3-oxo-5,6-didehydrosuberyl-
CoA 
phenylacetate-degradation-I-(aerobic)_2.3.1.223_RXN0-6512   : 1 acetyl-CoA + 1 2,3-
didehydroadipyl-CoA <-- 1 coenzyme_A + 1 3-oxo-5,6-didehydrosuberyl-CoA  
phenylacetate-degradation-I-(aerobic)_4.2.1.17_RXN0-6513  : 1 3-hydroxyadipyl-CoA <=> 1 2,3-
didehydroadipyl-CoA + 1 H2O 
benzoyl-CoA-degradation_phenylacetate-degradation_1.1.1.35_RXN0-2044   : 1 3-hydroxyadipyl-CoA 
+ 1 NAD+ <=> 1 H+ + 1 NADH + 1 3-oxoadipyl-CoA   
~metabolism-of-degradation_2.3.1.174_RXN-3641   : 1 acetyl-CoA + 1 succinyl-CoA <-- 1 coenzyme_A 
+ 1 3-oxoadipyl-CoA  
ubiquinol-6-biosynthesis-from-4-aminobenzoate_1.18.1.2_1.18.1.2-RXN   : 1 NADP+ + 2 |Reduced-
ferredoxins| + 1 H+ --> 1 NADPH + 2 |Oxidized-ferredoxins|  
phenylalanine-degra_1.13.11.27_4-HYDROXYPHENYLPYRUVATE-DIOXYGENASE-RXN : 1 keto-
phenylpyruvate + 1 oxygen --> 1 2-hydroxyphenylacetate + 1 CO2   
phenylalanine_degra_3.2.1.-_THIOESTERASE-RXN   : 1 phenylacetyl-CoA + 1 H2O --> 1 phenylacetate 
+ 1 coenzyme_A + 1 H+  
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phenylacetate-degradation_phenylalanine-degradation_6.2.1.30_RXN-10819 : 1 coenzyme_A + 1 
phenylacetate + 1 ATP --> 1 phenylacetyl-CoA + 1 diphosphate + 1 AMP  
phenylalanine_degra_3.2.1.-_THIOESTERASE2-RXN  : 1 2-(1,2-epoxy-1,2-dihydrophenyl)acetyl-CoA + 
1 H2O --> 1 2-(1,2-epoxy-1,2-dihydrophenyl)acetate + 1 coenzyme_A + 1 H+  
phenylalanine_degra_spontaneous-RXN  : 1 2-(1,2-epoxy-1,2-dihydrophenyl)acetate --> 1 2-
hydroxyphenylacetate 
 
# methionine degradation 
methionine-degradation-II_4.4.1.11_METHIONINE-GAMMA-LYASE-RXN : 1 L-methionine + 1 H2O 
<=> 1 methanethiol + 1 ammonium + 1 2-oxobutanoate 
2-oxobutanoate-degradation_PDH-RXN   : 1 2-oxobutanoate + 1 NAD+ + 1 coenzyme_A --> 1 
propanoyl-CoA + 1 NADH + 1 CO2  
 
# leucine degradation 
~no-pathway_1.4.1.9_LEUCINE-DEHYDROGENASE-RXN   : 1 NAD+ + 1 H2O + 1 L-leucine <=> 1 NADH 
+ 1 ammonium + 1 H+ + 1 4-methyl-2-oxopentanoate  
leucine-degra_1.2.7.8-RXN    : 1 4-methyl-2-oxopentanoate + 1 coenzyme_A + 1 |Oxidized-
ferredoxins| --> 1 |Reduced-ferredoxins| + 1 isovaleryl-CoA + 1 CO2   
~no-pathway_1.3.8.4_RXN-14264   : 1 isovaleryl-CoA + 1 FAD + 1 H+ <=> 1 3-methylcrotonyl-CoA + 1 
FADH2  
leucine-degradation-I_6.4.1.4_METHYLCROTONYL-COA-CARBOXYLASE-RXN  : 1 3-methylcrotonyl-
CoA + 1 bicarbonate + 1 ATP --> 1 phosphate + 1 3-methylglutaconyl-CoA + 1 H+ + 1 ADP 
leucine-degradation-I_4.2.1.18_METHYLGLUTACONYL-COA-HYDRATASE-RXN : 1 (S)-3-hydroxy-3-
methylglutaryl-CoA <=> 1 3-methylglutaconyl-CoA + 1 H2O  
~multiple-pathways_4.1.3.4_HYDROXYMETHYLGLUTARYL-COA-LYASE-RXN    : 1 (S)-3-hydroxy-3-
methylglutaryl-CoA --> 1 acetoacetate + 1 acetyl-CoA 
TCA-cycle_2.8.3.5_RXNI-2  : 1 acetoacetate + 1 succinyl-CoA <=> 1 succinate + 1 acetoacetyl-CoA  
 
# isoleucine degradation 
~no-pathway_1.4.1.9_ILEDEAMINE-RXN  : 1 H2O + 1 NAD+ + 1 L-isoleucine --> 1 H+ + 1 (S)-3-
methyl-2-oxopentanoate + 1 ammonium + 1 NADH 
isoleucine-degradation_2.6.1.42_BRANCHED-CHAINAMINOTRANSFERILEU-RXN  : 1 2-oxoglutarate + 
1 L-isoleucine <=> 1 L-glutamate + 1 (S)-3-methyl-2-oxopentanoate 
isoleucine-degra_1.2.7.8-RXN  : 1 (S)-3-methyl-2-oxopentanoate + 1 coenzyme_A + 1 |Oxidized-
ferredoxins| --> 1 |Reduced-ferredoxins| + 1 2-methylbutanoyl-CoA + 1 CO2   
isoleucine-degra_1.3.8.4_RXN-14264   : 1 FAD + 1 H+ + 1 2-methylbutanoyl-CoA <=> 1 (E)-2-
methylcrotonoyl-CoA + 1 FADH2   
isoleucine-degradation_2-methylbutyrate-biosynthesis_4.2.1.17_TIGLYLCOA-HYDROXY-RXN  : 1 2-
methyl-3-hydroxybutyryl-CoA <=> 1 (E)-2-methylcrotonoyl-CoA + 1 H2O  
isoleucine-degradation_2-methylbutyrate-biosynthesis_1.1.1.178_1.1.1.178-RXN   : 1 2-methyl-3-
hydroxybutyryl-CoA + 1 NAD+ <=> 1 NADH + 1 H+ + 1 2-methylacetoacetyl-CoA  
isoleucine-degradation_2-methylbutyrate-biosynthesis_2.3.1.9_METHYLACETOACETYLCOATHIOL-
RXN : 1 2-methylacetoacetyl-CoA + 1 coenzyme_A <=> 1 propanoyl-CoA + 1 acetyl-CoA 
 
# valine degradation 
~no-pathway_1.4.1.9_RXN-13184  : 1 NAD+ + 1 L-valine + 1 H2O <=> 1 ammonium + 1 3-methyl-2-
oxobutanoate + 1 H+ + 1 NADH 
valine-degra_2.6.1.42_BRANCHED-CHAINAMINOTRANSFERVAL-RXN  : 1 2-oxoglutarate + 1 L-valine 
<=> 1 L-glutamate + 1 3-methyl-2-oxobutanoate 
valine-degra_1.2.7.8_1.2.7.8-RXN   : 1 coenzyme_A + 1 3-methyl-2-oxobutanoate + 1 |Oxidized-
ferredoxins| --> 1 isobutanoyl-CoA  + 1 CO2 + 1 |Reduced-ferredoxins|   
valine-degra_1.3.8.4_RXN-14264   : 1 isobutanoyl-CoA + 1 FAD + 1 H+ <=> 1 FADH2 + 1 
methylacrylyl-CoA   
valine-degradation-I_4.2.1.17_METHYLACYLYLCOA-HYDROXY-RXN  : 1 (S)-3-hydroxy-isobutanoyl-
CoA <=> 1 methylacrylyl-CoA + 1 H2O 
valine-degradation-I_3.1.2.4_3-HYDROXYISOBUTYRYL-COA-HYDROLASE-RXN   : 1 (S)-3-hydroxy-
isobutanoyl-CoA + 1 H2O --> 1 H+ + 1 (S)-3-hydroxy-isobutanoate + 1 coenzyme_A   
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valine-degradation-I_1.1.1.31_3-HYDROXYISOBUTYRATE-DEHYDROGENASE-RXN : 1 NAD+ + 1 (S)-3-
hydroxy-isobutanoate --> 1 H+ + 1 NADH + 1 (S)-methylmalonate-semialdehyde  
2,4-dinitrotoluene-degradation_1.2.1.27_1.2.1.27-RXN  : 1 (S)-methylmalonate-semialdehyde + 1 
coenzyme_A + 1 NAD+ + 1 H2O --> 1 bicarbonate + 1 NADH + 1 propanoyl-CoA + 1 H+  
 
# histidine degradation 
histidine-degradation_4.3.1.3_HISTIDINE-AMMONIA-LYASE-RXN : 1 L-histidine --> 1 urocanate + 1 
ammonium 
histidine-degradation_4.2.1.49_UROCANATE-HYDRATASE-RXN : 1 4-imidazolone-5-propionate <-- 1 
urocanate + 1 H2O  
histidine-degradation_3.5.2.7_IMIDAZOLONEPROPIONASE-RXN  : 1 4-imidazolone-5-propionate + 1 
H2O --> 1 N-formimino-L-glutamate  
histidine-degradation-II_3.5.3.13_FORMIMINOGLUTAMATE-DEIMINASE-RXN  : 1 N-formimino-L-
glutamate + 1 H2O --> 1 ammonium + 1 N-formyl-L-glutamate   
histidine-degradation-II_3.5.1.68_N-FORMYLGLUTAMATE-DEFORMYLASE-RXN : 1 N-formyl-L-
glutamate + 1 H2O --> 1 L-glutamate + 1 formate   
 
# lysine degradation 
~multiple-pathways_4.1.1.18_LYSDECARBOX-RXN  : 1 L-lysine + 1 H+ --> 1 CO2 + 1 cadaverine 
lysine-degradation-X_2.6.1.-_RXN-10853   : 1 cadaverine + 1 pyruvate --> 1 H+ + 1 L-alanine + 1 H2O 
+ 1 1-piperideine   
lysine-degra_2.6.1.-_RXN   : 1 cadaverine + 1 pyruvate --> 1 L-alanine + 1 5-aminopentanal  
lysine-degradation-X_1.5.1.-_RXN-10854   : 1 1-piperideine + 1 NAD+ + 2 H2O --> 1 NADH + 1 H+ + 1 
5-aminopentanoate 
lysine-degra_1.2.1.-_RXN  : 1 5-aminopentanal + 1 NAD+ + 1 H2O --> 1 5-aminopentanoate + 1 NADH 
+ 1 H+  
L-lysine-degradation_2.6.1.48_VAGL-RXN  : 1 5-aminopentanoate + 1 2-oxoglutarate <=> 1 L-
glutamate + 1 glutarate_semialdehyde  
lysine-degradation_1.2.1.-_RXN-8182  : 1 glutarate_semialdehyde + 1 H2O + 1 NADP+ --> 1 glutarate + 
1 NADPH + 2 H+ 
lysine-degradation_2.8.3.13_RXN-14724 : 1 succinyl-CoA + 1 glutarate --> 1 succinate + 1 glutaryl-
CoA 
lysine-degradation-VI_2.6.1.36_L-LYSINE-AMINOTRANSFERASE-RXN  : 1 pyruvate + 1 L-lysine --> 1 
(S)-2-amino-6-oxohexanoate + 1 L-alanine   
spontaneous_lysine-degradation_lysine-biosynthesis_1.4.1.18_RXN-8173   : 1 (S)-2-amino-6-
oxohexanoate <=> 1 H2O + 1 (S)-2,3,4,5-tetrahydropiperidine-2-carboxylate + 1 H+ 
lysine-degradation_1.2.1.-_RXN-8162 : 1 (S)-2,3,4,5-tetrahydropiperidine-2-carboxylate + 1 NAD+ + 2 
H2O --> 1 H+ + 1 L-2-aminoadipate + 1 NADH 
lysine-degradation_lysine-biosynthesis_2.6.1.39_2-AMINOADIPATE-AMINOTRANSFERASE-RXN : 1 
pyruvate + 1 L-2-aminoadipate <=> 1 L-alanine + 1 2-oxoadipate   
lysine-degra_1.2.4.4._RXN   : 1 2-oxoadipate + 1 NAD+ + 1 coenzyme_A --> 1 glutaryl-CoA + 1 NADH + 
1 H+ + 1 CO2  
~no-pathway_1.3.8.6_RXN-14211  : 2 H+ + 1 glutaryl-CoA + 1 FAD --> 1 crotonyl-CoA + 1 CO2 + 1 
FADH2  
~no-pathway_4.3.1.28_RXN-13654  : 1 L-lysine <=> 1 L-pipecolate + 1 ammonium  
lysine-degradation-V_1.5.3.7_L-PIPECOLATE-OXIDASE-RXN  : 1 L-pipecolate + 1 oxygen --> 1 
hydrogen_peroxide + 1 H+ + 1 (S)-2,3,4,5-tetrahydropiperidine-2-carboxylate  
 
# threonine degradation 
threonine-degradation_aminopropanol-phosphate-biosynthesis_1.1.1.103_THREODEHYD-RXN : 1 L-
threonine + 1 NAD+ --> 2 H+ + 1 NADH + 1 2-amino-3-oxobutanoate 
threonine-degradation-II_2.3.1.29_AKBLIG-RXN  : 1 acetyl-CoA + 1 glycine <=> 1 H+ + 1 coenzyme_A 
+ 1 2-amino-3-oxobutanoate 
~multiple-pathways_1.8.1.4_1.4.4.2_2.1.2.10_GCVMULTI-RXN  : 1 tetrahydrofolate + 1 NAD+ + 1 
glycine --> 1 ammonium + 1 NADH + 1 5,10-methylenetetrahydrofolate + 1 CO2  
~metabolism-of-degradation_4.3.1.17_4.3.1.17-RXN: 1 L-serine --> 1 ammonium + 1 pyruvate 
~no-pathway_4.1.2.5_LTAA-RXN : 1 L-threonine --> 1 glycine + 1 acetaldehyde  
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# arginine and proline degradation 
~multiple-pathways_3.5.3.1_ARGINASE-RXN  : 1 L-arginine + 1 H2O <=> 1 urea + 1 L-ornithine  
putrescine-biosynthesis_superpathway-of-ornithine-degradation_4.1.1.17_ORNDECARBOX-RXN  : 1 
L-ornithine + 1 H+ --> 1 putrescine + 1 CO2 
arginine-degradation_ornithine-degradation_4.3.1.12_ORNITHINE-CYCLODEAMINASE-RXN : 1 L-
ornithine --> 1 L-proline + 1 ammonium  
~multiple-pathways_1.5.99.8_RXN-821  : 1 L-proline + 1 ubiquinone-10 --> 1 (S)-1-pyrroline-5-
carboxylate + 1 H+ + 1 ubiquinol-10   
spontaneous_multiple-pathways_SPONTPRO-RXN : 1 (S)-1-pyrroline-5-carboxylate + 1 H+ + 1 H2O 
<=> 1 L-glutamate-5-semialdehyde   
~multiple-pathways_1.2.1.88_RXN-14116 : 1 L-glutamate-5-semialdehyde + 1 NAD+ + 1 H2O <=> 1 
NADH + 1 L-glutamate + 2 H+   
arginine-degradation-X-(arginine-monooxygenase-pathway)_1.13.12.1_ARGININE-2-
MONOOXYGENASE-RXN : 1 L-arginine + 1 oxygen --> 1 H2O + 1 4-guanidinobutyramide + 1 CO2 
arginine-degradation-X-(arginine-monooxygenase-pathway)_3.5.1.4_GUANIDINOBUTANAMIDE-
NH3-RXN    : 1 4-guanidinobutyramide + 1 H2O --> 1 ammonium + 1 4-guanidinobutyrate 
arginine-degradation_3.5.3.7_GUANIDINOBUTYRASE-RXN : 1 4-guanidinobutyrate + 1 H2O --> 1 4-
aminobutanoate + 1 urea  
 
# cysteine degradation 
hydrogen-sulfide-biosynthesis_L-cysteine-degradation_2.6.1.1_CYSTEINE-AMINOTRANSFERASE-
RXN: 1 2-oxoglutarate + 1 L-cysteine <=> 1 L-glutamate + 1 3-mercaptopyruvate 
TCA-cycle_2.8.1.2_BR48100: 1 3-mercaptopyruvate + 1 hydrogen_cyanide <=> 1 thiocyanate + 1 
pyruvate + 1 H+ 
L-cysteine-degradation-II_4.4.1.1_LCYSDESULF-RXN  : 1 H2O + 1 L-cysteine --> 1 hydrogen_sulfide + 
1 pyruvate + 1 ammonium  
 
# tyrosine degradation 
~multiple-pathways_1.13.11.27_4-HYDROXYPHENYLPYRUVATE-DIOXYGENASE-RXN : 1 oxygen + 1 
4-hydroxyphenylpyruvate --> 1 homogentisate + 1 CO2 
tyrosine-degradation-I_1.13.11.5_HOMOGENTISATE-12-DIOXYGENASE-RXN  : 1 homogentisate + 1 
oxygen --> 1 4-maleyl-acetoacetate + 1 H+  
tyrosine-degradation-I_5.2.1.2_MALEYLACETOACETATE-ISOMERASE-RXN: 1 4-maleyl-acetoacetate -
-> 1 4-fumaryl-acetoacetate  
tyrosine-degradation-I_3.7.1.2_FUMARYLACETOACETASE-RXN: 1 4-fumaryl-acetoacetate + 1 H2O --> 
1 fumarate + 1 H+ + 1 acetoacetate  
 
 
# carbohydrate degradation 
 
# N-acetyl-glucosamine degradation 
chitin-derivatives-degradation_N-acetylglucosamine-degradation_2.7.1.59_N-ACETYLGLUCOSAMINE-
KINASE-RXN : 1 ATP + 1 N-acetyl-beta-D-glucosamine --> 1 ADP + 1 N-acetyl-D-glucosamine_6-
phosphate + 1 H+ 
chitin-derivatives-degradation_N-acetylglucosamine-degradation_3.5.1.25_NAG6PDEACET-RXN: 1 N-
acetyl-D-glucosamine_6-phosphate + 1 H2O --> 1 alpha-D-glucosamine_6-phosphate + 1 acetate  
 
# xylose degradation 
xylose-degradation-I_5.3.1.5_XYLISOM-RXN : 1 D-xylose <=> 1 D-xylulose   
~metabolism-of-degradation_2.7.1.17_XYLULOKIN-RXN : 1 ATP + 1 D-xylulose --> 1 ADP + 1 H+ + 1 
D-xylulose-5-phosphate 
 
# sucrose degradation 
~no-pathway_3.2.1.20_RXN-2141 : 1 sucrose + 1 H2O --> 1 alpha-D-glucose + 1 beta-D-
fructofuranose  
~multiple-pathways_2.7.1.4_FRUCTOKINASE-RXN : 1 ATP + 1 beta-D-fructofuranose --> 1 ADP + 1 D-
fructose-6-phosphate + 1 H+  
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# mannitol degradation 
mannitol-degra_1.1.1.67_MANNDEHYDR-RXN : 1 mannitol + 1 NAD+ --> 1 beta-D-fructofuranose + 1 
NADH + 1 H+  
 
 
# 4-aminobutanoate degradation 
~multiple-pathways_2.6.1.19_GABATRANSAM-RXN : 1 2-oxoglutarate + 1 4-aminobutanoate <=> 1 
succinate_semialdehyde + 1 L-glutamate 
4-aminobutyrate-degradation-III_1.2.1.16_RXN0-5293_NAD  : 1 H2O + 1 succinate_semialdehyde + 1 
NAD+ --> 1 succinate + 1 NADH + 2 H+   
4-aminobutyrate-degradation-III_1.2.1.16_RXN0-5293_NADP : 1 succinate_semialdehyde + 1 H2O + 1 
NADP+ --> 1 NADPH + 1 succinate + 2 H+  
 
 
# allantoin degradation 
allantoin-degradation-to-ureidoglycolate_3.5.2.5_ALLANTOINASE-RXN  : 1 H2O + 1 (S)-(+)-allantoin -
-> 1 H+ + 1 allantoate  
allantoin-degradation-to-ureidoglycolate-II-(ammonia-producing)_3.5.3.9_ALLANTOATE-
DEIMINASE-RXN : 1 H2O + 2 H+ + 1 allantoate --> 1 ammonium + 1 S-ureidoglycine + 1 CO2  
allantoin-degradation-to-glyoxylate_allantoin-degradation-to-ureidoglycolate_3.5.3.26_URUR-RXN  : 
1 S-ureidoglycine + 1 H2O --> 1 S-ureidoglycolate + 1 ammonium  
~no-pathway_3.5.1.116_BR29521  : 1 S-ureidoglycolate + 1 H2O --> 1 glyoxylate + 1 CO2 + 2 
ammonia  
allantoin-degradation-to-glyoxylate_4.3.2.3_UREIDOGLYCOLATE-LYASE-RXN : 1 S-ureidoglycolate --> 
1 urea + 1 glyoxylate 
# myo-inositol degradation 
~multiple-pathways_1.1.1.18_MYO-INOSITOL-2-DEHYDROGENASE-RXN  : 1 myo-inositol + 1 NAD+ 
<=> 1 NADH + 1 scyllo-inosose + 1 H+ 
myo-inositol-degradation-I_4.2.1.44_MYO-INOSOSE-2-DEHYDRATASE-RXN : 1 scyllo-inosose --> 1 
3D-(3,5_4)-trihydroxycyclohexane-1,2-dione + 1 H2O 
myo-inositol-degradation-I_3.7.1.22_RXN-14149 : 1 H2O + 1 3D-(3,5_4)-trihydroxycyclohexane-1,2-
dione --> 1 H+ + 1 5-deoxy-D-glucuronate 
myo-inositol-degradation-I_5.3.1.30_RXN-14150  : 1 5-deoxy-D-glucuronate <=> 1 2-deoxy-5-
dehydro-D-gluconate 
myo-inositol-degradation-I_2.7.1.92_5-DEHYDRO-2-DEOXYGLUCONOKINASE-RXN : 1 ATP + 1 2-
deoxy-5-dehydro-D-gluconate --> 1 H+ + 1 5-dehydro-2-deoxy-D-gluconate_6-phosphate + 1 ADP 
myo-inositol-degradation-I_4.1.2.29_4.1.2.29-RXN: 1 5-dehydro-2-deoxy-D-gluconate_6-phosphate --
> 1 dihydroxyacetone_phosphate + 1 malonate_semialdehyde 
myo-inositol-degradation_beta-alanine-degradation_1.2.1.18_RXN-2902  : 1 coenzyme_A + 1 NAD+ + 
1 malonate_semialdehyde --> 1 CO2 + 1 NADH + 1 acetyl-CoA  
~no-pathway_1.2.1.18_1.2.1.18-RXN  : 1 coenzyme_A + 1 malonate_semialdehyde + 1 NADP+ --> 1 
NADPH + 1 CO2 + 1 acetyl-CoA  
 
 
# butanoate degradation 
methyl-ketone-biosynthesis_6.2.1.2_BS143 : 1 n-butanoate + 1 coenzyme_A + 1 ATP --> 1 AMP + 1 
diphosphate + 1 butanoyl-CoA  
~no-pathway_1.3.8.1_RXN-14193 : 1 butanoyl-CoA + 1 H+ + 1 FAD <=> 1 FADH2 + 1 crotonyl-CoA  
 
 
# uracil degradation 
#uracil-degradation-I-(reductive)_1.3.1.2_1.3.1.2-RXN: 1 NADP+ + 1 5,6-dihydrouracil <=> 1 H+ + 1 
uracil + 1 NADPH  
#uracil-degradation-I-(reductive)_3.5.2.2_DIHYDROPYRIMIDINASE-RXN : 1 H2O + 1 5,6-
dihydrouracil <=> 1 H+ + 1 3-ureidopropionate  
#uracil-degradation-I-(reductive)_3.5.1.6_BETA-UREIDOPROPIONASE-RXN : 2 H+ + 1 H2O + 1 3-
ureidopropionate --> 1 CO2 + 1 ammonium + 1 beta-alanine 
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################################################################# 
 
# additional reactions 
~metabolism-of-biosynthesis_6.3.2.2_GLUTCYSLIG-RXN: 1 L-cysteine + 1 ATP + 1 L-glutamate --> 1 
H+ + 1 L-gamma-glutamylcysteine + 1 phosphate + 1 ADP 
glutathione-biosynthesis_6.3.2.3_GLUTATHIONE-SYN-RXN: 1 glycine + 1 L-gamma-glutamylcysteine 
+ 1 ATP --> 1 ADP + 1 phosphate + 1 glutathione + 1 H+  
~no-pathway_3.6.1.25_TRIPHOSPHATASE-RXN: 1 PPPi + 1 H2O --> 1 diphosphate + 1 phosphate  
~no-pathway_4.2.1.1_CARBODEHYDRAT-RXN: 1 bicarbonate <=> 1 CO2 + 1 H2O 
5,6-dimethylbenzimidazole-biosynthesis_1.5.1.38_FMNREDUCT-RXN_NADP : 1 FMNH2 + 1 NADP+ <-
- 1 FMN + 1 NADPH + 2 H+  
~no-pathway_1.5.5.1_1.5.5.1-RXN: 1 FADH2 + 1 ubiquinone-10 <=> 1 ubiquinol-10 + 1 FAD  
glycerol-degradation_glycerophosphodiester-degradation_1.1.5.3_RXN0-5258 : 1 sn-glycerol_3-
phosphate + 1 ubiquinone-10 <=> 1 ubiquinol-10 + 1 dihydroxyacetone_phosphate 
~multiple-pathways_1.2.1.2_1.2.1.2-RXN : 1 formate + 1 NAD+ --> 1 NADH + 1 CO2 
 
# spontaneous 
spontaneous_metabolism-of-degradation_5.1.3.3_ALDOSE-1-EPIMERASE-RXN : 1 alpha-D-glucose 
<=> 1 beta-D-glucose   
spontaneous_multiple-pathways_5.1.3.15_5.3.1.9_GLUCOSE-6-PHOSPHATE-1-EPIMERASE-RXN: 1 
alpha-D-glucose_6-phosphate <=> 1 beta-D-glucose-6-phosphate    
spontaneous_no-pathway_RXN-1181 : 1 ammonia + 1 H+ <=> 1 ammonium 
spontaneous_sulfate-reduction-IV-(dissimilatory)_RXN-8315: 1 sulfite + 1 H+ <=> 1 bisulfite 
 
##################################################################### 
 
# transport reactions 
 
# carbohydrate uptake 
T_ex_C_beta-D-glucose            : 1 beta-D-glucose_ex <=>  
T_trans_C_beta-D-glucose  : 1 beta-D-glucose + 1 ADP + 1 phosphate + 1 H+ <-- 1 beta-D-glucose_ex + 
1 ATP + 1 H2O  
T_ex_C_N-acetyl-beta-D-glucosamine    : 1 N-acetyl-beta-D-glucosamine_ex <=>  
T_trans_C_N-acetyl-beta-D-glucosamine : 1 N-acetyl-beta-D-glucosamine + 1 ADP + 1 phosphate + 1 
H+ <-- 1 N-acetyl-beta-D-glucosamine_ex + 1 ATP + 1 H2O  
T_ex_C_D-xylose                       : 1 D-xylose_ex <=>  
T_trans_C_D-xylose           : 1 D-xylose + 1 ADP + 1 phosphate + 1 H+ <-- 1 D-xylose_ex + 1 ATP + 1 H2O  
T_ex_C_sucrose           : 1 sucrose_ex <=>  
T_trans_C_sucrose          : 1 sucrose + 1 ADP + 1 phosphate + 1 H+ <-- 1 sucrose_ex + 1 ATP + 1 H2O  
T_ex_C_mannitol        : 1 mannitol_ex <=>  
T_trans_C_mannitol    : 1 mannitol + 1 ADP + 1 phosphate + 1 H+ <-- 1 mannitol_ex + 1 ATP + 1 H2O  
 
# amino acid uptake 
T_ex_C_L-alanine          : 1 L-alanine_ex <=>  
T_trans_C_L-alanine       : 1 L-alanine + 1 Na+ <-- 1 L-alanine_ex + 1 Na+_ex  
T_ex_C_L-arginine         : 1 L-arginine_ex <=>  
T_trans_C_L-arginine      : 1 L-arginine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-arginine_ex + 1 ATP + 1 
H2O 
T_ex_C_L-asparagine       : 1 L-asparagine_ex <=>  
T_trans_C_L-asparagine    : 1 L-asparagine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-asparagine_ex + 1 
ATP + 1 H2O  
T_ex_C_L-aspartate        : 1 L-aspartate_ex <=>  
T_trans_C_L-aspartate     : 1 L-aspartate + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-aspartate_ex + 1 ATP + 1 
H2O  
T_ex_C_L-cysteine         : 1 L-cysteine_ex <=>  
T_trans_C_L-cysteine      : 1 L-cysteine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-cysteine_ex + 1 ATP + 1 
H2O 
T_ex_C_L-glutamine        : 1 L-glutamine_ex <=>  
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T_trans_C_L-glutamine     : 1 L-glutamine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-glutamine_ex + 1 ATP 
+ 1 H2O  
T_ex_C_L-glutamate        : 1 L-glutamate_ex <=>  
T_trans_C_L-glutamate     : 1 L-glutamate + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-glutamate_ex + 1 ATP + 
1 H2O  
T_ex_C_glycine            : 1 glycine_ex <=>  
T_trans_C_glycine         : 1 glycine + 1 Na+ <-- 1 glycine_ex + 1 Na+_ex  
T_ex_C_L-histidine        : 1 L-histidine_ex <=>  
T_trans_C_L-histidine     : 1 L-histidine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-histidine_ex + 1 ATP + 1 
H2O  
T_ex_C_L-isoleucine       : 1 L-isoleucine_ex <=>  
T_trans_C_L-isoleucine    : 1 L-isoleucine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-isoleucine_ex + 1 ATP + 
1 H2O  
T_ex_C_L-leucine          : 1 L-leucine_ex <=>  
T_trans_C_L-leucine       : 1 L-leucine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-leucine_ex + 1 ATP + 1 H2O  
T_ex_C_L-lysine           : 1 L-lysine_ex <=>  
T_trans_C_L-lysine        : 1 L-lysine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-lysine_ex + 1 ATP + 1 H2O   
T_ex_C_L-methionine       : 1 L-methionine_ex <=>  
T_trans_C_L-methionine    : 1 L-methionine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-methionine_ex + 1 
ATP + 1 H2O 
T_ex_C_L-phenylalanine    : 1 L-phenylalanine_ex <=>  
T_trans_C_L-phenylalanine : 1 L-phenylalanine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-
phenylalanine_ex + 1 ATP + 1 H2O  
T_ex_C_L-proline          : 1 L-proline_ex <=>  
T_trans_C_L-proline       : 1 L-proline + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-proline_ex + 1 ATP + 1 H2O  
T_ex_C_L-serine           : 1 L-serine_ex <=>  
T_trans_C_L-serine        : 1 L-serine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-serine_ex + 1 ATP + 1 H2O 
T_ex_C_L-threonine        : 1 L-threonine_ex <=>  
T_trans_C_L-threonine     : 1 L-threonine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-threonine_ex + 1 ATP + 
1 H2O 
T_ex_C_L-tryptophan       : 1 L-tryptophan_ex <=>  
T_trans_C_L-tryptophan    : 1 L-tryptophan + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-tryptophan_ex + 1 
ATP + 1 H2O 
T_ex_C_L-tyrosine         : 1 L-tyrosine_ex <=>  
T_trans_C_L-tyrosine      : 1 L-tyrosine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-tyrosine_ex + 1 ATP + 1 
H2O 
T_ex_C_L-valine           : 1 L-valine_ex <=>  
T_trans_C_L-valine        : 1 L-valine + 1 ADP + 1 phosphate + 1 H+ <-- 1 L-valine_ex + 1 ATP + 1 H2O  
 
# additional C-sources 
T_ex_C_succinate           : 1 succinate_ex <=>  
T_trans_C_succinate        : 1 succinate + 1 H+ <-- 1 succinate_ex + 1 H+_ex  
T_ex_C_acetate             : 1 acetate_ex <=>  
T_trans_C_acetate          : 1 acetate + 1 H+ <-- 1 acetate_ex + 1 H+_ex 
T_ex_C_pyruvate            : 1 pyruvate_ex <=>  
T_trans_C_pyruvate         : 1 pyruvate + 1 H+ <-- 1 pyruvate_ex + 1 H+_ex 
T_ex_C_2-oxoglutarate      : 1 2-oxoglutarate_ex <=>  
T_trans_C_2-oxoglutarate   : 1 2-oxoglutarate + 1 H+ <-- 1 2-oxoglutarate_ex + 1 H+_ex 
T_ex_C_4-aminobutanoate    : 1 4-aminobutanoate_ex <=>  
T_trans_C_4-aminobutanoate : 1 4-aminobutanoate + 1 Na+ <-- 1 4-aminobutanoate_ex + 1 Na+_ex 
T_ex_C_myo-inositol        : 1 myo-inositol_ex <=>  
T_trans_C_myo-inositol     : 1 myo-inositol + 1 Na+ <-- 1 myo-inositol_ex + 1 Na+_ex 
T_ex_C_n-butanoate         : 1 n-butanoate_ex <=>  
T_trans_C_n-butanoate      : 1 n-butanoate + 1 Na+ <-- 1 n-butanoate_ex + 1 Na+_ex 
 
# additional N-sources 
T_ex_N_(S)-(+)-allantoin   : 1 (S)-(+)-allantoin_ex <=>  
T_trans_N_(S)-(+)-allantoin: 1 (S)-(+)-allantoin + 1 Na+ <-- 1 (S)-(+)-allantoin_ex + 1 Na+_ex 
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# mineral and organic ion 
T_ex_ammonium : 1 ammonium_ex <=> 
T_trans_ammonium : 1 ammonium <=> 1 ammonium_ex 
T_ex_sulfate : 1 sulfate_ex <=>  
T_trans_sulfate : 1 sulfate + 1 ADP + 1 phosphate + 1 H+ <-- 1 sulfate_ex + 1 ATP + 1 H2O 
T_ex_phosphate : 1 phosphate_ex <=> 
T_trans_Na+ : 1 Na+ + 2 H+_ex --> 1 Na+_ex + 2 H+   
 
# others 
T_ex_oxygen    : 1 oxygen_ex <=>  
T_trans_oxygen : 1 oxygen <=> 1 oxygen_ex 
T_ex_H2O       : 1 H2O_ex <=> 
T_trans_H2O    : 1 H2O <=> 1 H2O_ex 
T_ex_H+        : 1 H+ --> 
T_ex_H+_ex     : 1 H+_ex <=> 
 
# secondary metabolites 
T_ex_TDA    : 1 TDA_ex <=> 
T_trans_TDA : 1 TDA --> 1 TDA_ex 
 
# by-products/intermediates 
T_ex_CO2                       : 1 CO2_ex <=> 
T_trans_CO2                    : 1 CO2 <=> 1 CO2_ex 
T_ex_methanethiol              : 1 methanethiol_ex <=> 
T_trans_methanethiol           : 1 methanethiol --> 1 methanethiol_ex 
T_ex_hydrogen_sulfide          : 1 hydrogen_sulfide_ex <=> 
T_trans_hydrogen_sulfide       : 1 hydrogen_sulfide --> 1 hydrogen_sulfide_ex 
T_ex_nitrate                   : 1 nitrate_ex <=>  
T_trans_nitrate                : 1 nitrate --> 1 nitrate_ex 
T_ex_nitrite                   : 1 nitrite_ex <=>  
T_trans_nitrite                : 1 nitrite --> 1 nitrite_ex 
T_ex_formate                   : 1 formate_ex <=>  
T_trans_formate                : 1 formate --> 1 formate_ex 
T_ex_fumarate                  : 1 fumarate_ex <=>  
T_trans_fumarate               : 1 fumarate --> 1 fumarate_ex 
T_ex_urea                      : 1 urea_ex <=>  
T_trans_urea                   : 1 urea --> 1 urea_ex 
T_ex_(2S)-2-isopropylmalate    : 1 (2S)-2-isopropylmalate_ex <=>  
T_trans_(2S)-2-isopropylmalate : 1 (2S)-2-isopropylmalate --> 1 (2S)-2-isopropylmalate_ex 
T_ex_2-hydroxyphenylacetate    : 1 2-hydroxyphenylacetate_ex <=>  
T_trans_2-hydroxyphenylacetate : 1 2-hydroxyphenylacetate --> 1 2-hydroxyphenylacetate_ex 
T_ex_cadaverine                : 1 cadaverine_ex <=>  
T_trans_cadaverine             : 1 cadaverine --> 1 cadaverine_ex 
T_ex_anthranilate              : 1 anthranilate_ex <=>  
T_trans_anthranilate           : 1 anthranilate --> 1 anthranilate_ex 
T_ex_L-kynurenine              : 1 L-kynurenine_ex <=>  
T_trans_L-kynurenine           : 1 L-kynurenine --> 1 L-kynurenine_ex 
T_ex_keto-phenylpyruvate       : 1 keto-phenylpyruvate_ex <=>  
T_trans_keto-phenylpyruvate    : 1 keto-phenylpyruvate --> 1 keto-phenylpyruvate_ex 
 
T_ex_hydrogen_peroxide         : 1 hydrogen_peroxide_ex <=> 
T_trans_hydrogen_peroxide      : 1 hydrogen_peroxide --> 1 hydrogen_peroxide_ex 
 
 
################################################################# 
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# NGAM 
 
NGAM : 1 ATP + 1 H2O --> 1 ADP + 1 phosphate + 1 H+  
 
# biomass   
 
biomass_Ala_WT : 0.54 proteins + 0.016 dna + 0.045 rna + 0.068 phospholipids + 0.12 peptidoglycan 
+ 0.034 LPS + 0.07 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 85 ADP + 85 
phosphate + 85 H+ 
biomass_Phe_WT : 0.55 proteins + 0.013 dna + 0.054 rna + 0.061 phospholipids + 0.12 peptidoglycan 
+ 0.034 LPS + 0.13 PHB + 0.04 L-glutamate  + 0.02 solublepool + 85 ATP + 85 H2O --> 85 ADP + 85 
phosphate + 85 H+ 
biomass_Leu_WT : 0.53 proteins + 0.014 dna + 0.034 rna + 0.056 phospholipids + 0.12 peptidoglycan 
+ 0.034 LPS + 0.17 PHB + 0.04 L-glutamate  + 0.02 solublepool + 85 ATP + 85 H2O --> 85 ADP + 85 
phosphate + 85 H+ 
biomass_Ala_D262 : 0.56 proteins + 0.014 dna + 0.068 rna + 0.059 phospholipids + 0.12 
peptidoglycan + 0.034 LPS + 0.07 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 
85 ADP + 85 phosphate + 85 H+ 
biomass_Phe_D262 : 0.52 proteins + 0.02 dna + 0.058 rna + 0.053 phospholipids + 0.12 peptidoglycan 
+ 0.034 LPS + 0.14 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 85 ADP + 85 
phosphate + 85 H+ 
biomass_Leu_D262 : 0.59 proteins + 0.016 dna + 0.043 rna + 0.059 phospholipids + 0.12 
peptidoglycan + 0.034 LPS + 0.14 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 
85 ADP + 85 phosphate + 85 H+ 
biomass_Ala_tdaE : 0.59 proteins + 0.012 dna + 0.059 rna + 0.053 phospholipids + 0.12 peptidoglycan 
+ 0.034 LPS + 0.07 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 85 ADP + 85 
phosphate + 85 H+ 
biomass_Phe_tdaE : 0.51 proteins + 0.011 dna + 0.039 rna + 0.059 phospholipids + 0.12 
peptidoglycan + 0.034 LPS + 0.24 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 
85 ADP + 85 phosphate + 85 H+ 
biomass_Leu_tdaE : 0.50 proteins + 0.009 dna + 0.037 rna + 0.034 phospholipids + 0.12 
peptidoglycan + 0.034 LPS + 0.23 PHB + 0.04 L-glutamate + 0.02 solublepool + 85 ATP + 85 H2O --> 
85 ADP + 85 phosphate + 85 H+ 
 
PROTEIN : 0.6256 L-alanine + 0.4762 L-arginine + 0.3040 L-asparagine + 0.6993 L-aspartate +  
0.1329 L-cysteine + 0.2499 L-glutamine + 0.3999 L-glutamate + 0.9359 glycine + 0.1343 L-histidine + 
0.3658 L-isoleucine + 0.6430 L-leucine + 0.2375 L-lysine + 0.1185 L-methionine + 0.3173 L-
phenylalanine + 0.5352 L-proline + 0.4893 L-serine + 0.5569 L-threonine + 0.1049  L-tryptophan + 
0.1994 L-tyrosine + 0.5625 L-valine --> proteins 
 
DNA : 0.6604 dTMP + 1.0343 dCMP + 0.6414 dAMP + 0.9085 dGMP --> dna 
 
RNA : 0.6561 UMP + 0.9800 CMP + 0.6102 AMP + 0.8664 GMP --> rna 
 
PHOSPHOLIPIDS : 0.4360 L-1-phosphatidylethanolamine + 0.4712 L-1-phosphatidylglycerol + 0.2062 
phosphatidylcholine + 0.0070 cardiolipin --> phospholipids 
 
PEPTIDOGLYCAN : 0.174855744 a_peptidoglycan_with_D,D_cross-links_(meso-
diaminopimelate_containing) --> peptidoglycan 
 
LPS : 0.0371 (KDO)2-lipid_A + 3.6196 UDP-alpha-D-glucose + 1.6176 UDP-N-acetyl-alpha-D-
glucosamine --> 1 LPS + 5.2372 UDP + 1 H+ 
 
SOLUBLE POOL : 0.107 NAD+ + 0.00645 NADP+ + 0.0025 NADH + 0.0199 NADPH + 0.24876 
tetrahydrofolate + 0.0005 FAD + 0.00295 riboflavin + 0.00295 coenzyme_A + 0.00295 ubiquinol-10 + 
0.00295 S-adenosyl-L-methionine + 0.00015 succinyl-CoA + 0.0025 acetyl-CoA --> solublepool 
 
PHB: 11.50 [PHB] --> 1 PHB 
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